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A B S T R A C T
Background
Panic disorder is characterised by the presence of recurrent unexpected panic attacks, discrete periods of fear or anxiety that have a
rapid onset and include symptoms such as racing heart, chest pain, sweating and shaking. Panic disorder is common in the general
population, with a lifetime prevalence of 1% to 4%. A previous Cochrane meta-analysis suggested that psychological therapy (either
alone or combined with pharmacotherapy) can be chosen as a first-line treatment for panic disorder with or without agoraphobia.
However, it is not yet clear whether certain psychological therapies can be considered superior to others. In order to answer this question,
in this review we performed a network meta-analysis (NMA), in which we compared eight different forms of psychological therapy
and three forms of a control condition.
Objectives
To assess the comparative efficacy and acceptability of different psychological therapies and different control conditions for panic
disorder, with or without agoraphobia, in adults.
Search methods
We conducted the main searches in the CCDANCTR electronic databases (studies and references registers), all years to 16March 2015.
We conducted complementary searches in PubMed and trials registries. Supplementary searches included reference lists of included
studies, citation indexes, personal communication to the authors of all included studies and grey literature searches in OpenSIGLE.
We applied no restrictions on date, language or publication status.
Selection criteria
We included all relevant randomised controlled trials (RCTs) focusing on adults with a formal diagnosis of panic disorder with or without
agoraphobia. We considered the following psychological therapies: psychoeducation (PE), supportive psychotherapy (SP), physiological
therapies (PT), behaviour therapy (BT), cognitive therapy (CT), cognitive behaviour therapy (CBT), third-wave CBT (3W) and
psychodynamic therapies (PD). We included both individual and group formats. Therapies had to be administered face-to-face. The
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comparator interventions considered for this review were: no treatment (NT), wait list (WL) and attention/psychological placebo
(APP). For this review we considered four short-term (ST) outcomes (ST-remission, ST-response, ST-dropouts, ST-improvement on
a continuous scale) and one long-term (LT) outcome (LT-remission/response).
Data collection and analysis
As a first step, we conducted a systematic search of all relevant papers according to the inclusion criteria. For each outcome, we then
constructed a treatment network in order to clarify the extent towhich each type of therapy and each comparison had been investigated in
the available literature. Then, for each available comparison, we conducted a random-effects meta-analysis. Subsequently, we performed
a network meta-analysis in order to synthesise the available direct evidence with indirect evidence, and to obtain an overall effect size
estimate for each possible pair of therapies in the network. Finally, we calculated a probabilistic ranking of the different psychological
therapies and control conditions for each outcome.
Main results
We identified 1432 references; after screening, we included 60 studies in the final qualitative analyses. Among these, 54 (including
3021 patients) were also included in the quantitative analyses. With respect to the analyses for the first of our primary outcomes, (short-
term remission), the most studied of the included psychological therapies was CBT (32 studies), followed by BT (12 studies), PT (10
studies), CT (three studies), SP (three studies) and PD (two studies).
The quality of the evidence for the entire network was found to be low for all outcomes. The quality of the evidence for CBT vs NT,
CBT vs SP and CBT vs PD was low to very low, depending on the outcome. The majority of the included studies were at unclear risk
of bias with regard to the randomisation process. We found almost half of the included studies to be at high risk of attrition bias and
detection bias. We also found selective outcome reporting bias to be present and we strongly suspected publication bias. Finally, we
found almost half of the included studies to be at high risk of researcher allegiance bias.
Overall the networks appeared to be well connected, but were generally underpowered to detect any important disagreement between
direct and indirect evidence. The results showed the superiority of psychological therapies over theWL condition, although this finding
was amplified by evident small study effects (SSE). The NMAs for ST-remission, ST-response and ST-improvement on a continuous
scale showed well-replicated evidence in favour of CBT, as well as some sparse but relevant evidence in favour of PD and SP, over other
therapies. In terms of ST-dropouts, PD and 3W showed better tolerability over other psychological therapies in the short term. In
the long term, CBT and PD showed the highest level of remission/response, suggesting that the effects of these two treatments may
be more stable with respect to other psychological therapies. However, all the mentioned differences among active treatments must be
interpreted while taking into account that in most cases the effect sizes were small and/or results were imprecise.
Authors’ conclusions
There is no high-quality, unequivocal evidence to support one psychological therapy over the others for the treatment of panic disorder
with or without agoraphobia in adults. However, the results show that CBT - the most extensively studied among the included
psychological therapies - was often superior to other therapies, although the effect size was small and the level of precision was often
insufficient or clinically irrelevant. In the only two studies available that explored PD, this treatment showed promising results, although
further research is needed in order to better explore the relative efficacy of PD with respect to CBT. Furthermore, PD appeared to be
the best tolerated (in terms of ST-dropouts) among psychological treatments. Unexpectedly, we found some evidence in support of
the possible viability of non-specific supportive psychotherapy for the treatment of panic disorder; however, the results concerning SP
should be interpreted cautiously because of the sparsity of evidence regarding this treatment and, as in the case of PD, further research
is needed to explore this issue. Behaviour therapy did not appear to be a valid alternative to CBT as a first-line treatment for patients
with panic disorder with or without agoraphobia.
P L A I N L A N G U A G E S U M M A R Y
Psychological therapies for the treatment of panic disorder with or without agoraphobia
Why is this review important?
Many people suffer from panic disorder. Panic disorder can occur on its own or with agoraphobia. People with panic disorder experience
recurring panic attacks. During a panic attack people feel the sudden onset of intense fear alongside a series of bodily symptoms such as a
racing heart, chest pain, sweating, shaking, dizziness, flushing, stomach churning, faintness and breathlessness. People with agoraphobia
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feel an intense fear of developing a panic attack in situations where escape might be difficult or embarrassing. This fear often leads to
the avoidance of such situations.
There are many different types of talking therapies that are used to treat panic disorder with or without agoraphobia. However it is not
clear whether certain talking therapies are more effective than others at treating panic disorder with or without agoraphobia. In this
review we compared the effectiveness of different types of talking therapy.
Who will be interested in this review?
People with panic disorder with or without agoraphobia.
Friends and family of people with panic disorder with or without agoraphobia.
General practitioners, psychiatrists and psychologists.
Professionals working in adult mental health services.
What questions does this review aim to answer?
Are any of the included psychological therapies more effective and better tolerated than others in the rapid reduction of panic/
agoraphobia symptoms?
Can any of the included psychological therapies guarantee better results one year after termination?
Which studies were included in the review?
We searched medical databases up to 16 March 2015 to find all studies (specifically randomised controlled trials) of talking therapies
in the treatment of panic disorder with or without agoraphobia. To be included in the review studies had to include people with a clear
diagnosis of panic disorder with or without agoraphobia.
We included 60 studies in the review. Fifty-four of the included studies (involving 3021 participants) were used in numerical analyses.
The review authors rated the overall quality of the studies as low to very low.
What does the evidence from the review tell us?
The results of the review show that in general talking therapies are more effective than no treatment. There was no strong evidence to
support one talking therapy over the others for the treatment of panic disorder with or without agoraphobia in adults. However, there
was some low-quality evidence in favour of cognitive behaviour therapy (CBT), psychodynamic therapy and supportive psychotherapy
over other talking therapies for short-term remission and short-term reduction in symptoms. The results concerning supportive
psychotherapy should, however, be treated with caution because of the small amount of evidence available about this treatment. On the
other hand, beyond the evidence regarding its efficacy, psychodynamic therapy also showed promising results in terms of tolerability: as
a way of assessing how well people tolerated the talking therapies, we assessed short-term dropout rates. We found that there were fewer
dropouts in psychodynamic therapy and third-wave CBT, suggesting that people tolerate these therapies better than other therapies.
What should happen next?
More high-quality research is needed to be able to fully compare the effectiveness of different talking therapies. In particular, more
new studies are needed that compare the specific talking therapies CBT, psychodynamic therapy and supportive psychotherapy for the
treatment of panic disorder with or without agoraphobia.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Cognitive behaviour therapy compared to no treatment for panic disorder with or without agoraphobia in adults
Patient or population: adult pat ients with panic disorder with or without agoraphobia
Setting: outpat ients
Intervention: cognit ive behaviour therapy (CBT)
Comparison: no treatment (NT)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
No treatment (NT) Cognitive-behavioral ther-
apy (CBT)
Short-term remission
(follow-up: mean 3 months)
Study populat ion OR 2.78
(0.54 to 14.29)
No direct evidence available:
indirect evidence based on
357 part icipants (2 studies
via CT; 5 studies via PT)a
⊕©©©
VERY LOW 1,2,3
36 per 100 61 per 100
(24 to 89)
Short-term response
(follow-up: mean 3 months)
Study populat ion OR 7.14
(1.25 to 50)
No direct evidence available:
indirect evidence based on
357 part icipants (2 studies
via CT; 5 studies via PT)a
⊕©©©
VERY LOW 1,2,3
36 per 100 80 per 100
(42 to 97)
Short-term dropouts
(follow-up: mean 3 months)
Study populat ion OR 6.25
(0.26 to 100)
No direct evidence available:
indirect evidence based on
278 part icipants (4 studies
via PT)a
⊕©©©
VERY LOW 1,2,3
1 per 100 (no events were
observed in the available di-
rect evidence: this percent-
age was assumed in order
to calculate the correspond-
ing risk)
6 per 100
(0 to 50)
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Long-term remission/ re-
sponse
(follow-up: mean 12
months)
No data available for this com-
parison
- - - -
Short-term improvement as
measured on a cont inuous
scale
(follow-up: mean 3 months)
The mean short-term im-
provement as measured on
a cont inuous scale in the
control group was 0
The mean short-term im-
provement, measured on a
cont inuous scale as SMD
(NMA results), was -0.83
(95% CI -1.5 to -0.16), indi-
cat ing a large ef fect size in
favour of CBT
- 27 part icipants
(1 RCT)
⊕⊕©©
LOW 4,5
Reported ORs are derived (as reciprocal values) f rom the results of network meta-analyses presented in Table 1, Table 4 and Table 7 (for ST-remission and ST-response we
used the results of NMA adjusted for SSE). Reported SMD is derived f rom the results of network meta-analysis presented in Table 10.
a Indirect comparison is performed using all possible intermediate comparisons in the network. For brevity we report the number of studies contribut ing indirect evidence only
via a single intermediate comparator
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; NM A: network meta-analysis; OR: odds rat io; RCT: randomised controlled trial; SM D: standardised mean dif ference
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
We downgraded the quality of the evidence one step at a t ime when one or more of the following crit icisms was present:
1Only indirect evidence is available for this outcome.
2Wide 95% CI.
3The risk of bias of indirect evidence is of ten unclear.
4The risk of bias in the included study was unclear in almost every domain.
5Only one study, with a small sample size, available for direct comparison.
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B A C K G R O U N D
Description of the condition
A panic attack is a discrete period of fear or anxiety that has a
rapid onset, reaches a peak within 10 minutes and in which at
least four of 13 characteristic symptoms are experienced. Many
of these symptoms involve bodily systems, such as racing heart,
chest pain, sweating, shaking, dizziness, flushing, stomach churn-
ing, faintness and breathlessness. Further recognised panic attack
symptoms involve fearful cognitions, such as the fear of collapse,
going mad or dying, and derealisation (APA 2000).
According to theDiagnostic and Statistical Manual ofMental Dis-
orders (DSM-IV-TR) (APA 2000), panic disorder is characterised
by the presence of recurrent unexpected panic attacks, of which at
least one has been followed by one month (or more) of persistent
concern about having additional attacks, worry about the impli-
cations of the attack (or its consequences) or a significant change
in behaviour related to the attacks.
Panic disorder is common in the general population, with a life-
time prevalence of 1% to 4% (Bijl 1998; Eaton 1994). In pri-
mary care settings panic syndromes have been reported to have a
prevalence of around 10% (King 2008). The aetiology of panic
disorder is not fully understood and is probably heterogeneous.
Biological theories incorporate the faulty triggering of an inbuilt
anxiety response, possibly a suffocation alarm. Evidence for this
comes from biological challenge tests (lactate and carbon dioxide
trigger panic in those with the disorder) and from neuroimaging
studies that show activation of fear circuits, such as involving the
periaqueductal grey matter (Gorman 2000).
Agoraphobia is anxiety about being in places or situations from
which escape might be difficult or embarrassing, or in which help
may not be available in the event of having a panic attack (APA
2000). Agoraphobia can occur with panic disorder and in the gen-
eral population about one quarter of people suffering from panic
disorder also have agoraphobia but this proportion is much higher
in the clinical samples (Kessler 2006). The presence of agoraphobia
is associated with increased severity and worse outcomes (Kessler
2006). There are several risk factors that predict the development
of agoraphobia in people suffering from panic disorder including
female gender, more severe dizziness during panic attacks, cogni-
tive factors, dependent personality traits and social anxiety disor-
der (Starcevic 2009).
Panic disorder is more common among women, with a 2:1 ratio;
in the case of panic disorder with agoraphobia the ratio rises to
3:1. Most typically, the disorder strikes between late adolescence
and 35 years of age; early or late onset is possible, although less
common (APA 2000).
Panic disorder, with or without agoraphobia, is highly comorbid
with other psychiatric disorders such as drug dependence, major
depression, bipolar I disorder, social phobia, specific phobia and
generalised anxiety disorder (Grant 2006). It is estimated that
generalised anxiety disorder co-occurs in 68%of people with panic
disorder, whilst major depression has a prevalence of 24% to 88%
among people with panic disorder (Starcevic 2009).
Description of the intervention
Recent guidelines from theNational Institute forHealth andClin-
ical Excellence recommend three types of intervention in the care
of individuals with panic disorder, any of which should be offered
promptly, taking into account the preference of the patient (NICE
2011). According to the NICE guidelines, the interventions that
have evidence for the longest duration of effect, in descending or-
der, are psychological therapy, pharmacological therapy (antide-
pressant medication) and self help.
A psychological therapy can be defined as a therapeutic interaction
between a trainedprofessional and a patient (or a group of patients)
by way of their verbal and non-verbal communication for the
purpose of ameliorating the sufferings on the part of the patient(s).
Although NICE guidelines recommend the use of cognitive be-
haviour therapy (CBT) for the treatment of panic disorder, many
other psychological therapies have been proposed as viable thera-
peutic options. Each therapy is characterised by a certain theoreti-
cal framework, according to which a set of therapeutic ingredients
(or ’components’) and technical features can be defined and briefly
described as follows.
• Psychoeducation consists of providing patients with
information about their psychological disease. In this context, it
can be explained to patients that their symptoms can be
interpreted in the light of a certain cause-effect model, according
to a more general theoretical framework that can vary across the
different psychological approaches.
• Supportive psychotherapy is a dyadic treatment that uses
direct measures to ameliorate symptoms and maintain, restore or
improve self esteem, ego function and adaptive skills (according
to the manual of Winston, Rosenthal and Pinsker (Winston
2004)). Although different techniques can be used (e.g.
encouragement, rationalising and reframing, anticipatory
guidance, etc.) therapeutic alliance represents the most
important element of the therapy (Winston 2004). Rogerian
client-centred psychotherapy is probably the most representative
example of supportive psychotherapy (Rogers 1980). In this
approach, within the context of a warm, empathic and non-
directive therapeutic relationship clients are led to become aware
of their true feelings and to fully accept themselves as they are,
including imperfections and dysfunctions.
• Physiological therapies are represented by a set of different
possible treatments that use some kind of physical training (e.g.
breathing retraining, relaxation techniques, biofeedback) in order
to help the patient to control the physiological manifestations of
anxiety. Among the physiological therapies proposed for the
treatment of panic disorder, breathing retraining and relaxation
techniques are probably the most studied. Within the context of
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breathing retraining, different strategies have been proposed,
although most manuals and studies describe instructions in
abdominal breathing as their central technique (Meuret 2012).
Progressive muscle relaxation (PMR), as formalised by Bernstein
and Borkovec (Bernstein 1973), can be taught to panic patients
in order to reduce general tension and achieve a body state that
lowers the risk for stressors to elicit panic. The so-called applied
relaxation is a slightly different form of physiological therapy in
which relaxation training and exposure are combined (Ost 1987).
• The behavioural therapy of panic disorder consists of
graded exposure to the body sensations that accompany panic
(’interoceptive exposure’) or to situations perceived as
threatening (’in vivo exposure’, ’imagery exposure’, ’virtual reality
exposure’), or both, in order to progressively reduce the patient’s
apprehensive reaction towards them.
• Cognitive therapy finds its roots in the work of Albert Ellis
and Aaron Beck. Its main component is represented by cognitive
restructuring, a psychotherapeutic process of learning to identify
and modify irrational or maladaptive thoughts using strategies
such as Socratic questioning, thought recording and guided
imagery.
• CBT for panic disorder is usually administered according to
the manuals of Clark 1986b and Barlow 2000b. Its main
components are represented by psychoeducation, breathing
retraining, PMR, cognitive restructuring, behavioural
experiments, interoceptive exposure and in vivo exposure.
• The so-called ’third-wave’ therapies are represented by a set
of different therapies (e.g. mindfulness-based cognitive therapy,
acceptance and commitment therapy, compassionate mind
training, extended behavioural activation, metacognitive therapy,
schema therapy), all originating from the cognitive behavioural
approach but compared to which more importance is given to
the form, rather than the content, of patients’ thoughts. By
focusing on the function of cognition, third-wave therapies aim
to help patients to develop more adaptive emotional responses to
situations. When mindfulness and acceptance are applied to
anxiety disorders, the aim is for the individual to be able to
observe symptomatic processes without overly identifying with
them or without reacting to them in ways that cause further
distress (Roemer 2008). A systematic review and meta-analysis of
mindfulness-based and acceptance-based interventions for
anxiety disorders has been recently published (Vøllestad 2012).
• Psychodynamic therapies consist of a set of psychological
therapies, different in length and depth, represented by
psychoanalysis (as conceptualised by S Freud) and its further
developments. According to psychodynamic psychotherapy,
psychological symptoms can be seen as manifestations of
intrapsychic or unconscious conflicts; these therapies use
different therapeutic strategies (e.g. unconscious contents
exploration, dream analysis, analysis of past experiences, analysis
of parental relationships, analysis of transference, analysis of
resistances) in order to reveal, interpret and resolve such
conflicts. A brief panic-focused psychodynamic psychotherapy is
described in Milrod 1997. A sightly different approach, derived
from psychodynamic theories, is represented by so-called
emotion-focused therapy (EFT) in which the therapist is viewed
as an ’emotion coach’ who works to enhance emotion-focused
coping by helping people become aware of, accept and make
sense of their emotional experience (Greenberg 2004).
A further level of distinction among psychological therapies con-
cerns the form of delivery of the intervention. In this regard,
NICE guidelines suggest that the intervention (CBT) should be
optimally delivered in the form of one- to two-hour weekly ses-
sions, for a total of seven to 14 hours, within a maximum of four
months since commencement. However, different variables have
been and still remain the subject of investigation with regard to
cost-effectiveness analyses. A number of variables including the
number of sessions, the duration of treatment and the therapeutic
setting (group versus individual; face-to-face versus remote versus
self help) have been explored.
How the intervention might work
The main features and rationale of the psychological therapies
considered for this review can be summarised as follows.
The rationale of psychoeducation is that providing anxious pa-
tients with a better understanding of their sufferings may in itself
lead to symptom relief (Clark 1985; Sorby 1991). This may be
especially important in panic disorder, where the cognitive coping
mechanisms of the patients are disrupted and where anticipatory
anxietymay cause additional attacks (Dannon 2002). In this sense,
as the authors further suggest, a psychoeducational intervention
may increase the patients’ sense of control leading to a reduction
of catastrophic thoughts and emotions.
Supportive psychotherapy is non-specific in nature, so it is not
designed for the treatment of a psychiatric disorder in particular.
In this sense, the supportive treatment of panic disorder and ago-
raphobia does not differ from the treatment of any other disorder.
Although scarce, the available body of evidence does not exclude a
possible role of supportive psychotherapy in the treatment of ago-
raphobia (Klein 1983; Zitrin 1978); its efficacy in the treatment
of panic disorder without agoraphobia still remains unclear.
Respiratory abnormalities, with particular regard to hyperventila-
tion and hypocapnia, have been postulated as being important fac-
tors in the development or maintenance of panic disorder (Klein
1993; Ley 1985; for a review seeMeuret 2010b). According to the
model proposed by Ley 1985, panic attacks are caused by acute
states of hypocapnia in a positive feedback loop between hyper-
ventilation and anxiety. Therefore, amelioration of panic symp-
toms is expected when patients achieve reductions in transient and
sustained hypocapnia. Results on the efficacy of breathing training
in the treatment of panic disorder are mixed (Meuret 2010b). The
purpose of applied relaxation is to teach the patient to observe the
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very first signs of a panic attack and to apply a rapid and effec-
tive relaxation technique to cope with, and eventually abort, these
symptoms before they develop into a panic attack. In a direct com-
parison with regard to remission from panic disorder at the end
of treatment, applied relaxation was not found to be significantly
better than PMR, although it performed better than PMR on six
out of 11 measures (Ost 1988).
Behaviour therapy (BT) is characterised by the use of some kind
of exposure in order to modify dysfunctional behaviours that may
contribute to the development and persistence of psychological
symptoms. The principle of exposure in the treatment of phobic
disorders is to persuade the patient to enter and stay in his or
her phobic situation until he or she feels better, and to do this
repeatedly until it becomes so customary that the situation no
longer holds terror (Marks 1981). There is evidence that exposure
strategies alone are effective in the treatment of panic disorder
(Gloster 2011; Ost 2004; Williams 1996).
In the case of cognitive therapy (CT) for panic disorder, it has been
proposed that panic attacks result from the catastrophic misinter-
pretation of certain bodily sensations (Clark 1986a). This involves
the sufferer perceiving sensations involved in normal anxiety re-
sponses as much more dangerous than they really are, for exam-
ple perceiving palpitations as evidence of impending heart attack.
The cognitive approach would involve identifying patients’ nega-
tive interpretations of the bodily sensations experienced in panic
attacks, suggesting alternative non-catastrophic interpretations of
the sensations, and then helping the patient to test the validity
of these alternative interpretations. As pointed out in a recent re-
view (Meuret 2012), CT is often intermingled with behavioural
techniques (for example, ’behavioural experiments’, ’hypothesis
testing’, ’instructions’ involving exposure), which complicates the
testing of the efficacy of CT in its ’pure’ form. Nonetheless, there
is some evidence that training in cognitive procedures in full iso-
lation from exposure and behavioural procedures is efficacious in
reducing aspects of panic (Beck 1994; Meuret 2010a; Salkovskis
1991; Van den Hout 1994).
Cognitive behaviour therapy (CBT) combines elements of both in
order to reduce emotional distress and psychological symptoms,
assuming that cognitions, behaviours and emotions are interre-
lated. A fairly consistent body of evidence exists in support of the
efficacy of CBT for panic disorder, administered either in indi-
vidual or group sessions (among others: Clark 1999; Dow 2000;
Hendriks 2010; Telch 1993). Furthermore, a growing body of ev-
idence supports the efficacy of self administered versions (for ex-
ample, book-based, internet-based) of this psychological therapy
(Carlbring 2006; Nordin 2010; Wims 2010).
As summarised in Ludwig 2008, mindfulness involves attending
to relevant aspects of experience in a non-judgemental manner.
The goal of mindfulness is to maintain awareness moment by
moment, disengaging oneself from strong attachment to beliefs,
thoughts or emotions, thereby developing a greater sense of emo-
tional balance and well-being. An aim of mindfulness practice is to
take greater responsibility for one’s life choices. Although scarce,
some evidence exists in support of the efficacy of this therapy for
the treatment of generalised anxiety disorder and panic disorder
(Kim 2009; Lee 2007). As originally developed (Hayes 1999), ac-
ceptance and commitment therapy (ACT) was intended for the
treatment of psychopathology in general rather than a specific dis-
order in particular. ACT conceptualises psychological events as a
set of ongoing interactions between whole organisms and histori-
cally and situationally defined contexts. Removal of a client’s prob-
lematic behaviours from the contexts that participate in that event
(for example, merely analysing manifested behavioural symptoms
themselves) is thought to miss the nature of the problem and the
avenues for its solution. ACT clients are therefore encouraged to
embrace a passionate and ongoing interest in how to live according
to their values. In ACT there is a conscious posture of openness
and acceptance toward all psychological events, even if they are
formally ’negative’, ’irrational’ or even ’psychotic’. For example, if
the client feels trapped, frustrated, confused, afraid, angry or anx-
ious, the ACT stance suggests this is not so much a problem as it
is an opportunity to work on how powerful events in the here and
now can become barriers to growth (Hayes 2004). Some evidence
supports ACT possibly being as effective as CBT in the treatment
of anxiety disorders including panic disorder (Arch 2012).
Following a psychodynamic approach, Busch and colleagues pro-
posed that during childhood, a sense of fearful dependency on the
parent may lead to the development of anger towards him or her
(Busch 1996). As a consequence, a vicious cycle develops in which
the child’s anger threatens the needed tie to the parent and thereby
increases fearful dependency, which promotes further frustration
and rage at the parent. This cycle may then recur in adulthood
when threats to attachment trigger intense feelings of abandon-
ment, anger and anxiety, leading to the development of the disor-
der. The aim of psychodynamic psychotherapy is to address such
underlying psychological factors in order to obtain an improve-
ment of panic symptoms. Although only a few studies have ex-
plored the effects of psychodynamic psychotherapy for panic dis-
order, the available evidence suggests the viability of this approach
as a valid therapeutic option (Milrod 2007; Wiborg 1996).
Why it is important to do this review
A previous Cochrane meta-analysis comparing combined psycho-
logical therapy plus antidepressants versus psychological therapy
alone or pharmacotherapy alone showed the superiority of com-
bined therapy over either monotherapies in the short term, and
of combined therapy and psychological therapy alone over phar-
macotherapy alone in the long term, thus suggesting that either
combined therapy or psychological therapy alone can be chosen as
first-line treatment for panic disorder with or without agorapho-
bia (Furukawa 2007). In particular, behavioural and cognitive be-
havioural psychological therapies showed the strongest evidence.
Another meta-analysis, aimed at analysing the efficacy of psycho-
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logical interventions versus control conditions in the treatment of
panic disorderwith orwithout agoraphobia (Sánchez-Meca 2010),
showed a general efficacy of psychological therapies over different
clusters of symptoms, with the most consistent results in favour of
the combination of exposure strategies with relaxation training or
breathing retraining techniques, or both. The study conducted by
Sánchez-Meca et al revealed the presence of substantial heterogene-
ity among included studies (I2 = 70.4%). Exploratory secondary
analyses suggested that variables such as type of therapy and type
of control group may explain part of the observed heterogeneity.
The observed degree of heterogeneity due to differences in the
psychological therapies suggests that some psychological therapies
may be more effective than others in the treatment of the disorder.
However, both the existence and the eventual magnitude of such
differences remain unclear. This is partly due to the presence of
methodological diversity among available studies; as suggested by
Sánchez-Meca et al, the type of control group may significantly
influence the measured effect size, limiting the possibility of draw-
ing conclusions. A further consideration is that only a few trials
compared different psychological approaches with each other and,
more generally, psychological therapies have not been all equally
investigated.
In an attempt to overcome these issues, in this review we per-
formed a network meta-analysis (NMA), also known as multiple
treatment meta-analysis, in which eight different forms of psy-
chological therapy and three forms of a control condition (see
Types of interventions) have been independently compared with
each other. We expected this methodological strategy to reduce
the amount of heterogeneity that was observed in previous stud-
ies. Furthermore, by synthesising the available direct and indirect
evidence via NMA, it was possible to obtain an overall effect size
estimate for each possible pair of therapies in the network, even
for interventions that had not been directly compared with each
other in previous trials. Finally, it was possible to calculate a prob-
abilistic ranking in order to help the identification of those inter-
ventions that are more likely to be more effective than others in
the treatment of panic disorder.
This review along with several others in progress, contributes to
the production of a comprehensive portfolio of Cochrane reviews
in the area of panic disorder (Furukawa 2007; Guaiana 2013;
Guaiana 2013a; Guaiana 2013b; Watanabe 2009; Xiao 2011).
O B J E C T I V E S
To assess the comparative efficacy and acceptability of different
psychological therapies and different control conditions for panic
disorder, with or without agoraphobia, in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials (RCTs).
We included cluster-randomised trials when the effects of cluster-
ing were taken account of (however, we found no such cases).
We included cross-over randomised trials, but we only considered
results from the first randomisation period.
We included studies in which the replacement of dropouts was
allowed as long as replacements were low in number (less than
15% of the final sample) and evenly distributed among treatment
arms.
We excluded quasi-randomised controlled trials (in which treat-
ment assignment was decided through methods such as alternate
days of the week).
Types of participants
Age range
Patients, aged 18 years or older, of both sexes. We included studies
that included some participants under the age of 18 as long as at
least 80% of patients were aged 18 years or above.
Diagnosis
We included studies that had enlisted participants with a primary
diagnosis of panic disorder with or without agoraphobia diag-
nosed according to any of the following criteria: Feighner crite-
ria (Feighner 1972), Research Diagnostic Criteria (Spitzer 1978),
DSM-III (APA 1980), DSM-III-R (APA 1987), DSM-IV (APA
2000), DSM-5 (APA 2013) or ICD-10 (WHO 1992). When
ICD-10 or DSM-5 were used, in which panic disorder and ago-
raphobia are separately diagnosable, this review focused on panic
disorder comorbid with or without agoraphobia. We took the lat-
ter decision in order to be concordant with the current body of
literature, most of which used DSM-III-R or DSM-IV and little,
if any, used ICD-10 or DSM-5.
There is evidence that over 95% of patients with agoraphobia who
are seen clinically suffer from panic disorder as well (Goisman
1995). According to this finding, we included studies focusing on
agoraphobia, rather than panic disorder, if operationally diagnosed
according to the above-mentioned criteria and when it could be
safely assumed that at least 80% of the participants were suffering
frompanic disorder.We explored the effect of the inclusionof trials
with different percentages of patients suffering from agoraphobia
in a meta-regression analysis.
Setting
Participants must have been outpatients at the time of enrolment.
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Previous treatment
We included both treatment-naive patients and patients who had
already undergone some previous treatment (either psychological
or pharmacological), as long as they satisfied the above-mentioned
inclusion criteria. However, we excluded studies where all partici-
pants had shown resistance to previously administered psycholog-
ical therapies.
Comorbidities
We included studies where participants had other anxiety disorders
(for example, generalised anxiety disorder, specific phobias) orwith
subthreshold panic disorder if: 1) separate results for patients with
panic disorder were reported and 2) randomisation was stratified
by specific diagnoses. Stratification by diagnosis was not required
if the total sample included at least 40 participants with panic
disorder.
We included studies in which the participants had physical co-
morbidities. However, we excluded studies explicitly focusing on
panic disorder or agoraphobia among patients with a certain phys-
ical comorbidity.
We excluded studies in which all participants had a concurrent
primary diagnosis of Axis I or II disorders other than panic disorder
or agoraphobia.
Types of interventions
For this review, we chose to focus on most representative psycho-
logical therapy schools (that is CBT and its components or de-
velopments, psychodynamic psychotherapy and supportive psy-
chotherapy) and their control conditions.
Experimental interventions
We included the following psychological therapies.
1. PE: psychoeducation, intended as sessions in which patients
were only provided information about their disease.
2. SP: supportive psychotherapy, with or without a
psychoeducational component, intended as sessions in which
patients were administered an active, although non-specific,
psychological treatment.
3. PT: physiological therapies that used some kind of physical
training (e.g. breathing retraining, progressive muscle relaxation,
applied relaxation) in order to reduce the physiological
manifestations of anxiety.
4. BT: behaviour therapy, with or without physiological
components, aiming at patients’ habituation to anxiety-
provoking situations and sensations through some kind of
exposure (e.g. interoceptive, in vivo).
5. CT: cognitive therapy, with or without physiological
components and behavioural experiments, aiming at the
modification of maladaptive thoughts through some kind of
cognitive restructuring.
6. CBT: cognitive behaviour therapy, with or without
physiological components, containing both cognitive and
behavioural therapy elements.
7. 3W: third-wave CBT, including acceptance and
commitment therapy, mindfulness-based therapy, and other so-
called ’third-wave’ therapies administered with or without other
CBT components (e.g. exposure, cognitive restructuring,
breathing retraining, muscle relaxation).
8. PD: psychodynamic therapies focused on revealing and
resolving intrapsychic or unconscious conflicts.
When psychoeducation or psychological support, or both, were
accompanied by any other psychological intervention, we classi-
fied the study arms according to the latter and we regarded psy-
choeducation and psychological support as components of that
intervention.
Therapies could be of any length so that we accepted those given
in a single session.
We included both individual and group therapies.
We included the so-called component studies (for example, dis-
mantling studies) as long as each arm could be regarded as any
of the above-defined experimental interventions compared against
another experimental or comparator treatment. Eventually, study
arms could be regarded as giving information about the same ex-
perimental intervention and thus be combined.
Therapies had to be administered face-to-face.We excluded thera-
pies administered in their self help (for example, book, computer,
Internet) or remote (for example, telephone, video-conference)
versions. In the case of psychoeducation, the simple provision of
informational material without any face-to-face session was not
considered an active intervention but rather a comparator inter-
vention, such as no psychological treatment or wait list (however,
we found no similar cases).
We excluded combination therapies.However, we included studies
in which a pharmacological co-administration was allowed as long
as there were no systematic differences in drug administration
between the study arms. The percentage of studies in which a
drug co-administration was allowed, the percentage of studies that
required a stabilisation of therapy and, in this latter case, the time
required for stabilisation, is reported.
We excluded any other psychological approach (such as interper-
sonal therapy (IPT), eye movement desensitisation and reprocess-
ing (EMDR) and Morita therapy) on the grounds that they do
not meet the criteria for a CBT (and its components and develop-
ments), psychodynamic psychotherapy or supportive psychother-
apy.
We excluded family therapy, couple therapy andother psychosocial
interventions whose focus was not the individual but rather the
family system or couple as a whole.
Comparator interventions
1. NT: no psychological treatment (participants received
assessment only, with or without simple provision of
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informational material or minimal therapist contact, or both,
and they knew that they would have not received the active
treatment in question after the trial).
2. WL: wait list (participants received assessment, with or
without simple provision of informational material or minimal
therapist contact, or both, and they knew that they would have
received the active treatment in question after the waiting phase).
3. APP: attention or psychological placebo (participants
received a face-to-face inactive intervention*).
Given the general inconsistency of the definitions of comparator
interventions among different studies, the attribution of a control
group to one of these prespecified categories relied on its detailed
description rather than on the name given by the authors. How-
ever, where a sufficiently detailed description was unavailable, ei-
ther from the paper or by contacting the original authors, the at-
tribution relied solely on the given definition. Particular inconsis-
tency exists in the definition of what is intended for treatment as
usual (TAU). When TAU was intended as no treatment, wait list
or supportive psychotherapy, we classified groups accordingly.
*Attention placebo is defined as any form of inactive intervention
designed by the original authors to be perceived as ineffective by
patients; psychological placebo is defined as any form of inactive
intervention designed by the original authors to be perceived as
effective by patients. The inclusion of an intervention among at-
tention or psychological placebo groups required the intervention
to be inactive. Any form of active intervention was therefore in-
cluded among experimental interventions even if defined as a con-
trol condition by the original authors.
We excluded studies inwhich a pharmacological placebowas either
co-administered or used as the control condition.
In total we expected the network to have 11 nodes, each one
representing an intervention or control (see Data synthesis).
Types of outcome measures
Primary outcomes
1. Short-terma remissionb of panic disorder with or without
agoraphobia
2. Short-term responsec of panic disorder with or without
agoraphobia
3. Dropouts for any reason in the short term (as a proxy for
treatment acceptability)
(a) Short-term, i.e. within six months from treatment commence-
ment. When multiple time point measures in the short term were
available, we gave preference to measures at approximately three
months after treatment commencement.
(b) ’Remission’ was intended as a dichotomous outcome express-
ing the number of patients who reached a satisfactory end state
as defined by global judgement by the original investigators. Ex-
amples are ’panic-free’ and ’no or minimal symptom’ according to
the Clinical Global Impression Severity Scale (Guy 1976).
(c) ’Response’ was intended as a dichotomous outcome expressing
the number of patients who had a substantial improvement from
baseline as defined by the original investigators. Examples are ’very
much ormuch improved’ according to theClinical Global Impres-
sion (CGI) Change Scale (Guy 1976), more than 40% reduction
in the score of the Panic Disorder Severity Scale (PDSS) (Shear
1997), and more than 50% reduction in the Fear Questionnaire
Agoraphobia Subscale (FQ-ag) (Marks 1979).
Whenmore than one index of remission or response was reported,
we gave preference to the most global measure (e.g. in the case of
remission, ’high end-state functioning’ status was usually a more
global index than ’panic-free’ status); when more than one index
was available but measures were equally ’global’, we gave prefer-
ence according to the same criteria used for the continuous scale
outcome (see below). The actual measure entered into the meta-
analysis is indicated in the table of included studies.
Secondary outcomes
4. Short-term improvement of panic disorder with or without
agoraphobia as measured on a continuous scaled
5. Long-terme remission or responsef of panic disorder with or
without agoraphobia
(d) Examples are Panic Disorder Severity Scale (total score 0 to 28),
Panic and Agoraphobia Scale (total score 0 to 45), Clinical Global
Impression Severity Scale (1 to 7), Clinical Global Impression
Change Scale (1 to 7), etc.Whenmore than one scale was available
in the paper, we gave preference in the following order:
• PDSS > Panic and Agoraphobia Scale (PAS) > ASI-R > ASI
> ACQ > BSQ > other scales specific for panic disorder;
• CGI-S > CGI-I > GAS > GAF > other global scales;
• FQ-ag > FQ-global > Mobile Inventory for Agoraphobia-
Avoidance-Alone (MI-AAL) > MI-Avoidance-Accompanied
(MI-AAC) > other scales specific for agoraphobia only;
• panic frequency > panic severity > other scales specific for
panic attacks only.
Once the scale was chosen, if both self and observer-rated assess-
ments were available, we gave preference to the latter. The actual
measure entered into the meta-analysis is indicated in the table of
Characteristics of included studies.
(e) Long-term, i.e. sixmonths or longer after treatment commence-
ment, either on treatment discontinuation or on continued treat-
ment (in the case of long-term therapies). When multiple time
point measures in the long term were available, we gave prefer-
ence to measures at approximately 12 to 15 months after treat-
ment commencement. In the case of missing data at the long-
term assessment, we considered studies for the analyses as long as
dropouts were low in number (< 30% of the original sample) and
evenly distributed across treatment arms.
(f ) ’Response’ and ’Remission’ were intended as above.When both
remission and response rates were reported, we considered the
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former.However, if remission rates were not reported but response
rates were available, we used these for the analyses.
Search methods for identification of studies
CCDAN Specialised Register (CCDANCTR)
The Cochrane Depression, Anxiety and Neurosis Group (CC-
DAN) maintain two clinical trials registers at their editorial base
in Bristol, UK: a references register and a studies-based register.
The CCDANCTR-References Register contains over 40,000 re-
ports of trials in depression, anxiety and neurosis. Approximately
50% of these references have been tagged to individual, coded tri-
als. The coded trials are held in the CCDANCTR-Studies Regis-
ter and records are linked between the two registers through the
use of unique Study ID tags. Coding of trials is based on the
EU-Psi coding manual. Please contact the CCDAN Trials Search
Co-ordinator for further details. Reports of trials for inclusion in
the Group’s registers are collated from routine (weekly), generic
searches ofMEDLINE (1950-), EMBASE (1974-) and PsycINFO
(1967-); quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL) and review-specific searches of ad-
ditional databases. Reports of trials are also sought from interna-
tional trials registers c/oWorldHealthOrganization (WHO) trials
portal (ICTRP), drug companies, handsearching of key journals,
conference proceedings and other (non-Cochrane) systematic re-
views and meta-analyses.
Details of CCDAN’s generic search strategies can be found on the
Group’s website.
Electronic searches
We conducted the following searches (all years) to 16March 2015.
We searched the CCDANCTR-Studies Register using the follow-
ing terms:
Condition/Comorbidity = panic
AND
Intervention = (attention* or behav* or biblio* or biofeedback or
cognitive or collaborative or contact or counsel* or desensiti* or
educat* or expos* or feedback or ”group” or imag* or interpersonal
or intervention or management or panic or prevention or psycho*
or relaxation or self* or stress* or support* or *therap* or *train*
or treatment or unclear or ”not stated”)
We searched the CCDANCTR-References Register using a more
sensitive set of terms to identify additional untagged or uncoded
reports of RCTs (Appendix 1).
We conducted a further search of the CCDANCTR to identify
reports of studies for ‘Anxiety Disorders Not Otherwise Specified’
(ADNOS):
The CCDANCTR-Studies Register was searched for CONDI-
TION = “Anxiety Disorder*”
We manually screened out pharma studies and studies in children
and adolescents.
We searched the CCDANCTR-References Register using the fol-
lowing terms to identify additional untagged or uncoded reports
of RCTs for ADNOS:
(“anxiety disorder*” and not (agoraphobi* or panic or (social and
(anxi* or phobi*)) or generalised or generalized or obsessive or
compulsive or OCD or PTSD or post-trauma* or “post trauma*”
or posttrauma* )) +(terms for psychotherapies as listed inAppendix
1).
We manually screened out pharma studies and studies in children
and adolescents retrieved from this sensitive search of the references
register.
Supplementary searches
We conducted complementary searches in PubMed (Appendix 2)
as well as in trials registries such as the WHO International Clini-
cal Trials Registry Platform (http://apps.who.int/trialsearch/) and
ClinicalTrials.gov (http://clinicaltrials.gov/).
There were no restrictions on date, language or publication status
applied to the searches.
Searching other resources
Reference lists
We checked the reference lists of all included studies and relevant
systematic reviews to identify additional studies missed from the
original electronic searches.
Citation indexes
We conducted a citation search on the Web of Science to identify
articles citing any of the included studies.
Personal communication
We contacted trialists and subject experts for information on un-
published or ongoing studies or to request additional trial data.
Grey literature
We searched the databaseOpenSIGLE (http://www.opengrey.eu/)
to identify reports of trials not formally published in books or
journals.
Data collection and analysis
Selection of studies
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At least two out of three review authors (AP, AT, HI) examined the
titles and abstracts of references identified by the electronic search
strategies described above to check whether the study was likely
to be relevant. We then obtained each potentially relevant study
located in the search as a full article and the same two review au-
thors independently assessed each for inclusion. In the case of dis-
cordance, we sought resolution by discussion. When disagreement
could not be solved by discussion, arbitration was provided by a
fourth author (TAF). Agreement between review authors in the
study selection is reported.We evaluated the discordance in the se-
lection of studies by quantifying both the percentage of agreement
and Cohen’s Kappa (k) (Cohen 1960). Where it was not possible
to evaluate the study because of missing information, we classified
the study as a ’Study awaiting assessment’. The reasons for the
exclusion of trials are reported in the Characteristics of excluded
studies table. Decisions made in the study selection process (along
with number of references and studies, and reasons for exclusion
of studies) are presented in a PRISMA flow diagram.
Data extraction and management
At least two out of three review authors (AP, AT, HI) used a struc-
tured, pilot-tested, Excel data collection form to independently ex-
tract the data from the included studies. Extracted data concerned:
study design, administered interventions (format and timing of
psychological therapy and control condition, therapist training,
intervention components), participants’ characteristics (diagnos-
tic criteria, percentage of agoraphobic patients), outcomes, risk of
bias and publication. Again, we resolved any disagreement either
by discussion or by consultation of a fourth member of the review
team (TAF). If necessary, we contacted authors of studies to obtain
further clarification. Agreement between the data extractors with
regard to primary outcomes is reported.
Assessment of risk of bias in included studies
At least two out of three review authors (AP, AT, HI) indepen-
dently assessed the risk of bias of the included studies using the
tool described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We assessed the following domains.
1. Random sequence generation and allocation concealment
(selection bias).
2. Therapist and researcher allegiance, treatment fidelity
(performance bias).
3. Blinding of outcome assessor (detection bias).
4. Incomplete outcome data reporting (attrition bias).
5. Selective outcome reporting (reporting bias).
We assessed and categorised the risk of bias, in each domain and
overall, into:
• low risk of bias, plausible bias unlikely to seriously alter the
results;
• high risk of bias, plausible bias that seriously weakens
confidence in the results;
• unclear risk of bias, plausible bias that raises some doubt
about the results.
Where inadequate details of randomisation and other characteris-
tics of trials were provided, we classified the risk of bias as unclear,
unless further information could be obtained by contacting the
authors. If the assessors disagreed, we made the final rating by dis-
cussion or with the involvement of another member of the review
group (TAF), if necessary. Agreement between the two indepen-
dent raters in the ’Risk of bias’ assessment is reported (see Risk of
bias in included studies).
We assessed therapist and researcher allegiance, as well as treat-
ment fidelity, as possible sources of performance bias. Blinding of
therapists, the common way to minimise the risk of performance
bias, is not feasible in these kinds of studies.
We evaluated the risk of detection bias for the first of the pri-
mary outcomes only. We classified studies as having a low risk of
detection bias when the identification of a patient as a ’remitter’
required at least one observer rating and the observer was blind to
the treatment allocation.
We separately calculated risk of attrition bias for short-term and
long-term outcomes, whenever such outcomes had been extracted.
We classified a study as being at low risk of attrition bias when data
for all randomised patients were available at short and long-term
assessment. In the case of dropouts, a study may still be assessed
as being at low risk of attrition bias when:
• missing outcome data were few and balanced in numbers
across intervention groups, with similar reasons for missing data
across groups;
• reasons for missing outcome data were unlikely to be
related to true outcome;
• missing data had been imputed using appropriate methods
(last observation carried forward (LOCF) was not considered an
appropriate method in itself. It was considered appropriate only
when the LOCF cases were few and balanced between arms).
Whenever possible, we retrieved study protocols in order to assess
the risk of reporting bias. We considered a study to be at low risk
of reporting bias when the study protocol was available and all
of the study’s prespecified (primary and secondary) outcomes that
are of interest in the review had been reported in the prespecified
way. When the study protocol was not available, we classified the
study as being at unclear risk of reporting bias unless the reported
information was enough to make a judgement (text of this nature
was uncommon).
Measures of treatment effect
Dichotomous data
As the measure of treatment effect for binary outcomes we used
the odds ratio (OR) and its 95% confidence interval (CI).
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Continuous data
Since different studies have used different panic rating scales, we
used the standardised mean difference (SMD) and its 95% confi-
dence interval (CI).
Endpoint versus change data
We first planned to use scale endpoint data, which typically can-
not have negative values and are easier to interpret from a clinical
point of view. However, as a post hoc decision, we decided to use
change data in an attempt to reduce the amount of heterogeneity
due to the baseline imbalance found across studies. This decision,
which is in line with theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011, section 9.4.5.2: “In some circum-
stances an analysis based on changes from baseline will be more effi-
cient and powerful than comparison of final values”) actually led to
a great reduction of heterogeneity, for the continuous outcome, as
compared to the analysis of final scores. In order to compute the
change-from-baseline standard deviationswe followed themethod
described in theCochraneHandbook for Systematic Reviews of Inter-
ventions (Higgins 2011, section 16.1.3.2), assuming a correlation
coefficient of 0.5.
Unit of analysis issues
Cluster-randomised trials
In cluster-randomised trials, groups of individuals rather than indi-
viduals are randomised to different interventions (Higgins 2011).
We planned to include cluster-randomised trials only when the
effects of clustering were taken account of. However, we found no
such cases.
Cross-over trials
Cross-over trials are trials where all participants receive both the
control and intervention treatment but in a different order. The
major problem is a carry-over effect from the first phase to the
second phase of the study, especially if the condition of interest is
unstable (Elbourne 2002). As this is the case with panic disorder,
randomised cross-over studies were eligible but we only used data
up to the point of the first cross-over.
Studies with multiple treatment groups
For both pair-wise and network meta-analyses, where a study in-
volved more than two treatment arms, especially in the case of
dismantling studies, we combined arms as long as they could be
regarded as subtypes of the same psychological therapy under re-
view. When arms could not be regarded as if in each of them a
different subtype of the same intervention was administered, we
compared each arm with the common comparator separately.
When such a situation occurred, we subdivided the common com-
parator arm for pairwise meta-analyses (for example, we halved the
sample size and the number of responders of that arm for dichoto-
mous outcomes; for continuous outcomes, the mean and SD will
remain the same but we halved the number of patients included.
The common comparator was not subdivided for NMA.
Dealing with missing data
We tried to contact the study authors for all relevant missing data.
Dichotomous outcomes
We calculated the proportion of remissions and responses using
an intention-to-treat analysis (ITT) following the principle ’once
randomised always analysed’. To this end, we assumed all ran-
domised patients for which outcome data were not available to be
non-responders. This assumption has been used in two previous
NMAs (comparing antidepressants and antimanic drugs) and has
proven to be a sensible assumption (Spineli 2013). We applied the
same principle to short and long-term outcomes. When dichoto-
mous outcomes were not reported but the means and standard
deviations on a panic disorder scale were reported, we calculated
the number of responding or remitted participants according to a
validated imputation method (Furukawa 2005). In order to check
the reliability of imputed data, we used the ANOVA intraclass cor-
relation coefficient (ICC) to calculate agreement between reported
and imputed data (absolute numbers of remitters and responders)
whenever they were calculated on the same scale. The ANOVA
ICC was 0.81 (0.58 to 0.93) for short-term remission and 0.99
(0.94 to 1.000) for short-term response, showing an excellent cor-
relation between reported and imputed data.
Continuous outcomes
We performed an ’available cases analysis’ in which outcomes were
analysed on the basis of a pre-post change. Where change scores
were not reported but baseline and endpoint data were available
(including patients with either a final assessment or a LOCF to the
final assessment as reported in the original report), we calculated
change scores and entered them in the analyses.
Missing statistics
When only P or standard error (SE) values were reported, we
calculated standard deviations (SDs) (Altman 1996). If none of
these values were available, and in the absence of supplementary
data after requests to the authors, we calculated the SDs according
to a validated imputation method (Furukawa 2006).
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Assessment of heterogeneity
Pairwise meta-analyses
For each direct comparison, we calculated the Chi2 test and I2
statistic in order to detect the presence of heterogeneity and, re-
spectively, assess its degree. I2 provides an estimate of the percent-
age of variability in effect estimates that is due to heterogeneity
rather than chance alone (Higgins 2003). We interpreted I2 val-
ues according to the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011), section 9.5.2. We also report τ 2,
the between study variance in random-effects model meta-analy-
sis. We also used visual inspection of the forest plots in order to
investigate the presence and nature of statistical heterogeneity.
Network meta-analysis (NMA)
An assumption underlying NMA is that effect modifiers are sim-
ilarly distributed across comparisons in the network. That means
that an effect modifier should be similar in AB and BC trials in
order to obtain a valid AC estimate. Equivalent formulations of
the transitivity assumption are presented in Salanti 2012. In or-
der to verify this assumption, for each comparison we compiled
a table of important trial and patient characteristics and visually
inspected the similarity of factors we considered likely to mod-
ify treatment effect. We also assessed the inclusion and exclusion
criteria of every trial in the network to ensure that patients, trial
protocols, etc. were similar in those aspects which might modify
the treatment effect.
Lack of transitivity can be manifested in the data as disagreement
between direct and indirect evidence (Caldwell 2005; Lu 2004;
Lumley 2002). This can be evaluated statistically by contrasting
the direct and the indirect estimates and calculating a test within
each closed loop (Bucher 1997; Salanti 2009). The percentage
of inconsistent loops in the network is reported. We examined
further the data of loops that appeared particularly inconsistent. As
this approach does not provide an omnibus test and is associated
with multiple testing we also employed other approaches to make
inferences about the statistical inconsistency. More precisely, we
performed a design-by-treatment interaction test (Higgins 2012).
When a small amount of inconsistencywas found,we incorporated
this in the estimation by fitting inconsistency models (Higgins
2012; Lu 2004).
Assessment of reporting biases
We examined the funnel plots for those pairwise comparisons for
which at least 10 studies were available. We investigated the pres-
ence of small study effects for the primary outcomes only; along
with visual inspection of the plots, we formally examined whether
the association between estimated intervention effects and the
study size was greater than it might have been expected to occur
by chance.
Data synthesis
Main planned comparisons
The present study is a network meta-analysis and therefore aims to
compare all the listed interventions and control conditions against
one another in terms of the listed primary and secondary out-
comes. In the network, each node represents an experimental or
control condition; comparisons explored in included trials are rep-
resented by lines connecting the nodes. Ideally, the network should
consist of 11 nodes, each connected with all the others, mean-
ing that all the listed interventions and each possible comparison
among them has been directly explored in at least one included
trial (see Figure 1). Please refer to Appendix 3 for details about the
software used for the analyses described below.
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Figure 1. Ideal network of included treatment and control conditions.
Pairwise meta-analyses
For each available comparison explored by at least two trials, we
performed a pairwise meta-analysis in order to provide overall es-
timates of treatment effect. Since we expected some clinical het-
erogeneity between studies, we planned to use a random-effects
model to incorporate the assumption that the different studies are
estimating different, yet related, treatment effects (Higgins 2011).
We therefore calculated an ’average’ treatment effect across the
studies for each available comparison. For dichotomous outcomes,
we calculated the average odds ratio with the 95% CI; for con-
tinuous outcomes we calculated the average SMD (or the MD if
all trials use the same scale) with the 95% CI. Studies with zero
events in all arms (as in the case of short-term dropouts) were not
included in the analyses.
In order to have comparable results with the NMA (see below),
beside performing standard pairwise meta-analyses, we also per-
formed the analyses assuming a common heterogeneity standard
deviation across all comparisons. This way, all pairwise meta-anal-
yses were essentially analysed as random-effects (they include un-
certainty due to heterogeneity), even for those comparisons only
being reported by one study.
For this review, the results of pairwise comparisons are part of the
more complex network meta-analyses. However, in order to better
show the available ’direct’ evidence, forest plots are presented for
pairwise comparisons when at least 10 studies are available.
Network meta-analysis (NMA)
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An indirect comparison allows an estimate of the effect of treat-
ment B relative to treatment A via a common comparator C by
statistically combining the summary effects from ’A versus C’ and
’B versus C’ studies (Caldwell 2005; Glenny 2005). A NMA com-
bines direct and indirect evidence across a network of studies to
make inferences regarding the relative effectiveness of multiple in-
terventions.
A NMA is only possible for a connected set of treatments. A net-
work diagram is constructed for our primary and secondary out-
comes in order to evaluate the extent to which treatments are con-
nected.
We conducted a random-effects model NMA, taking into account
the correlations induced by multi-arm trials (Lu 2004; Salanti
2008; White 2012). For each comparison, an average effect esti-
mate along with its 95% confidence interval (CI) is reported.
Besides yielding relative treatment effects for each comparison, a
NMA allows an estimate of the relative ranking of treatments. To
rank the treatments according to each outcome accounting for the
uncertainty in the treatment effects, we used the surface under the
cumulative ranking curve (SUCRA) (Salanti 2011). The absolute
ranks of the treatments per outcome is presented using ’Ranko-
grams’ that visually show the distribution of ranking probabilities
(Salanti 2011).NMAmodels typically employ a single heterogene-
ity parameter. We reported it and, for dichotomous outcomes, we
judged its magnitude against the distribution of values typically
found in Cochrane reviews, as presented in Turner 2012.
Subgroup analysis and investigation of heterogeneity
Subgroup and meta-regression analyses are often exploratory in
nature and should be interpreted cautiously. Firstly, because these
analyses often involve multiple analyses, they may yield false pos-
itive results; secondly, because these analyses lack power and are
more likely to result in false negative results. Keeping in mind the
above reservations, we performed meta-regression analyses to in-
vestigate, for the first of the primary outcomes only (short-term
remission of panic disorder with or without agoraphobia), the fol-
lowing candidate explanatory variables.
• Year of publication (measured as a continuous variable) as a
general proxy for various aspects (e.g. trial quality, definition of
diagnosis and outcomes).
• Mean number of treatment sessions: fewer than four
sessions, from four to 12 sessions, more than 12 sessions.
Considerable differences exist in the number of treatment
sessions between studies. It seems reasonable to expect this
variability to yield some degree of heterogeneity.
• Therapist training: therapist with or without formally
recognised specific training in the type of psychological therapy
administered.
• Percentage of patients with agoraphobia: measured as a
continuous variable.
• Percentage of patients with depression: measured as a
continuous variable. We explored this variable in order to
investigate if a psychological intervention specifically designed
for panic disorder is less effective in patients with depressive
comorbidity.
• Percentage of patients on drug treatment: measured as a
continuous variable. Since we were not including studies
exploring combined therapies, drug-treated patients, when
included, were often those who meet the diagnosis of panic
disorder despite being on psychopharmacologic treatment. By
considering such patients as being ’drug-resistant’, we may have
expected them to have a poorer outcome; however, since there is
evidence that combined therapies are more effective than
psychological therapies alone in the short term (Furukawa 2007),
we could also have expected that such patients had a better
outcome compared with patients who were not on drug
treatment.
Sensitivity analysis
The process of undertaking a systematic review and meta-analysis
involves a sequence of decisions, some of which are somewhat
arbitrary or unclear (Higgins 2011). A sensitivity analysis is a repeat
of the primary analysis, substituting alternative decisions or range
of values for decisions that were arbitrary or unclear. We planned
to perform the following sensitivity analyses for the first of the
primary outcomes only (short-term remission of panic disorder
with or without agoraphobia).
• Restrict the inclusion in the analyses only to studies
considered to be at low risk of selection and detection bias (i.e.
adequate allocation sequence generation, adequate allocation
concealment, blinding of assessor).
• Exclude from the analyses group therapy trials.
• Exclude from the analyses trials in which a concomitant
pharmacotherapy is allowed.
• Exclude from the analyses trials in which drug therapy is
not stabilised*.
• For pairwise meta-analyses, use a fixed-effect model instead
of a random-effects model.
(*) Drug therapy was considered stabilised when: 1) drug admin-
istration remained stable before randomisation (for at least four
weeks in the case of antidepressants and for at least two weeks in
the case of benzodiazepine and other drugs), and 2) patients were
asked to avoid any drug therapy change for the whole duration of
the study.
’Summary of findings’ tables
Aiming to summarise the results in away that could be as ’clinically
informative’ as possible, we originally planned to present the main
results of pairwise meta-analyses in three ’Summary of findings’
tables.
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In a first table we planned to present the NMA results of the
comparison between the psychological therapy that would have
ranked first versus the no treatment condition (NT) in order to
show the effects of the supposedly most effective treatment when
compared to no intervention at all.
In a second table we planned to present the NMA results of the
comparison between the psychological therapy that would have
ranked first versus supportive psychotherapy (SP) in order to show
the effects of the supposedly most effective treatment when com-
pared to a non-specific psychological intervention.
In a third table we planned to present the NMA results of the
comparison between the psychological therapy that would have
ranked first versus the one that would have ranked second, in order
to show the magnitude of the effect sizes across the two active
interventions representing the supposedly most viable therapeutic
options.
Since the ’wait list’ and ’attention or psychological placebo’ con-
ditions are useful comparators for clinical trials, but do not rep-
resent treatment options in a ’real’ clinical setting, we considered
the choice of using the NT and SP conditions as comparators to
be more clinically informative.
As a post-hoc decision, we decided to add an extra SoF table to
summarize the overall results of networkmeta-analyses by present-
ing the ranking of treatments yielded by these analyses for each out-
come. We came to this decision because we found the simple pre-
sentation of pairwise comparisons, singularly taken, insufficient to
adequately depict the overall complexity of this type of analyses.
SoF table formats for NMAs are currently under development by
the Cochrane GRADEing Group (http://methods.cochrane.org/
gradeing/research), so we adapted the standard SoF for pairwise
comparisons in order to present treatment hierarchy.
All the presented Sof tables include an assessment of the qual-
ity of evidence obtained by following the approach proposed by
the Grading of Recommendations, Assessment, Development and
Evaluation (GRADE) Working Group. This approach consists in
rating the quality of evidence according to study design (RCT or
observational studies) and other five factors: risk of bias of the in-
cluded studies, consistency of results, directness of evidence, pre-
cision of results and presence of publication bias. It must be noted
that at the time of writing, standard GRADE tools (usually em-
ployed to assess the quality of evidence in pairwise meta-analyses)
were not yet developed for NMA, where many comparisons, each
with its own quality of evidence, contribute to the overall quality
with different weights. Therefore, our assessments of the quality
of evidence for the results of network meta-analyses were imple-
mented by adapting the GRADE tools to this type of analysis,
in line with the methodology suggested in Salanti 2014 and with
interim guidance from the Cochrane Comparing Multiple In-
terventions Group (Cochrane Comparing Multiple Interventions
Group).
R E S U L T S
Description of studies
Results of the search
The number of references identified by the searches, run toMarch
2015,was 2468.Of these, 1482 remained after de-duplication.We
excluded 885 references after assessment of the titles and abstracts.
We retrieved a total of 597 full-text papers (345 studies) for full
inspection. Of these 345 studies, we excluded 269 with reasons,
five were ongoing trials and 11 presented too little information
to be classified. We included the remaining 60 studies in the final
qualitative analyses; among these, we also included 54 in the final
quantitative analyses. See Figure 2 for a PRISMA flow diagram
depicting the study selection process.
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Figure 2. Study selection process: PRISMA flow diagram
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Cohen’s weighted kappa among assessors for the selection of 338
studies was 0.66 (percentage of agreement = 79.6%).
We contacted authors of 67 studies for additional information: in
25 cases we received a complete reply, in eight cases we received
an incomplete reply and in the remaining 34 cases we received no
reply. For six studies we have been unable to contact the author.
Included studies
We included 60 studies in this review, among which we included
54 in quantitative analyses. Five studies were published only as
doctoral dissertations (Creager Berger 2001;Griegel 1995;Karekla
2004; Muncy 1991), or briefly described in a book chapter (Beck
1987; Karekla 2004).
The characteristics of the included studies can be summarised as
follows (see also Characteristics of included studies).
Design
All included studies were randomised controlled trials. In only one
case the study had a cross-over design (Beck 1992), although only
patients firstly assigned to the control group did actually cross over
in the second phase of the treatment. Only three studies had a
multicentre design.
Sample sizes
In four cases the total number of randomised patients was unclear;
for the remaining 56 studies, the total sample size went from 17
(Malbos 2011) to 369 patients (Gloster 2010), with amean sample
size of 60 patients (standard deviation (SD) 52). The total number
of patients included in the analyses is 3021.
Setting
Apart from one single case (Hoffart 1995), which was conducted
in an inpatient setting, all studies were conducted in an outpatient
setting.
Participants
The presence of agoraphobia was never an exclusion criteria. Par-
ticipants were therefore diagnosed with panic disorder with or
without agoraphobia, and diagnosis was mostly based on DSM-
III, DSM-III-R orDSM-IV; in only one case it was based on ICD-
10.
Age usually ranged between 30 and 40 years. The percentage of
agoraphobic patients, when specified, ranged from 18% to 100%,
being above 65% in the majority of cases. In about half of the in-
cluded studies participants were required to be off medication for
the duration of the trial; in the remaining cases, the percentage of
patients on drug treatment, when reported for the full intention-
to-treat (ITT) sample, varied from 19% to 67%. In only a few
studies comorbid depression was an exclusion criteria; the percent-
age of depressed patients in the remaining cases, when reported
for the full ITT sample, varied from 7% to 52%.
Interventions
Among experimental interventions, cognitive behaviour therapy
(CBT) was by far the most studied (42 of the 54 studies included
in quantitative analyses), followed by behaviour therapy (13 stud-
ies) and physiological therapies (12 studies). Other psychological
therapies were studied to a lesser degree: CT in six studies, SP in
three studies, 3W in two studies, PD in two studies and PE in
one study. In the majority of studies, the control condition was
represented by a wait list (30 studies); APP was used in only three
studies and NT in two.
Psychological therapy was individually administered in 18 studies,
whereas a group therapywas used in 13 studies. In one case patients
could receive both types of therapy evenwithin the same study arm.
In 22 studies the therapy format was not specified. The number of
sessions went from 1 to 24 (the average was 10 sessions): sessions
were weekly in almost every study. Each session could last from
30 to 150 minutes (average 73 minutes).
Therapists were specifically trained in the administered interven-
tion in most of the studies (n = 37). No specific training was re-
quired in six studies. No detail about therapist training was re-
ported in the remaining 11 studies.
Only 25 of the 54 studies included in quantitative analyses spec-
ified the percentage of patients receiving a drug therapy during
the trial. Among these, 12 studies reported that patients were not
receiving any drug therapy; the remaining 13 studies reported per-
centages from 19% to 67% (average value 45%). Drug stabilisa-
tion before study commencement was required in 27 studies, and
the stabilisation period ranged from 1 to 24 weeks. Furthermore,
30 studies required patients not to change the dosages of taken
medications for the entire duration of the study whereas four stud-
ies left the patients free to change dosages; in the remaining 20
studies no information on this issue were reported.
Outcomes
In terms of outcomes, we observed great variability. The most
common measures were: panic frequency, Anxiety Sensitivity In-
dex (ASI), Body Sensations Questionnaire (BSQ), Agoraphobic
Cognitions Questionnaire (ACQ), Panic Disorder Severity Scale
(PDSS), Mobility Inventory for Agoraphobia (MI), Fear Ques-
tionnaire (FQ), State-Trait Anxiety Inventory (STAI) and Beck
Anxiety Inventory (BAI). Remission was often defined as being
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panic-free, although many other measures were used, such as scor-
ing below a certain cut-off for any of the above mentioned scales,
ormeeting a composite index of high end-state functioning (where
the set of criteria varied among different studies).
Excluded studies
We excluded a total of 269 studies because they did not meet our
inclusion criteria regarding the type of study (n=60), the type of
participants (n=102) or the type of interventions (experimental
intervention, n=57; comparator intervention, n=50).
Among the excluded studies, 12 initially seemed to meet our in-
clusion criteria, but were subsequently excluded for the reasons
reported in Characteristics of excluded studies.
Ongoing studies
We identified five ongoing studies. Two of these are two-arm trials
exploring respectively CBT versus BT and CBT versus NT. The
remaining four studies are multi-arm trials exploring, respectively:
two different types of CBT versus WL; CBT versus two differ-
ent types of BT; CBT versus PD versus PT; randomised CBT/
PD versus chosen CBT/PD versus WL. For further details, see
Characteristics of ongoing studies.
Studies awaiting classification
We identified 11 potentially eligible studies that have not yet been
incorporated into the review. Details of these studies are presented
in the table of Characteristics of studies awaiting classification.
Apart from the case of Franklin 1990 (for which we were unable
to contact the authors), all other authors have been contacted. We
received a reply for two studies: Irgens 2009 (author unwilling to
release full report before publication) and Richards 1997 (author
himself was unable to retrieve the full paper).
Risk of bias in included studies
For details of the risk of bias judgements for each study, see
Characteristics of included studies. A graphical representation of
the overall risk of bias in included studies is presented in Figure
3 and Figure 4. The reporting and methodological quality of in-
cluded studieswas overall not good.This type of reportinghas been
associated with an overestimate of the estimate of effect (Schulz
1995), and this should be considered when interpreting the re-
sults. Agreement between the two independent raters in the ’Risk
of bias’ assessment was overall low, ranging from 47% to 88%
(weighted Kappa showed an even lower agreement, although this
estimate may be negatively influenced by skewed distribution of
assessments): this may be due to the relatively poor expertise of
raters together with the generally low quality of reporting and to
the high degree of methodological variability between studies.
Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 4. ’Risk of bias’ summary. Note that we left the boxes empty when the RoB assessment was not
applicable (e.g. in the case of incomplete outcome data in the long term when the study did not report any
long term measure that could be included in the analyses).
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Allocation
The majority of studies did not report the methods of generating
the random sequence, nor details about allocation concealment.
We assessed only four studies as being at low risk of bias for both
sequence generation and allocation concealment (Botella 2004;
Malbos 2011; Meulenbeek 2008; Milrod 2006a). Agreement be-
tween the two independent raters in the risk of allocation bias as-
sessment was 88% (weighted Kappa 0.47 for sequence generation
and 0.29 for allocation concealment).
Blinding
We have rated the risk of bias for blinding of outcome assessment
in relation to the first of our primary outcomes only (short-term
remission), whenever available (either reported or imputed from
continuous scale), in relation to the measure actually entered in
the analyses (in this sense, our aim was not to rate study quality but
rather the quality of available data). We considered eight studies
to be at low risk of bias (Al Kubaisy 1992; Beutel 2013; Clark
1994; Clark 1999; Griegel 1995; Hoffart 1995; Klosko 1988;
Milrod 2006a); we considered 22 studies to be at high risk of
bias; 10 studies did not report enough information to make a
judgement. In the remaining cases, we did not rate blinding of
outcome assessment because data regarding short-term remission
were not available. Agreement between the two independent raters
in the risk of detection bias assessment was 47% (weighted Kappa
0.16).
Incomplete outcome data
We have rated the risk of incomplete outcome reporting when at
least one relevant outcome was available (as for blinding, our aim
was not to rate study quality but rather the quality of available
data). Agreement between the two independent raters in the risk
of attrition bias assessment was 59% (weighted Kappa 0.36) for
short-term outcomes and 50% (weighted Kappa 0.12) for long-
term outcomes.
Short-term
We have rated the risk of bias for incomplete outcome data as-
sessment in relation to short-term outcomes whenever at least one
of such outcomes was reported (ST-remission, ST-response, ST-
dropouts, ST-improvement as measured on a continuous scale).
We have rated 22 studies as being at low risk of attrition bias and
27 studies as being at high risk; five studies did not report enough
information to make a judgement.
Long-term
We have rated the risk of bias for incomplete outcome data as-
sessment in relation to long-term remission or response, whenever
reported. Long-term outcome data were available in 13 studies,
among which we rated five as being at low risk of attrition bias and
six as being at high risk; three studies did not report enough infor-
mation to make a judgement. In two cases (Cottraux 2009; Shear
1994), we did not enter long-term outcome data in the analyses
because of excessive loss of data at follow-up assessments (see also
Secondary outcomes).
Selective reporting
A study protocol was available for seven of the included studies
(Beutel 2013; Cottraux 2009; Hendriks 2010; Meulenbeek 2008;
Meyerbroker 2011;Milrod 2006a;Wollburg 2011).We rated only
three studies as being at low risk of selective outcome reporting
(Cottraux 2009; Hendriks 2010; Milrod 2006a). We rated 12
studies as being at high risk (assessment was sometimes possible
in the absence of a study protocol, when the results of measures
planned in the methods section were omitted from the study re-
port). In all the remaining cases reporting bias could not be as-
sessed. Agreement between the two independent raters in the risk
of reporting bias assessment was 85% (weighted Kappa 0.56).
Other potential sources of bias
Researcher allegiance
In almost 50% of cases we rated studies as being at high risk of bias
due to researcher allegiance, which can be considered a general
proxy of various forms of bias that could affect results in favour of
one or more study arms towards which authors may have a vested
interest (i.e. authors may be involved in the conceptualisation of
the treatment or in the developing of a treatment manual). In this
sense, this source of bias can be considered analogue to sponsor-
ship bias in studies involving pharmacological treatments. Agree-
ment between the two independent raters in the risk of researcher
allegiance bias assessment was 50% (weighted Kappa 0.34).
Therapist allegiance
We first hypothesised that therapist allegiance may constitute a
risk of bias (as backed up by our own clinical sense and some
literature). When we rated this item, however, the agreement was
low. We went back to the original studies and found that they
rarely provided enough information to make solid judgements.
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We therefore re-rated the risk of bias for therapist allegiance as
’unclear’ when there was not enough information, which was the
case for all studies except two, that is Addis 2004 and Telch 1993,
rated as being respectively at low and high risk of bias. Agreement
between the two independent raters in assessing the risk of this
performance bias was 55% (weighted Kappa -0.02).
Treatment fidelity
We rated 26 of the included studies as being at low risk of bias
with regard to treatment fidelity and three studies as being at high
risk. In the remaining 31 studies, the available information was
not enough to make a judgement. Agreement between the two
independent raters in the risk of this performance bias assessment
was 79% (weighted Kappa 0.63).
Effects of interventions
See: Summary of findings for the main comparison Cognitive
behaviour therapy compared to no treatment for panic
disorder with or without agoraphobia in adults; Summary of
findings 2 Cognitive behaviour therapy compared to supportive
psychotherapy for panic disorder with or without agoraphobia
in adults; Summary of findings 3 Cognitive behaviour therapy
compared to psychodynamic psychotherapy for panic disorder
with or without agoraphobia in adults; Summary of findings
4 Network meta-analysis rankings of psychological therapies for
panic disorder with or without agoraphobia in adults
1. Short-term remission of panic disorder with or
without agoraphobia
1.1 Network plot
Figure 5 shows a graphical representation of the network. Nodes
and edges were weighted according to the number of studies in-
cluding the respective treatments and comparisons. As shown in
the figure, short-term (ST)-remission data were available for six
active and two comparison interventions. No study explored ST-
remission for third-wave CBT (3W), psychoeducation (PE) and
attention-psychological placebo (APP). CBT was the most stud-
ied intervention, followed by behaviour therapy (BT), physiolog-
ical therapies (PT), cognitive therapy (CT) and supportive psy-
chotherapy (SP). Waiting list (WL) was the most studied among
comparator interventions. Themost studied comparisonwasCBT
versus WL, followed by CBT versus BT. The network appeared
to be well connected, with the only exception being supportive
psychotherapy (SP), studied only in the comparison versus CBT.
Forty studies including 2491 participants contributed data to this
outcome.
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Figure 5. Short-term remission: network plot
1.2 Pairwise meta-analyses and their heterogeneity and
small study effects
Pairwise meta-analyses
As explained in the methods section, in order to have comparable
results with the NMA, beside standard pairwise meta-analyses, we
have performed the analyses assuming a common heterogeneity
standard deviation across all comparisons. The (common) hetero-
geneity standard deviation was estimated to be τ = 0.69.
As summarised in the left part of Table 1, direct evidence was
available for 15 comparisons. For seven of these comparisons there
was only one study available; for the remaining eight comparisons
we performed a random-effects meta-analysis. As shown in the
table, only two comparisons were informed by 10 or more studies,
that is CBT versus WL (18 studies) and CBT versus BT (10 stud-
ies): their forest plots are respectively presented in Figure 6 and
Figure 7. Among psychological therapies, four were shown to be
significantly better thanWL in terms of short-term remission: PT
(four studies; odds ratio (OR) 4.8, 95% confidence interval (CI)
1.4 to 17), BT (three studies; OR 8.3, 95% CI 2.3 to 25), CT
(two studies; OR 8.3, 95% CI 1.6 to 50) and CBT (18 studies;
OR 7.7, 95% CI 4.5 to 14.3). The comparison CBT versus BT is
the only comparison among two active treatments that showed a
statistically significant difference in terms of short-term remission,
which was in favour of CBT (10 studies; OR 2.09, 95% CI 1.10
to 3.97).
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Figure 6. Short-term remission: forest plot for the comparison WL vs CBT
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Figure 7. Short-term remission: forest plot for the comparison CBT vs BT
Heterogeneity
The I² values and their 95% CIs, for the comparisons reported in
three studies or more, are presented in Table 2. As shown in the
table, we observed the highest I² values in the comparisons CBT
versusWL (I² = 58,1%) and PT versus WL (I² = 56%). According
to the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011, section9.5.2) these values suggest that, in these two
comparisons, a moderate percentage of the observed variability in
the effect estimates was due to heterogeneity rather than sampling
error (chance). In the comparison CBT versus WL, heterogeneity
appeared to be related to small study effect (see below); in the
case of PT versus WL (four studies), heterogeneity was due to the
study Griegel 1995, a three-arm trial (PT versus PT versusWL) in
which no remission (i.e. panic-free status) was observed in the two
active treatment arms whereas one case of remission was observed
in the wait list. In this study, therefore, the unexpected OR was
due to the low number of events across all arms.
Small study effects
Following the protocol, we produced funnel plots for all compar-
isons appearing in more than 10 studies. There were two com-
parisons appearing in 10 studies or more, that is WL versus CBT
(Figure 8) andCBTversusBT (Figure 9). From the first funnel plot
there was evidence of asymmetry. More specifically, small studies
were missing in the lower right part of the funnel plot. This means
that small studies comparing WL to CBT that (relatively) favour
WL seemed to be missing: in other words, small studies showed
CBT to be more efficacious. We performed a meta-regression for
the WL versus CBT comparison, which formally confirmed the
presence of a statistically significant correlation between the effect
size (log odds ratio) and the variance. The contour-enhanced fun-
nel plot for the comparison WL versus CBT (Figure 10) showed
that studies were missing in the area of non-significance, thus sug-
gesting the role of publication bias behind the small study effect
(SSE). We found no evidence of asymmetry in the funnel plot for
the comparison CBT versus BT.
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Figure 8. Short-term remission: funnel plot for the comparison CBT vs WL
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Figure 9. Short-term remission: funnel plot for the comparison CBT vs BT
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Figure 10. Short-term remission: contour-enhanced funnel plot for the comparison CBT vs WL
1.3 Network meta-analysis and its inconsistency
Network meta-analysis
As explained in the previous paragraph, it was evident from the
funnel plots that there were small study effects (SSE) present in
the network for the comparison CBT versus WL. We found it
reasonable to assume that there were SSE in all other comparisons
versus WL, even though we might not have had enough studies to
see this effect. The presence of SSE implies that a simpleNMAmay
produce biased results. For this reason we performed a network
meta-analysis adjusting for SSE in studies comparing all other
treatments to WL, by regressing on the variance of the study (see
Discussion). We performed the network meta-analysis adjusted
for SSE in WinBUGS. Thus the results are expressed in terms
of credible intervals (CrI) and we use the median (instead of the
mean) because the posterior distribution of the estimated odds
ratios is asymmetrical.
Results of the networkmeta-analysis (NMA) for short-term remis-
sion, unadjusted and adjusted for SSE, are presented in Table 1.
Indirect evidence could be calculated for 13 comparisons forwhich
direct evidence was unavailable. The comparison between CBT
and WL remained statistically significant also within the context
of NMA, showing an OR of 3.0 in favour of CBT (95% CrI 1.5
to 6.3) in the analyses adjusted for SSE (note that the point esti-
mate in standard NMA was higher, with an OR of 8.3). Although
unadjusted NMA basically confirmed the results of pairwise meta-
analyses for PT, CT and BT in the comparison versus WL, re-
sults ceased to be statistically significant in the NMA adjusted for
SSE. We found supportive psychotherapy (SP) to be significantly
better than WL (OR 4.5, CrI 1.3 to 16.7); however, this finding
must be interpreted with caution since SP is included in the net-
work as a node with a single connection (see Discussion). Finally,
two comparisons among active treatments, that is CBT versus BT
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and CBT versus PT, showed a statistically significant difference
in terms of short-term remission, in both cases in favour of CBT,
with an OR respectively of 1.77 (CrI 1.02 to 3.11) and 1.95 (CrI
1.02 to 3.97).
Network heterogeneity and inconsistency
For both adjusted and unadjusted NMAs, the estimated values of
heterogeneity lay well within the range of values usually found in
Cochrane reviews, as presented by Turner 2012.
We compiled a table of important trial and patient characteris-
tics including therapy duration and percentage of agoraphobic,
depressed and drug treated patients. Its visual inspection showed
that those effect modifiers were similarly distributed across com-
parisons in the network: we therefore concluded that there wasn’t
important evidence against the transitivity assumption.
We compared the inconsistency factors using the loop-specific ap-
proach (where we allow the same τ for all comparisons in a loop)
before and after the adjustment for small study effects. We ob-
served no important differences and all inconsistency factors were
statistically non-significant in both cases. One, however, should
note that this does not constitute a proof for consistency in the
network: some of the loops include few studies and the corre-
sponding factors are estimated with much uncertainty. In Figure
11 we give all inconsistency factors for the network. As shown in
the figure, we observed the highest inconsistency factor in the loop
PT-CBT-PD.
Figure 11. Short-term remission: inconsistency factors for the network
The design-by-treatment interaction model provided no proof of
global inconsistency in the network (Chi2 = 4.32 with 13 degrees
of freedom; P value for the null hypothesis of consistency in the
network 0.98). Also, using the design-by-treatment inconsistency
model we got an estimate of τ = 0.85, a value higher than the one
we obtained from the consistency model. Thus, we conclude that
therewas noproof of inconsistency in the network. Again, this does
not constitute a proof of the absence of consistency because the
network was underpowered to detect any important disagreement
between direct and indirect evidence.
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1.4 Ranking of treatments
The ranking of treatments with respect to short-term remission,
according to the surface under the cumulative ranking curve (SU-
CRA) value derived from NMA adjusted for small study effects,
is presented in Table 3. We observed the highest rankings respec-
tively for supportive psychotherapy, cognitive behaviour therapy
and psychodynamic therapy. However, results regarding support-
ive psychotherapy must be interpreted with caution because, as
specified earlier, SP is included in the network as a node with a
single connection to the network, being compared only with CBT
(three studies, OR 1.5 in favour of SP, 95% CrI 0.6 to 4).
2. Short-term response of panic disorder with or
without agoraphobia
2.1 Network plot
Figure 12 shows a graphical representation of the network. Nodes
and edges were weighted according to the number of studies in-
cluding the respective treatments and comparisons. The network
is similar to the one for ST-remission: as shown in the figure, ST-
response datawere available for six psychological therapies and two
control interventions. No study explored ST-response for third-
wave CBT (3W), psychoeducation (PE) and attention-psycholog-
ical placebo (APP). CBT appeared to be the most studied inter-
vention, followed by behaviour therapy (BT), physiological ther-
apies (PT), cognitive therapy (CT) and supportive psychotherapy
(SP). Wait list (WL) was the most studied among comparator in-
terventions. The most studied comparison was CBT versus WL,
followed by CBT versus BT. The network appeared to be well con-
nected, with the only exception being supportive psychotherapy
(SP), studied only in the comparison versus CBT. Thirty-seven
studies including 2240 participants contributed data to this out-
come.
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Figure 12. Short-term response: network plot
2.2 Pairwise meta-analyses and their heterogeneity and
small study effects
Pairwise meta-analyses
As for short-term remission, in order to have comparable results
with the NMA we have performed the pairwise meta-analyses as-
suming a common heterogeneity variance across all comparisons.
The (common) heterogeneity standard deviation was estimated to
be τ = 0.55.
As summarised in the left part of Table 4, direct evidence was
available for 15 comparisons. For eight of these comparisons there
was only one study available; for the remaining seven comparisons
we performed a random-effects meta-analysis. As shown in the
table, only two comparisons were informed by 10 or more studies,
that is CBT versus WL (17 studies) and CBT versus BT (10 stud-
ies): their forest plots are respectively presented in Figure 13 and
Figure 14. Among psychological therapies, three were shown to
be significantly better than WL in terms of short-term response:
PT (four studies; OR 6.67, 95% CI 2.27 to 20), BT (four studies;
OR 3.13, 95% CI 1.37 to 7.14) and CBT (17 studies; OR 5.26,
95% CI 3.23 to 20). The comparison CBT versus BT is the only
comparison among two active treatments that showed a statisti-
cally significant difference in terms of short-term remission, which
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was in favour of CBT (10 studies; OR 1.78, 95% CI 1.0 to 3.18).
Figure 13. Short-term response: forest plot for the comparison WL vs CBT
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Figure 14. Short-term response: forest plot for the comparison CBT vs BT
Heterogeneity
I² values and their 95% CIs, for the comparisons reported in three
studies or more, are presented in Table 5. As shown in the table,
we observed the highest I² values in the comparisons CBT versus
PT (I² = 45%) and WL versus CBT (I² = 39%). According to
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011, section 9.5.2) these values suggest that, in these two
comparisons, a moderate percentage of the observed variability in
the effect estimates was due to heterogeneity rather than sampling
error (chance). In the case of CBT versus PT (four studies) we
could not find a clear explanation for the observed heterogeneity;
in the comparison CBT versus WL heterogeneity appeared to be
related to small study effects (see below), as was the case for short-
term remission.
Small study effects
Following the protocol, we produced funnel plots for all compar-
isons appearing in more than 10 studies. There were two com-
parisons appearing in 10 studies or more, that is WL versus CBT
(Figure 15) and CBT versus BT (Figure 16). From the first fun-
nel plot there was evidence of asymmetry. More specifically, small
studies were missing in the lower right part of the funnel plot. This
means that small studies comparing WL to CBT that (relatively)
favour WL seemed to be missing: in other words, small studies
showed CBT to be more efficacious. Similar to ST-remission, the
contour-enhanced funnel plot for the comparisonWLversus CBT
(not presented) showed that studies were missing mainly in the
area of non-significance, thus suggesting the role of publication
bias behind the SSE. We found no evidence of asymmetry in the
funnel plot for the comparison CBT versus BT.
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Figure 15. Short-term response: funnel plot for the comparison WL vs CBT
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Figure 16. Short-term response: funnel plot for the comparison CBT vs BT
2.3 Network meta-analysis and its inconsistency
Network meta-analysis
As was the case for short-term remission, it was evident from the
funnel plots that there were small study effects (SSE) present in
the network for the comparison CBT versus WL. We found it
reasonable to assume that there were SSE in all other comparisons
versus WL, even though we might not have had enough studies
to see this effect. For this reason we performed a network meta-
analysis adjusting for SSE in studies comparing all other treatments
to WL, by regressing on the variance of the study. We performed
the network meta-analysis adjusted for SSE in WinBUGS. Thus
the results are expressed in terms of credible intervals and we use
themedian (instead of themean) because the posterior distribution
of the estimated odds ratios is asymmetrical.
Results of the network meta-analysis (NMA) for short-term re-
sponse, unadjusted and adjusted for SSE, are presented in Table 4.
Indirect evidence could be calculated for 13 comparisons forwhich
direct evidence was unavailable. The three comparisons CBT ver-
sus WL, BT versus WL and PT versus WL lost statistical signif-
icance within the context of NMA adjusted for SSE. The same
happened for the comparison CBT versus BT. Interestingly, all
cited comparisons showed a statistically significant difference in
the standard NMA (central part of Table 4), but lost significance
when adjusting the analyses for SSE. The only comparison that
showed a statistically significant difference in the NMA adjusted
for SSE was CBT versus NT (indirect evidence only), with an OR
of 7.14 (95% CrI 1.25 to 50).
Network heterogeneity and inconsistency
For both adjusted and unadjusted NMAs, the estimated values of
heterogeneity lay well within the range of values usually found in
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Cochrane reviews, as presented by Turner 2012.
We compiled a table of important trial and patient characteris-
tics including therapy duration and percentage of agoraphobic,
depressed and drug treated patients. Its visual inspection showed
that those effect modifiers were similarly distributed across com-
parisons in the network: we therefore concluded that there wasn’t
important evidence against the transitivity assumption.
We compared the inconsistency factors using the loop-specific ap-
proach (where we allow the same τ for all comparisons in a loop)
before and after the adjustment for small study effects. We ob-
served no important differences and all inconsistency factors were
statistically non-significant in both cases. However, as explained
in section 1.3, this does not constitute a proof of consistency in
the network: some of the loops include few studies and the corre-
sponding factors are estimated with much uncertainty. In Figure
17 we give all inconsistency factors for the network. Again, as in
the network for short-term remission, we observed the highest in-
consistency factor in the loop PT-CBT-PD.
Figure 17. Short-term response: inconsistency factors for the network
We found no proof of global inconsistency using the design-by-
treatment inconsistency model (Chi2 = 7.74 with 12 degrees of
freedom; P value for the null hypothesis of consistency in the
network 0.80).
2.4 Ranking of treatments
The ranking of treatments with respect to short-term response,
according to the SUCRA value derived from NMA adjusted for
small study effects, is presented in Table 6. We observed the high-
est rankings respectively for cognitive behaviour therapy (CBT),
psychodynamic therapy (PD) and supportive psychotherapy (SP).
Again, results regarding supportive psychotherapy must be inter-
preted with caution because SP is included in the network as a
node with a single connection to the network, being compared
only with CBT (three studies, OR 1.02, 95% CrI 0.38 to 2.73).
3. Dropouts for any reason in the short term
3.1 Network plot
Figure 18 shows a graphical representation of the network. Nodes
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and edges were weighted according to the number of studies in-
cluding the respective treatments and comparisons. As shown in
the figure, ST-dropout data were available for all the psychological
therapies and the control conditions considered for this review.
CBT appeared to be the most studied intervention, followed by
behaviour therapy (BT), physiological therapies (PT) and cogni-
tive therapy (CT). Wait list (WL) was the most studied among
comparator interventions. Themost studied comparisonwasCBT
versus WL. The network appeared to be moderately connected,
with three interventions represented as nodes with a single con-
nection to the network (SP, PE and 3W). Forty-seven studies in-
cluding 2535 participants contributed data to this outcome.
Figure 18. Short-term dropouts: network plot
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3.2 Pairwise meta-analyses and their heterogeneity and
small study effects
Pairwise meta-analyses
We excluded all studies with zero events in all arms (n=10) in the
analyses. The study Ost 1993 is a three-arm study with zero events
in two of the arms (CBT, PT) and one event in the third (BT).
For the pairwise meta-analysis, we excluded the CBT versus PT
comparison for this study andonly kept the other two comparisons
(CBT versus BT, PT versus BT).
As summarised in the left part of Table 7, direct evidence was avail-
able for 14 comparisons. For seven of these comparisons there was
only one study available; for the remaining seven comparisons we
performed a random-effects meta-analysis. As shown in the table,
only two comparisons were informed by 10 or more studies, that
is CBT versus WL (14 studies) and CBT versus BT (10 studies):
their forest plots are respectively presented in Figure 19 and Figure
20. Only two comparisons showed statistically significant results:
we found that WL was associated with significantly fewer drop-
outs than BT (four studies, OR 0.34, 95% CI 0.16 to 0.69), and
that PD was associated with significantly fewer dropouts than PT
(one study, OR 0.16, 95% CI 0.03 to 0.84).
Figure 19. Short-term dropouts: forest plot for the comparison WL vs CBT
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Figure 20. Short-term dropouts: forest plot for the comparison CBT vs BT
Heterogeneity
I² values and their 95% CIs, for the comparisons reported in three
studies or more, are presented in Table 8. We observed the highest
I² value in the comparisons CBT versus SP (I² = 49%). According
to the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011, section9.5.2) these values suggest that, in these two
comparisons, a moderate percentage of the observed variability in
the effect estimates was due to heterogeneity rather than sampling
error (chance).
Small study effects
Following the protocol, we produced funnel plots for all compar-
isons appearing in more than 10 studies. There were two com-
parisons appearing in 10 studies or more, that is WL versus CBT
(Figure 21) and CBT versus BT (Figure 22). We found no evi-
dence of asymmetry in either of the funnel plots.
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Figure 21. Short-term dropouts: funnel plot for the comparison WL vs CBT
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Figure 22. Short-term dropouts: funnel plot for the comparison CBT vs BT
3.3 Network meta-analysis and its inconsistency
Network meta-analysis
Results of the network meta-analysis (NMA) for short-term drop-
outs are presented in the right part of Table 7. Indirect evidence
could be calculated for 41 comparisons for which direct evidence
was unavailable. Results for comparisons WL versus BT remained
statistically significant also within the context of NMA, with an
OR of 0.52 (95% CI 0.30 to 0.93).
Network heterogeneity and inconsistency
The estimated value of heterogeneity lay well within the range of
values usually found in Cochrane reviews, as presented by Turner
2012.
We compiled a table of important trial and patient characteris-
tics including therapy duration and percentage of agoraphobic,
depressed and drug treated patients. Its visual inspection showed
that those effect modifiers were similarly distributed across com-
parisons in the network: we therefore concluded that there wasn’t
important evidence against the transitivity assumption.
Using a loop-specific approach, we found no evidence of inconsis-
tency in the network. In Figure 23 we give all inconsistency factors
for the network. The study Ost 1993 was a three-arm study with
zero events in two of the arms (CBT, PT) and one event in the
third (BT). For estimating inconsistencywe excluded theCBT-PT
comparison from this study. As a sensitivity analysis we excluded
the study Ost 1993 but there were no qualitative changes in the
inconsistency factors.
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Figure 23. Short-term dropouts: inconsistency factors for the network
The test for global inconsistency (design-by-treatment inconsis-
tency) provided no proof of inconsistency in the network (Chi2 =
11.67 with 14 degrees of freedom; P value = 0.63).
3.4 Ranking of treatments
The ranking of treatments with respect to short-term dropouts,
according to the SUCRA value derived from NMA, is presented
in Table 9. We observed the highest rankings (that correspond
with a lower dropout rate) respectively for no treatment (NT),
psychodynamic therapy (PD) and third-wave CBT (3W).
4. Short-term improvement of panic disorder with or
without agoraphobia as measured on a continuous
scale
4.1 Network plot
Figure 24 shows a graphical representation of the network. Nodes
and edges were weighted according to the number of studies in-
cluding the respective treatments and comparisons. As shown in
the figure, ST-improvement data were available for all the psycho-
logical therapies and the control conditions considered for this re-
view. CBT appeared to be themost studied intervention, followed
by behaviour therapy (BT), physiological therapies (PT) and cog-
nitive therapy (CT). Wait list (WL) was the most studied among
comparator interventions. Themost studied comparisonwasCBT
versus WL. The network appeared to be poorly connected, with
two interventions represented as nodes with a single connection
(SP and 3W); two interventions were connected only with each
other but not with the rest of the network (PE and APP), so they
could not be included in the analyses. Excluding those four inter-
ventions, the rest of the network appeared to be moderately well
connected. Fifty-seven studies including 2318 participants con-
tributed data to this outcome.
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Figure 24. Short-term improvement: network plot
4.2 Pairwise meta-analyses and their heterogeneity and
small study effects
Pairwise meta-analyses
As summarised in the left part of Table 10, direct evidence was
available for 18 comparisons. For 11 of these comparisons there
was only one study available; for the remaining seven comparisons
we performed a random-effects meta-analysis. As shown in the
table, only two comparisons were informed by 10 or more studies,
that is CBT versus WL (17 studies) and CBT versus BT (10 stud-
ies): their forest plots are respectively presented in Figure 25 and
Figure 26. Among psychological therapies, three were shown to be
significantly better thanWL in terms of short-term improvement:
PT (four studies: standardised mean difference (SMD) 0.87, 95%
CI 0.09 to 1.65), BT (three studies: SMD 0.92, 95% CI 0.59 to
1.26) and CBT (seventeen studies: SMD 1.14, 95% CI 0.87 to
1.41). CBT was also found to be significantly better thanNT (one
study: SMD1.30, 95%CI 0.46 to 2.14). Finally, two comparisons
among two active treatments showed a statistically significant dif-
ference in terms of short-term improvement: CBT versus BT (10
studies: SMD -0.24 in favour of CBT, 95% CI -0.45 to -0.03)
and PD versus PT (one study: SMD -1.18 in favour of PD, 95%
CI -1.59 to -0.57).
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Figure 25. Short-term improvement: forest plot for the comparison WL vs CBT
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Figure 26. Short-term improvement: forest plot for the comparison CBT vs BT
Heterogeneity
I² values and their 95% CIs, for the comparisons reported in three
studies or more, are presented in Table 11. As shown in the table,
we observed the highest I² values in the comparisons WL versus
PT (I² = 79%) and WL versus CBT (I² = 61%). According to
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011, section 9.5.2) these values suggest that, in these two
comparisons, a substantial percentage of the observed variability in
the effect estimates was due to heterogeneity rather than sampling
error (chance). In the comparison WL versus PT (four studies),
heterogeneity appeared to be related to the study Meuret 2008,
which shows an unexpectedly high SMD in favour of PT, possibly
related to a strong researcher allegiance bias (see Characteristics
of included studies); in the case of WL versus CBT (17 studies),
heterogeneity seems to be mainly due to two outlier studies, one
showing a very high SMD in favour of CBT (Schmidt 1997a,
SMD -2.36, 95% CI -3.19 to -1.54) and the other showing no
effect in either direction (Gould 1993, SMD 0.00, 95% CI -0.88
to 0.88).
Small study effects
Following the protocol, we produced funnel plots for all compar-
isons appearing in more than 10 studies. There were two com-
parisons appearing in 10 studies or more, that is CBT versus WL
(Figure 27) and CBT versus BT (Figure 28). We found no evi-
dence of asymmetry in either of the funnel plots.
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Figure 27. Short-term improvement: funnel plot for the comparison WL vs CBT
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Figure 28. Short-term improvement: funnel plot for the comparison CBT vs BT
4.3 Network meta-analysis and its inconsistency
Network meta-analysis
Results of the network meta-analysis (NMA), for short-term im-
provement on a continuous scale, are presented in the right part
of Table 10. Indirect evidence could be calculated for 19 compar-
isons for which direct evidence was unavailable. The comparison
PE versus APP, for which direct evidence was available, is not in-
cluded in the NMA because it is disconnected from the rest of the
network (see Figure 24). Four comparisons remained statistically
significant also within the context of NMA: WL versus PT (SMD
0.80, 95% CI 0.47 to 1.13), WL versus BT (SMD 0.89, 95%
CI 0.57 to 1.20), WL versus CBT (SMD 1.09, 95% CI 0.88 to
1.31) and NT versus CBT (SMD 0.83, 95% CI 0.16 to 1.50).
The comparisons CBT versus BT and PD versus PT lost signifi-
cance in the NMA. We also found supportive psychotherapy (SP)
and cognitive therapy (CT) to be significantly better than WL,
showing a SMD of respectively 1.05 (95% CI 0.49 to 1.60) and
0.88 (95% CI 0.34 to 1.42).
Inconsistency
We compiled a table of important trial and patient characteris-
tics including therapy duration and percentage of agoraphobic,
depressed and drug treated patients. Its visual inspection showed
that those effect modifiers were similarly distributed across com-
parisons in the network: we therefore concluded that there wasn’t
important evidence against the transitivity assumption.
Using a loop-specific heterogeneity (where we allowed the same
τ for all comparisons in a loop), we identified one inconsistent
loop out of a total of 14 loops. The inconsistent loop was PT-
CBT-PD (IF 1.79, 95% CI 0.78 to 2.60; see Figure 29 for other
inconsistency factors for the network). This loop was found to be
inconsistent also when allowing for a comparison-specific hetero-
geneity. Although in NMA 5% of the loops are expected to be in-
consistent by chance, it must be noted that this same loop showed
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the highest inconsistency factor (although non-significant) also in
the NMA for ST-remission and ST-response. Furthermore, two
of the three edges of the loop were only informed by one study
each, both considered to be at high risk of researcher allegiance
bias. We can summarise the inconsistency in available direct evi-
dence as follows: CBT appeared to perform better than PD (one
study: SMD 0.57, 95% CI -0.07 to 1.20) and PD appeared to
perform better than PT (one study: SMD -1.18, 95% CI -1.79 to
-0.57); however, the comparison CBT versus PT showed almost
no difference between the two treatments (five studies: SMD -
0.05, 95% CI -0.3 to 0.19).
Figure 29. Short-term improvement: inconsistency factors for the network
The global test for inconsistency did not reveal any definite proof about
inconsistency in the network (Chi2 = 9.13 with 14 degrees of freedom,
P value 0.82).
4.4 Ranking of treatments
The ranking of treatments with respect to short-term improve-
ment, according to the SUCRA value derived from NMA, is pre-
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sented in Table 12. We observed the highest rankings respectively
for psychodynamic psychotherapy (PD), cognitive behaviour ther-
apy (CBT) and supportive psychotherapy (SP). However, results
regarding PDmust be interpreted with caution because they relied
on only two studies (Beutel 2013; Milrod 2006a), both included
in the inconsistent loop PT-CBT-PD mentioned above.
5. Long-term remission or response of panic disorder
with or without agoraphobia
5.1 Network plot
Figure 30 shows a graphical representation of the network. Nodes
and edges were weighted according to the number of studies in-
cluding the respective treatments and comparisons. As shown in
the figure, long-term data were available for only six active inter-
ventions. No study explored long-term (LT)-remission/response
for third-wave CBT (3W) and psychoeducation (PE), nor for any
control condition (WL, NT, APP). CBT was the most studied
intervention, followed by behaviour therapy (BT), physiological
therapies (PT) and cognitive therapy (CT).Themost studied com-
parison was CBT versus BT. With the exception of SP and PD,
both represented as nodes compared only with CBT, the network
appeared to be well connected. Nine studies including 464 partic-
ipants contributed data to this outcome.
Figure 30. Long-term remission/response: network plot
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5.2 Pairwise meta-analyses and their heterogeneity and
small study effects
Pairwise meta-analyses
As summarised in the left part of Table 13, direct evidence was
available for eight comparisons. For six of these comparisons there
was only one study available; for the remaining two comparisons
we performed a random-effects meta-analysis. As shown in the
table, no comparison was informed by 10 or more studies. None
of the available comparisons showed statistically significant differ-
ences, in terms of long-term remission/response, between active
treatments. However, this finding must be interpreted while tak-
ing into account the exiguity of available long-term data.
Heterogeneity
Only the comparison CBT versus BT was informed by more than
two studies and it showed an I2 value of 37%, with a 95% CI go-
ing from 0% to 77% (standard pairwise meta-analysis). According
to the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011, section 9.5.2) this value suggests that the percent-
age of the observed variability in the effect estimates due to hetero-
geneity rather than sampling error may not have been important.
Small study effects
For this outcome, no comparison was informed by enough studies
to produce a funnel plot in order to explore the presence of small
study effects.
5.3 Network meta-analysis and its inconsistency
Network meta-analysis
Results of the network meta-analysis (NMA) for long-term remis-
sion/response are presented in the right part of Table 13. Indirect
evidence could be calculated for seven comparisons for which di-
rect evidence was unavailable. None of the available comparisons
showed statistically significant differences between active treat-
ments. Again, this finding must be interpreted while taking into
account the exiguity of available long-term data.
Network heterogeneity and inconsistency
The estimated value of heterogeneity lay well within the range of
values usually found in Cochrane reviews, as presented by Turner
2012.
We compiled a table of important trial and patient characteris-
tics including therapy duration and percentage of agoraphobic,
depressed and drug treated patients. Its visual inspection showed
that those effect modifiers were similarly distributed across com-
parisons in the network: we therefore concluded that there wasn’t
important evidence against the transitivity assumption.
Using a loop-specific heterogeneity (where we allow the same τ for
all comparisons in a loop), we found no evidence of inconsistency
in the network. In Figure 31 we give all inconsistency factors for
the network.
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Figure 31. Long-term remission/response: inconsistency factors for the network
The global test for inconsistency showed no signs of inconsistency
in the network (Chi2 = 1.80 with 4 degrees of freedom, P value =
0.77).
5.4 Ranking of treatments
The ranking of treatments with respect to long-term remission/
response, according to the SUCRA value derived from NMA,
is presented in Table 14. The highest ranking was observed for
cognitive behaviour therapy, followed by psychodynamic therapy.
6. Subgroup analyses
The following analyses were aimed at exploring possible sources of
heterogeneity for the first of the primary outcomes, that is short-
term remission of panic disorder with or without agoraphobia.
6.1 Year of publication
For the two pairwise comparisons for which there were enough
studies available (CBT versus BT and CBT versus WL) we per-
formed a meta-regression to investigate the effect of the year of
publication. In both pairwise comparisons older studies seemed
to favour CBT (compared to BT and WL) but the effect was not
found to be statistically significant in either of the cases. It must
be noted that older studies tended to be smaller than newer ones.
Thus, the small trend found was probably due to SSE. The meta-
regression parameters were, respectively, -0.02 (95% CI -0.10 to
0.05) for the comparison CBT versus BT, and 0.04 (95% CI -
0.06 to 0.15) for the comparison WL versus CBT.
6.2 Mean number of treatment sessions
Following the protocol, we divided the included studies that re-
ported the mean number of treatment sessions into three groups.
The first group was for studies with fewer than four sessions, the
second was for studies with four to 12 sessions and the last group
was for studies with more than 12 sessions. We performed a sub-
group analysis for comparisons reported by enough studies (CBT
versus BT and CBT versus WL).
Figure 32 shows the forest plot for the comparison WL versus
CBT, subgrouping the studies that reported the mean number
of treatment sessions, along with their meta-analysis (note that
Clark 1999 had two CBT arms, one with 15 sessions and one with
eight: for the purposes of this analysis we broke this study in two).
It is evident from the plot that the number of sessions was not
associated with the treatment effect (test for subgroup differences:
P value = 0.937; I2 = 0.0%). A meta-regression also showed no
difference between the groups and no reduction in heterogeneity.
A meta-regression on the exact number of treatment sessions also
showed no effect (Figure 33).
53Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 32. Subgroup analysis: number of treatment sessions, forest plot for the comparison WL vs CBT
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Figure 33. Subgroup analysis: number of treatment sessions, regression line for the comparison WL vs CBT
Figure 34 shows the forest plot for the comparison CBT versus
BT, subgrouping the studies that reported the mean number of
treatment sessions, along with their meta-analysis. Again, the plot
showed no important differences among the two available groups
(test for subgroup differences: P value = 0.269; I2 = 18.2%). Re-
sults of the meta-regression on the (standardised) number of ses-
sions showed that the increase in the number of sessions tended
to increase the relative efficacy of CBT versus BT (Figure 35), but
the increase was not statistically significant.
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Figure 34. Subgroup analysis: number of treatment sessions, forest plot for the comparison CBT vs BT
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Figure 35. Subgroup analysis: number of treatment sessions, regression line for the comparison CBT vs BT
6.3 Therapist training
Following the protocol, we divided the included studies into
groups depending on the assessment of therapist training in the
delivered treatments. We performed a subgroup analysis for com-
parisons reported by enough studies (WL versus CBT and CBT
versus BT).
For the comparison WL versus CBT we divided the studies into
two groups depending on the assessment of therapist training on
CBT: therapist trained (group 1) and therapist untrained (group
2). We did not include in the analysis studies that were unclear
about therapist training. The forest plots (Figure 36) showed an
overlap of the confidence intervals among the groups. We thus
concluded that our data showed no proof that therapist training
affects the comparison between CBT and WL (test for subgroup
differences: P value = 0.175; I2 = 45.6%).
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Figure 36. Subgroup analysis: therapist training, forest plots for the comparison WL vs CBT
For the comparison CBT versus BT we found three groups of
studies: therapists trained in both treatments (group 1), therapists
trained in BT with unclear training in CBT (group 2, one study
only) and therapists with unclear training in both arms (group 3,
one study only). We could only analyse the first group (Figure 37).
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Figure 37. Subgroup analysis: therapist training, forest plot for the comparison CBT vs BT
6.4 Percentage of patients with agoraphobia
We performed a subgroup analysis for comparisons reported by
enough studies (WL versus CBT and CBT versus BT).
For the comparison WL versus CBT there were 10 studies report-
ing on agoraphobia: we found no statistically significant linear
dependency between the percentage of patients with agoraphobia
and the effect size for this comparison (Figure 38).
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Figure 38. Subgroup analysis: percentage of agoraphobic patients, regression line for the comparison WL vs
CBT
For the comparison CBT versus BT there were nine studies re-
porting on agoraphobia: all studies had 100% of patients with
agoraphobia except one, so we could not perform an informative
meta-regression for this comparison.
6.5 Percentage of patients with depression
We performed a subgroup analysis for comparisons reported by
enough studies (WL versus CBT and CBT versus BT).
For the comparison WL versus CBT there were 10 studies report-
ing on depression: we found no statistically significant linear de-
pendency between the percentage of patients with depression and
the effect size for this comparison (Figure 39).
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Figure 39. Subgroup analysis: percentage of depressed patients, regression line for the comparison WL vs
CBT
For the comparison CBT versus BT there were only four studies
reporting on depression so we could not perform an informative
meta-regression for this comparison.
6.6 Percentage of patients on drug treatment
We performed a subgroup analysis for comparisons reported by
enough studies (WL versus CBT and CBT versus BT).
For the comparison WL versus CBT there were 11 studies report-
ing on drug treatment: we found no statistically significant linear
dependency between the percentage of patients on drug treatment
and the effect size for this comparison (Figure 40).
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Figure 40. Subgroup analysis: percentage of drug-treated patients, regression line for the comparison WL
vs CBT
For the comparison CBT versus BT there were only four studies
reporting on drug treatment so we could not perform an informa-
tive meta-regression for this comparison.
7. Sensitivity analyses
Following the protocol, we performed sensitivity analyses for the
first of the primary outcomes only (short-term remission of panic
disorder with or without agoraphobia).
7.1 Analyses restricted to studies considered to be at
low risk of selection and detection bias
Among the 54 studies included in quantitative analyses, only one
met the criteria (Milrod 2006a). Therefore, this sensitivity analyses
could not be performed.
7.2 Analyses restricted to individual therapy trials
We excluded from the analysis group therapy studies and redid
the analysis. We excluded 10 studies (Beck 1994; Carter 2003;
Hoffart 1995; Korrelboom2013; Lidren 1994;Meulenbeek 2008;
Schmidt 1997a; Schmidt 1997b; Sharp 2004; Telch 1993).
7.2.1 Network plot
Figure 41 shows a graphical representation of the network. Nodes
and edges were weighted according to the number of studies in-
cluding the respective treatments and comparisons. As shown in
the figure, ST-remission data were available for six active and one
comparison interventions. Different from the primary analyses,
NT was no longer included in the network. CBT remained the
most studied intervention, followed by behaviour therapy (BT),
physiological therapies (PT) and cognitive therapy (CT). Wait list
(WL) was the only comparator intervention available. The most
studied comparison remained CBT versus WL, followed by CBT
versus BT. The network remained well connected, again with the
only exception of supportive psychotherapy (SP), studied only in
the comparison versus CBT. Thirty studies including 1821 par-
ticipants contributed data to this outcome.
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Figure 41. Sensitivity analyses: network plot for short-term remission excluding from the analyses group
therapy trials
7.2.2 Pairwise meta-analyses and their heterogeneity and
small study effects
Pairwise meta-analyses
As for the primary analyses, in order to have comparable results
with the NMA, we performed the pairwise meta-analyses assum-
ing a common heterogeneity variance across all comparisons. This
way, all pairwise meta-analyses were essentially analysed as ran-
dom-effects (they include uncertainty due to heterogeneity), even
for those comparisons only being reported by one study.The (com-
mon) heterogeneity standard deviation was estimated to be τ =
0.05.
As summarised in the left part of Table 15, direct evidence was
available for 12 comparisons. For four of these comparisons there
was only one study available; for the remaining eight comparisons
we performed a random-effects meta-analysis. As shown in the
table, only one comparison was informed by 10 or more studies,
that is CBT versus WL (11 studies, Figure 42); the comparison
CBT versus BT was informed by nine studies, however we will
present its forest plot in order to ease the comparison with primary
analyses results (Figure 43). Results appear to be similar to those
observed in primary analyses, with the exception of the compar-
ison PD versus PT, which became statistically significant in this
sensitivity analysis (OR 4.22, 95% CI 1.17 to 15.15), showing
a superiority of PD in terms of short-term remission. However,
this comparison was informed by only one study in both analy-
ses, therefore this difference is only due to the smaller common
heterogeneity standard deviation (τ = 0.05 instead of 0.69) in this
sensitivity analysis.
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Figure 42. Sensitivity analyses: forest plot for the comparison WL vs CBT excluding group therapy trials
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Figure 43. Sensitivity analyses: forest plot for the comparison CBT vs BT excluding group therapy trials
Heterogeneity
I² values and their 95% CIs, for the comparisons reported in three
studies or more, are presented in Table 16. As shown in the table,
we observed the highest I² values in the comparisons WL versus
PT (I² = 56%). According to theCochraneHandbook for Systematic
Reviews of Interventions (Higgins 2011, section 9.5.2) these values
suggest that, in these two comparisons, a moderate percentage of
the observed variability in the effect estimates was due to hetero-
geneity rather than sampling error (chance). In the comparison
WL versus PT (four studies), heterogeneity was due to the study
Griegel 1995, a three-arm trial (PT versus PT versusWL) in which
no remission (i.e. panic-free status) was observed in the two active
treatment arms whereas one case of remission was observed in the
wait list. In this study, therefore, the unexpected OR was due to
the low number of events across all arms.
Small study effects
We produced funnel plots for the comparisons WL versus CBT
(Figure 44) and CBT versus BT (Figure 45). From the first funnel
plot there was evidence of asymmetry. More specifically, small
studies were missing in the lower right part of the funnel plot. This
means that small studies comparing WL to CBT that (relatively)
favour WL seemed to be missing: in other words, small studies
showedCBTtobemore efficacious. The contour-enhanced funnel
plot for the comparison WL versus CBT (not presented) showed
that studies were missing in the area of non-significance, thus
suggesting the role of publication bias behind the SSE. We found
no evidence of asymmetry in the funnel plot for the comparison
CBT versus BT. Taken together, these findings are similar to those
found in the primary analyses.
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Figure 44. Sensitivity analyses: funnel plot for the comparison WL vs CBT excluding group therapy trials
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Figure 45. Sensitivity analyses: forest plot for the comparison CBT vs BT excluding group therapy trials
7.2.3 Network meta-analysis and its inconsistency
Network meta-analysis
As explained in the previous paragraph, it was evident from the
funnel plots that there were small study effects (SSE) present in the
network for the comparison CBT versus WL. As for the primary
analyses, we found it reasonable to assume that there were SSE
in all other comparisons versus WL, even though we might not
have had enough studies to see this effect. The presence of SSE
implies that a simple NMA may produce biased results. For this
reason we performed a network meta-analysis adjusting for SSE
in studies comparing all other treatments to WL, by regressing on
the variance of the study.We performed the networkmeta-analysis
adjusted for SSE in WinBUGS. Thus the results are expressed in
terms of credible intervals and we use the median (instead of the
mean) because the posterior distribution of the estimated odds
ratios is asymmetrical.
Results of the network meta-analysis (NMA), adjusted for SSE,
for short-term remission are presented in the right part of Table
15. Indirect evidence could be calculated for nine comparisons
for which direct evidence was unavailable. The comparison be-
tween CBT and WL remained statistically significant also within
the context of NMA, showing an OR of 3.0 in favour of CBT
(95%CrI 1.4 to 6.3). PT, CT and BT lost significance in the com-
parison versus WL. We found supportive psychotherapy (SP) to
be significantly better than WL (OR 4.5, CrI 1.3 to 16.7); again,
this finding must be interpreted with caution since SP is included
in the network as a node with a single connection to the network.
Two comparisons among active treatments, that is CBT versus BT
and CBT versus PT, showed a statistically significant difference
in terms of short-term remission, in both cases in favour of CBT,
with an OR respectively of 1.76 (CrI 1.02 to 3.13) and 1.94 (CrI
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1.02 to 3.97). Taken together, these sensitivity analyses confirmed
the findings of primary analyses.
Network heterogeneity and inconsistency
The estimated value of heterogeneity lay well within the range of
values usually found in Cochrane reviews, as presented by Turner
2012.
Using a loop-specific heterogeneity (where we allow the same τ for
all comparisons in a loop), we found no evidence of inconsistency
in the network. In Figure 46 we give all inconsistency factors for
the network. As shown in the figure, the highest inconsistency
factor was observed in the loop PT-CBT-PD.
Figure 46. Sensitivity analyses: inconsistency factors for the network of short-term remission excluding
from the analyses group therapy trials
The global test for inconsistency showed no proof of inconsistency
(Chi2 = 3.21 with 5 degrees of freedom, P value = 0.67).
7.2.4 Ranking of treatments
The ranking of treatments with respect to short-term remission,
according to the SUCRA value derived from NMA adjusted for
small study effects, is presented in Table 17. Results confirmed
the primary analyses, showing the highest rankings respectively
for supportive psychotherapy, cognitive behaviour therapy and
psychodynamic therapy. Again, results regarding supportive psy-
chotherapy must be interpreted with caution because, as specified
earlier, SP is included in the network as a node with a single con-
nection to the network, being compared only with CBT.
7.3 Analyses restricted to trials in which a
concomitant pharmacotherapy is not allowed
We excluded from the analysis studies in which a concomitant
pharmacotherapy was allowed and redid the analysis. Only nine
studies remained and could be included in these analyses (Beck
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1994; Carter 2003; Cottraux 2009; Craske 1995; Craske 2005a;
Gloster 2010; Hoffart 1995; Reinecke 2013; Shear 1994).
7.3.1 Network plot
Figure 47 shows a graphical representation of the network. Nodes
and edges were weighted according to the number of studies in-
cluding the respective treatments and comparisons. As shown in
the figure, ST-remission data were available for five active and two
comparison interventions. Different from the primary analyses,
the network was no longer connected, but consisted in two sepa-
rated sub-networks.
Figure 47. Sensitivity analyses: network plot for short-term remission excluding from the analyses trials in
which a concomitant pharmacotherapy is allowed
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7.3.2 Pairwise meta-analyses and their heterogeneity and
small study effects
Pairwise meta-analyses
As summarised in Table 18, direct evidence was available for seven
comparisons. For four of these comparisons there was only one
study available; for the remaining three comparisonswe performed
a random-effects meta-analysis. As shown in the table, the most
represented comparison was CBT versus WL (three studies). Re-
sults appear to be similar to those observed in primary analyses.
The main difference was represented by the comparison WL ver-
sus CBT, which showed a larger effect (but also a larger CI) in
favour of CBT compared with the primary analyses (OR 14.3,
95% CI 3.3 to 100).
Heterogeneity
I² values, for the comparisons reported in two studies or more,
are presented in Table 18. As shown in the table, we found no
heterogeneity in the small sub-samples of studies available for these
sensitivity analyses.
Small study effects
Since three or fewer studies were available for each comparison,
we could not explore the presence of small study effects.
7.3.3 Network meta-analysis and its inconsistency
Network meta-analysis
A network meta-analysis could not be performed because the net-
work was disconnected.
7.4 Analyses restricted to trials requiring stabilisation
of drug therapy
We excluded from the analysis studies in which stabilisation of
drug therapy was not explicitly required and redid the analysis.
Only 11 studies remained and could be included in these analyses
(Barlow 1989; Clark 1994; Craske 2005a; Dow 2000; Griegel
1995; Korrelboom 2013; Lidren 1994; Meuret 2008; Ost 1995;
Ost 2004).
7.4.1 Network plot
Figure 48 shows a graphical representation of the network. Nodes
and edges were weighted according to the number of studies in-
cluding the respective treatments and comparisons. As shown in
the figure, ST-remission data were available for three active and
one comparison interventions. Although with only a few treat-
ments were included, the network appeared to be well connected,
with direct evidence missing only for the comparison BT versus
PT.
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Figure 48. Sensitivity analyses: network plot for short-term remission excluding from the analyses trials in
which pharmacotherapy stabilisation was not required
7.4.2 Pairwise meta-analyses and their heterogeneity and
small study effects
Pairwise meta-analyses
As summarised in Table 19, direct evidence was available for five
comparisons. For one of these comparisons there was only one
study available; for the remaining four comparisons we performed
a random-effects meta-analysis. As shown in the table, the most
represented comparison was CBT versus WL (six studies). Differ-
ent from the primary analyses, the comparison CBT versus BT
was no longer significant, although a trend in favour of CBT re-
mained. The comparisons CBT versus WL and BT versus WL
remained statistically significant, showing larger effects in favour
of the active treatment with respect to primary analyses.
Heterogeneity
I² values, for the comparisons reported in two studies or more,
are presented in Table 19. As shown in the table, we observed the
highest I² values in the comparisonsCBTversusBT (I² = 72%) and
PTversusWL (I² = 69%). According to theCochraneHandbook for
Systematic Reviews of Interventions (Higgins 2011, section 9.5.2)
these values suggest that, in these two comparisons, a substantial
percentage of the observed variability in the effect estimates was
due to heterogeneity rather than sampling error (chance). The low
number of studies available for these comparisons does not allowus
tomake inferences about the nature of the observed heterogeneity.
Small study effects
Since six or fewer studies were available for each comparison, we
could not explore the presence of small study effects.
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7.4.3 Network meta-analysis and its inconsistency
Results of the networkmeta-analysis (NMA) for short-term remis-
sion are presented in the right part of Table 19. Indirect evidence
could be calculated for the only comparison for which direct ev-
idence was unavailable. The comparisons CBT versus WL (OR
16.7, 95% CI 6.3 to 50) and BT versus WL (OR 5.3, 95% CI
1.1 to 25) remained statistically significant also within the context
of NMA. Furthermore, the comparison WL versus PT became
statistically significant, showing an OR of 9.09 (95% CI 2.7 to
33.3).
Compared with the primary analyses, these results tended to show
larger (and statistically significant) effects of active treatments
when comparedwithWL.Comparisons between active treatments
seemed to be less affected by the exclusion of studies in which the
stabilisation of drug therapy was not required.
Network heterogeneity and inconsistency
The estimated value of heterogeneity lay well within the range of
values usually found in Cochrane reviews, as presented by Turner
2012.
We found no evidence of inconsistency in the network using a
loop-specific approach.
The global test for inconsistency also showed no proof of incon-
sistency (Chi2 = 3.21 with 5 degrees of freedom, P value = 0.67).
7.4.4 Ranking of treatments
The ranking of treatments with respect to short-term remission,
according to the SUCRA value derived from NMA adjusted for
small study effects, was CBT (SUCRA 95), PT (SUCRA 62), BT
(SUCRA 42) andWL (SUCRA 0). With regard to the treatments
included in this sensitivity analysis, the results were similar to those
observed in the primary analyses.
7.5 Pairwise meta-analyses performed using a fixed-
effect model instead of a random-effects model
For these analyses we considered the same 40 studies included in
the primary analyses. As summarised in Table 20, direct evidence
was available for 15 comparisons, for which we performed a fixed-
effect meta-analysis and compared with the random-effects meta-
analyses results. With respect to primary analyses, we observed the
main difference in the comparison CBT versusWL. As we pointed
out in results section 1.2, this comparison is biased in favour of
CBT by the presence of small study effects; as expected, the mag-
nitude of the effect size for this comparison was reduced using the
fixed-effect model, which gives a relatively lower weight to small
studies compared to the random-effectsmodel, thus reducing their
influence on meta-analysis results. A similar explanation can also
account for the effect size reduction observed in the comparison
BT versus WL.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Cognitive behaviour therapy compared to supportive psychotherapy for panic disorder with or without agoraphobia in adults
Patient or population: adult pat ients with panic disorder with or without agoraphobia
Setting: outpat ients
Intervention: cognit ive behaviour therapy (CBT)
Comparison: support ive psychotherapy (SP)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Supportive psychotherapy
(SP)
Cognitive behaviour ther-
apy (CBT)
Short-term remission
(follow-up: mean 3 months)
Study populat ion OR 0.67
(0.25 to 1.82)
176
(3 RCTs)
⊕⊕©©
LOW 1,2
38 per 100 29 per 100
(13 to 52)
Short-term response
(follow-up: mean 3 months)
Study populat ion OR 1.12
(0.4 to 3.26)
176
(3 RCTs)
⊕©©©
VERY LOW 1,2,3,4
32 per 100 34 per 100
(16 to 60)
Short-term dropouts
(follow-up: mean 3 months)
Study populat ion OR 0.64
(0.28 to 1.43)
176
(3 RCTs)
⊕©©©
VERY LOW 1,2,3
46 per 100 35 per 100
(19 to 55)
Long-term remission/ re-
sponse
(follow-up: mean 12
months)
Study populat ion OR 2.09
(0.73 to 5.98)
80
(1 RCT)
⊕⊕©©
LOW 1,5
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24 per 100 40 per 100
(19 to 65)
Short-term improvement as
measured on a cont inuous
scale
(follow-up: mean 3 months)
The mean short-term im-
provement as measured on
a cont inuous scale in the
control group was 0
The mean short-term im-
provement, measured on a
cont inuous scale as SMD
(NMA results), was -0.05
(95% CI -0.56 to 0.47), indi-
cat ing almost no dif ference
between CBT and SP (the
negat ive value of the point
est imate indicates a slight
trend in favour of CBT)
- 152
(3 RCTs)
⊕⊕©©
LOW 1,2
Reported ORs and SMD are derived f rom the network meta-analyses
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; NM A: network meta-analysis; OR: odds rat io; RCT: randomised controlled trial; SM D: standardised mean dif ference
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
We downgraded the quality of the evidence one step at a t ime when one or more of the following crit icisms was present:
1Risk of bias for the included studies was in many cases unclear.
2Only a few studies available for direct comparison. 95% CI st ill w ide and non-signif icant even af ter combining direct and
indirect evidence.
3Results were inconsistent across studies, although with wide conf idence intervals.
4ST-response data were imputed f rom the cont inuous outcome for all the included studies.
5Only one study available for direct comparison. 95% CI st ill w ide and non-signif icant even af ter combining direct and indirect
evidence.
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Cognitive behaviour therapy compared to psychodynamic psychotherapy for panic disorder with or without agoraphobia in adults
Patient or population: adult pat ients with panic disorder with or without agoraphobia
Setting: outpat ients
Intervention: cognit ive behaviour therapy (CBT)
Comparison: psychodynamic psychotherapy (PD)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Psychodynamic
psychotherapy (PD)
Cognitive behaviour ther-
apy (CBT)
Short-term remission
(follow-up: mean 3 months)
Study populat ion OR 0.94
(0.27 to 3.45)a
54
(1 RCT)
⊕©©©
VERY LOW 1,2,3,4
44 per 100 43 per 100
(18 to 73)
Short-term response
(follow-up: mean 3 months)
Study populat ion OR 1.05
(0.28 to 4)a
54
(1 RCT)
⊕©©©
VERY LOW 1,2,3,4
47 per 100 48 per 100
(20 to 78)
Short-term dropouts
(follow-up: mean 3 months)
Study populat ion OR 1.92
(0.56 to 6.67)a
54
(1 RCT)
⊕©©©
VERY LOW 1,2,3,4
19 per 100 32 per 100
(12 to 62)
Long-term remission/ re-
sponse
(follow-up: mean 12
months)
Study populat ion OR 1.25
(0.37 to 4.17)a
54
(1 RCT)
⊕⊕©©
LOW 1,4
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50 per 100 56 per 100
(27 to 81)
Short-term improvement as
measured on a cont inuous
scale
(follow-up: mean 3 months)
The mean short-term im-
provement as measured on
a cont inuous scale in the
control group was 0
The mean short-term im-
provement as measured on
a cont inuous scale in the in-
tervent ion group was 0.17
standard deviat ions higher
(0.5 lower to 0.83 higher)
, indicat ing a small ef fect
size in favour of PDb
- 54
(1 RCT)
⊕©©©
VERY LOW 1,3,4,5
a Reported ORs are derived (as reciprocal values) f rom the results of network meta-analyses presented in Table 1, Table 4, Table 7 and Table 13 (for ST-remission and ST-
response we used the results of NMA adjusted for SSE)
b Reported SMD is derived f rom the results of network meta-analysis presented in Table 10.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CBT: cognit ive behaviour therapy; CI: conf idence interval; NM A: network meta-analysis; OR: odds rat io; PD: psychodynamic psychotherapy; PT: physiological therapies; RCT:
randomised controlled trial; SM D: standardised mean dif ference
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
We downgraded the quality of the evidence one step at a t ime when one or more of the following crit icisms was present:
1The available direct evidence was af fected by a high risk of bias in various important domains.
2Relevant (although non-signif icant) inconsistency was found in the loop PD-CBT-PT.
3Indirect evidence important ly inf luences the NMA results.
4Only one study available for direct comparison. 95% CI st ill w ide and non-signif icant even af ter combining direct and indirect
evidence.
5Stat ist ically signif icant inconsistency was found in the loop PD-CBT-PT.
7
6
P
sy
c
h
o
lo
g
ic
a
l
th
e
ra
p
ie
s
fo
r
p
a
n
ic
d
iso
rd
e
r
w
ith
o
r
w
ith
o
u
t
a
g
o
ra
p
h
o
b
ia
in
a
d
u
lts:
a
n
e
tw
o
rk
m
e
ta
-a
n
a
ly
sis
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
6
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
NM A Rankings of psychological therapies for panic disorder with or without agoraphobia in adults
Patient or population: adult pat ients with panic disorder with or without agoraphobia
Setting: outpat ients
Intervention: psychoeducat ion (PE), support ive psychotherapy (SP), physiological therapies (PT), behaviour therapy (BT),
cognit ive therapy (CT), cognit ive-behaviour therapy (CBT), third-wave CBT (3W), psychodynamic psychotherapy (PD)
Comparison: no treatment (NT), wait ing list (WL), attent ion/ psychological placebo (APP)
Outcomes Treatment hierarchy (in de-
scending order)
of participants
(studies)
Quality of the evidence
(GRADE)
Short-term remission
(follow up: mean 3 months)
(SP)-CBT-PD-CT-BT-PT-NT-
WL
2491
(40 RCTs)
⊕⊕©©
LOW 12
Short-term response
(follow up: mean 3 months)
CBT-PD-(SP)-BT-PT-WL-CT-
NT
2240
(37 RCTs)
⊕⊕©©
LOW 12
Short-term dropouts
(follow up: mean 3 months)
NT-PD-WL-3W-CBT-APP-PE-
PT-CT-BT-SP
2535
(47 RCTs)
⊕⊕©©
LOW 13
Long-term remission/
response
(follow up: mean 12 months)
CBT-PD-PT-BT-SP-CT 464
(9 RCTs)
⊕⊕©©
LOW 13
Short-term improvement as
measured on a cont inuous
scale
(follow up: mean 3 months)
(PD)-CBT-SP-CT-3W-BT-PT-
NT-WL
2318
(57 RCTs)
⊕⊕©©
LOW 13
Reported rankings are based on absolute SUCRA values, which are derived f rom network meta-analyses (NMA)
The ranking of treatments reported in parenthesis must be interpreted with caut ion, because the evidence support ing those
rankings is either too scarce or hampered by relevant inconsistency
The assessment of quality of evidence has been made by adapt ing the GRADE tool, designed for pairwise meta-analyses, to
network meta-analyses, as suggested in Salant i 2014.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of
the ef fect, but there is a possibility that it is substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate
of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent
f rom the est imate of ef fect
1 Downgraded for study lim itat ions because the risk of bias was unclear or high in more than one important domain for many
of the included studies.
2 Downgraded for imprecision because too few comparisons remained clinically important af ter adjust ing the results of NMA
for SSE (See addit ional Table 1 and Table 4)
3 Downgraded for imprecision because too few comparisons showed clinically important results in NMA (See addit ional Table
7, Table 10 and Table 14)
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D I S C U S S I O N
Summary of main results
Overall results in terms of short-term (ST)-remission, ST-response
and ST-improvement on a continuous scale were similar, suggest-
ing a superiority of cognitive behaviour therapy (CBT), psycho-
dynamic therapies (PD) and supportive psychotherapy (SP) over
other treatments for the management of the acute phase of panic
disorder.
However, results concerning SP should be interpreted cautiously
because the efficacy of this treatment was explored only in the
comparison with CBT and thus was not included in any closed
loop of the network (in which SP appeared as a node with a single
connection). As a result, the ranking of this treatment was strongly
influenced by this unique available comparison, whichwas directly
explored in three studies (Addis 2004; Craske 2005a; Shear 1994),
none of which found a statistically significant difference between
the two treatments in terms of ST-remission and ST-response. We
suspect that this situation may have produced a spuriously high
ranking of SP, because the estimation of the relative treatment
effects of CBT versus SP was only informed by these three trials
(and no additional indirect evidence from the rest of the network)
while the comparison of SP versus all other treatments was only
informed by indirect evidence (via the three CBT versus SP trials).
The two remaining treatments, that is PD and CBT, were directly
compared in only one study (Beutel 2013), which suggested a su-
periority of CBT over PD, although the results were not statisti-
cally significant either in terms of ST-remission or in terms of ST-
response (it must be noted that the lack of significance may be due
to the relatively small sample size).
In terms of ST-dropouts, PD ranked higher than CBT (odds ratio
(OR) 0.52, 95% confidence interval (CI) 0.15 to 1.8); a high
ranking was also achieved by third-wave CBT (3W), suggesting a
possible better tolerability of PD and 3W over other psychological
treatments in the short term.
In the long term, CBT showed the highest ranking, followed by
PD, suggesting that the effects of these two treatments may be
more stable with respect to other psychological interventions. As
for the short-term outcomes, only one study explored the direct
comparison between PD and CBT in the long term with regard
to remission, showing comparable rates of remission at six months
follow-up for the two treatments (Beutel 2013); however, these re-
sults should be interpreted while taking into account the relatively
high number of dropouts (almost 30%of the original sample). The
superiority of CBT in the long term may be due to the adminis-
tration of the so-called ”relapse prevention“ psychological compo-
nent; however, we did not explore this specific issue and a separate
review should be run in order to precisely evaluate the effects of
this therapeutic component for the long-term management of the
disorder. It must also be noted that in this review we did not ex-
plore the effects of drug therapy co-administration (and its adher-
ence) on long-term remission/response, as this type of secondary
analysis was limited to the first of our primary outcomes only (for
the reasons explained in Subgroup analysis and investigation of
heterogeneity). Taken together, the relative scarcity of long-term
evidence (with respect to short-term data), the high number of
dropouts at long-term assessments and the above-mentioned lack
of analyses regarding concomitant drug treatment, limit the re-
liability of our findings regarding long-term remission/response,
which therefore should be interpreted with caution.
More generally, the results showed a statistically significant supe-
riority of psychological therapies over the wait list condition. In
particular: SP, PT, behaviour therapy (BT) and CBTwere superior
to wait list (WL) both in terms of ST-remission and in terms of
ST-response. It must be noted, however, that the relative efficacy
of psychological therapies over WL was found to be consistently
affected by small study effects (SSE), as shown in the two funnel
plots comparing CBT versus WL (the only available comparison
versus WL for which there was a sufficient number of studies to
build a funnel plot) in relation to ST-remission and ST-response.
In the presence of SSE, studies with a lower standard error (i.e.
larger sample size and higher number of events) tend to show
smaller effects (in the case of ’positive’ outcomes) than studies with
a higher standard error (Sterne 2000), which implies that the latter
may lead to an overestimation of the effect (in this case, an overesti-
mation of ST-remission and ST-response of CBT when compared
to WL). Since the presence of SSE is difficult to detect when only
a few studies are available for a comparison, we found it reason-
able to assume that what we clearly observed in the comparison
CBT versusWL could probably be extended to other comparisons
versus WL. In other words, we assumed that there were SSE in
all other comparisons versus WL, even though we might not have
had enough studies to see this effect. Since the presence of SSE
implies that a simple network meta-analysis (NMA) may produce
biased results, we decided to repeat the NMA analyses adjusting
for small study effects in studies comparing all other treatments
to WL, by regressing on the variance of the study. As suspected,
in adjusted analyses, many of the comparisons mentioned above
lost statistical significance (only CBT and SP remained superior
to WL in terms of ST-remission; no treatment remained superior
in terms of ST-response).
The results showed a statistically significant difference between
two active treatments only for the comparisons CBT versus BT
and CBT versus PT, where CBT appeared to be superior in terms
of ST-remission. However, the confidence interval was large and
its lower end was very close to 1 (i.e. no difference) for both com-
parisons, which limits the relevance of these findings in clinical
terms. A similar trend in favour of CBT over BT and PT was
found in terms of ST-response, ST-improvement and LT-remis-
sion/response, although this was not statistically significant.
As planned in the protocol, we produced three ’Summary of find-
ings’ tables presenting the NMA results for the comparison be-
tween the psychological therapy that ranked first versus, respec-
tively: no treatment (NT), supportive psychotherapy (SP) and
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the psychological therapy that ranked second. The ranking we re-
ferred to was the one related to the first of our primary outcomes
(short-term remission), presented in Table 3. According to these
results, the treatment that ranked first was supportive psychother-
apy; however, for the reasons explained above, results concerning
SP were not reliable, which left CBT as the treatment with the
highest ranking. Therefore, in the ’Summary of findings’ tables
we present the NMA results for the following comparisons: CBT
versus NT (Summary of findings for the main comparison), CBT
versus SP (Summary of findings 2) and CBT versus PD (Summary
of findings 3). We also produced an extra summary of findings ta-
ble, not planned in the protocol, in order to summarize the overall
results of network meta-analyses in terms of treatment hierarchy,
together with the corresponding assessment of quality of the evi-
dence (Summary of findings 4).
Overall completeness and applicability of
evidence
Sufficient evidence supports our findings in relation to the com-
parison between CBT and waiting list: despite the evidence of
small study effects affecting results for ST-remission and ST-re-
sponse in favour of CBT, the stability of results when adjusting
NMA for SSE suggests a good reliability of this finding. We found
evidence in relation to the comparison BT versus CBT, support-
ing the superiority of the latter. Some evidence exists in support
of the possible viability of psychodynamic and supportive psycho-
logical therapies as valid alternatives to CBT for the treatment of
panic disorder with or without agoraphobia; scarce evidence exists
in support of other psychological therapies as valid alternatives to
CBT.
Quality of the evidence
For the three comparisons presented in the SoF tables (CBT vs
NT, CBT vs SP, CBT vs PD), the quality of evidence was rated
as low to very low for ST-remission, very low for ST-response,
very low for ST-dropouts, low for LT-remission/response and low
to very low for ST-improvement as measured on a continuous
scale (Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3).
We found low quality evidence, for each of the included out-
comes, in support of NMA analyses regarding treatment hierarchy
(Summary of findings 4).
The main factor affecting the quality of evidence was the presence
of an unclear or high risk of bias, for many included studies, in
more thanone important domain. As shown in Figure 3 andFigure
4, the majority of included studies were at unclear risk of bias with
regard to the randomisation process; we found almost half of the
included studies to be at high risk of attrition bias (both in the
short and in the long term) and detection bias (with regard to
ST-remission); we also found selective outcome reporting to be
present. Finally, we found almost half of the included studies to
be at high risk of researcher allegiance bias: however, we found no
clear evidence of this bias affecting our findings (extra analyses,
not reported).
We strongly suspected the presence of publication bias based on
evidence of SSE and analysis of contour-enhanced funnel plots for
both ST-remission and ST-response, for the comparisons between
psychological therapies and WL. As a post-hoc analysis we also
performed theHarbord and Peters tests, which showed no proof of
small study effects. However, given that the funnel plots provided
strong evidence for publication bias, we employed a hierarchical
network meta-regression model to adjust the NMA results (for
this reason we decided not to downgrade the quality of evidence
because of publication bias).
Another factor affecting the quality of evidence was the lack of
precision of results formany comparisons, which inmany cases did
not show statistically significant differences: this was probably due
to the lack of enough (and adequately powered) studies exploring
such comparisons.
Despite the above mentioned limitations of available evidence, we
found substantial heterogeneity to be present in very few pairwise
comparisons, limited to one of the secondary outcomes, that is
ST-improvement as measured on a continuous scale. For this same
outcome, the network analyses revealed the presence of relevant
inconsistency in one loop (PT-CBT-PD). This was the only clear
case of inconsistency identified in our analyses, although it must
be said that the networks were generally underpowered to detect
any important disagreement between direct and indirect evidence.
Finally, with regard to the directness of evidence, we found the
networks to be moderately connected, which means that direct
evidence was available for about half of the possible comparisons
among included psychological therapies/control conditions. Only
in the case of ST-dropouts results were informed by a higher pro-
portion of indirect evidence; on the other hand, however, this out-
come was informed by the highest number of studies (47 RCTs,
2535 participants).
Potential biases in the review process
Although this is the largest and most comprehensive systematic
review and network meta-analysis of psychological therapies for
panic disorder, there is reason to suspect that the available literature
may be affected by publication bias. Even when a study was pub-
lished, lack of unified outcome measures across studies, especially
in the older trials, left suspicion of outcome reporting bias. Many
of the included studies were not ideal in terms of risk of bias as in-
dividual studies. Our comprehensive literature search, unified and
reliable data extraction and study assessment, and methodological
rigour in the analyses have been able to guard against some but
not all of these limitations.
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Agreements and disagreements with other
studies or reviews
To our knowledge, this is the most extensive and methodologi-
cally rigorous systematic review ever run on psychological thera-
pies for the treatment of panic disorder. Furthermore, this is the
first time in which such therapies have been compared with each
other through a network meta-analysis.
Our results confirm the findings of a previous pairwise meta-anal-
ysis (Mitte 2005), in which CBT was found to be superior to wait-
ing list in the reduction of anxiety and depressive symptoms and
in the improvement of quality of life. However, in Mitte 2005 no
difference was found between CBT and BT in terms of anxiety
reduction. The results of a more recent meta-analysis suggested
that the combination of exposure, relaxation/breathing techniques
and cognitive therapy may represent the most effective treatment
for panic disorder, with smaller effect sizes for any of these com-
ponents if administered alone (Sánchez-Meca 2010). This finding
is more in line with our results, where CBT appeared to perform
better than CT, BT and PT.
Different from Sánchez-Meca 2010 and Mitte 2005, where pub-
lication bias was discarded as a possible threat to the validity of
results, we found clear evidence of small study effects (which may
be due, at least partly, to publication bias) affecting the compari-
son of CBT versus waiting list.
In Mitte 2005, the author hypothesised that the difference in ef-
fect sizes found between the comparisons (C)BT versus wait list
and (C)BT versus placebo suggested a relatively large common
factor, explaining more than half of the efficacy. In another meta-
analysis CBT was compared with placebo (both psychological and
pill placebo) for various anxiety disorders, among which the small-
est effect size was observed for panic disorder (Hedges’ g = 0.35,
95% CI 0.04 to 0.65), suggesting again that non-specific fac-
tors may play an important role in the treatment of this disorder
(Hofmann 2008). Although psychological placebo and supportive
psychotherapy are deeply different concepts, it is often difficult
to draw a clear line between them in psychotherapy trials. The
evidence we found in favour of supportive psychotherapy could
therefore be considered in line with the findings of above men-
tioned reviews, suggesting that non-specific factors may actually
play an important role in the treatment of panic disorder.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There was no high-quality, unequivocal evidence to support one
psychological therapy over the others for the treatment of panic
disorder with or without agoraphobia in adults. The ranking of
treatments according to the SUCRA value, derived from NMAs,
showed that cognitive behaviour therapy (CBT), the most exten-
sively studied among the included psychological therapies, was of-
ten superior to other therapies, although the effect size was small
and the level of precision was often insufficient or clinically irrel-
evant.
In the only two available studies exploring psychodynamic psy-
chotherapies, this treatment showed promising results, although
further research is needed in order to better explore the relative
efficacy of psychodynamic therapies (PD) with respect to CBT.
Unexpectedly, we found some evidence in support of the possible
viability of non-specific supportive psychotherapy for the treat-
ment of panic disorder; however, the results concerning support-
ive psychotherapy (SP) should be interpreted cautiously because
of the sparsity of evidence regarding this treatment and, as was
the case for PD, further research is needed to explore this issue.
Behaviour therapy did not appear to be a valid alternative to CBT
as a first-line treatment for patients with panic disorder with or
without agoraphobia.
Implications for research
An important finding of this review regards the quality level of
trials. It is desirable that future trials present more detailed de-
scriptions of the randomisation process, ensure the blinding of
outcome assessors and provide an a priori specification of primary
and secondary outcomes.
There seems to be no further need to explore the comparison be-
tween CBT and wait list (WL), nor between CBT and behaviour
therapy (BT); rather, there is a need for studies exploring the
comparison between active treatments, with particular regard to
CBT, PD and supportive psychotherapy, possibly in the context
of multi-arm trials, with large sample sizes, including long-term
assessments.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Addis 2004
Methods Study design: randomised controlled trial
Participants Inclusion criteria: participants were eligible for the study if theymetDSM-IV diagnostic
criteria for panic disorder with or without agoraphobia or were subthreshold for a strict
diagnosis of panic disorder but identified panic symptoms as their primary reason for
seeking treatment (no subthreshold patient actually entered the study: ”seventy-three
percent of participantsmet criteria for panic disorderwith agoraphobia, and 27%met criteria
for panic disorder without agoraphobia“)
Exclusion criteria: participants were excluded if they were seeking treatment for a prob-
lem other than panic or anxiety, had an untreated substance-use problem in the last
6 months, had a diagnosis of psychosis in the past 5 years, were currently judged to
be at risk for suicide, or were concurrently involved in other individual psychotherapy.
No exclusions were made on the basis of medication use for anxiety or other comorbid
psychological or medical problems
Characteristics of the sample:
• Age: mean age 39.9 years (SD 12.9, range 18 to 70)
• Percentage of agoraphobic patients: 73%
• Percentage of patients on drug therapy: 65%
• Percentage of patients with major depression: 39%
Interventions Participants (n = 80) were randomly assigned to either:
1) Panic control therapy (classified as CBT, n = 38)
• Therapy format: not stated
• Duration of each session: not stated
• Mean number of sessions: 12 to 15
• Duration of intervention: 12 to 15 weeks
2) Treatment as usual (classified as SP, n = 42)
• Therapy format: not stated
• Duration of each session: not stated
• Mean number of sessions: not stated
• Duration of intervention: not stated
Outcomes Time points for assessment: baseline, 5.5 months, 8.5 months, 1 year, 2 years
Measures: Panic Disorder Severity Scale (PDSS), Fear Questionnaire (FQ), Beck De-
pression Inventory (BDI-1), Outcome Questionnaire (OQ-45)
The following outcomes were used for quantitative analyses:
ST-Remission: PDSS below a cut-off score* at 5.5-month follow-up
ST-Response: not measured (imputed from continuous scale)
ST-Dropouts: patients who completed fewer than 6 sessions
Continuous scale: PDSS at baseline and at 5.5 months
LT-Remission/Response: PDSS below a cut-off score* at 1 year follow-up
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Addis 2004 (Continued)
Notes * ”Cut scores from published norms were obtained for the PDSS (Shear et al., 2001), the OQ-
45 (Lambert et al., 1996), the FQ (Gillis, Haaga, & Ford, 1995), and the BDI-1 (Seggar,
Lambert, & Hansen, 2002)“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
Low risk All randomised patients (n = 80) were as-
sessed at 5.5-month follow-up
Incomplete outcome data (attrition bias)
Long-term
Low risk All randomised patients (n = 80) were as-
sessed at 1-year follow-up
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Low risk ”Ten therapists agreed to participate. None of
them identified their primary theoretical ori-
entation as cognitive-behavioral; as a group
they were approximately equally distributed
between eclectic, family systems, psychody-
namic, and humanistic in their self-described
orientation.“
Treatment fidelity Low risk ”We rated therapist adherence for 67 of the 80
cases in the study. Data were missing for 11
cases in which the clients did not attend any
treatment sessions and 2 cases in which the
therapists had audiotaping difficulties. Cases
with missing adherence data did not differ
from the rest of the sample on any of the pri-
mary outcome measures at pre- or posttreat-
ment.
PCT therapists scored higher than TAU ther-
apists on all of the PCT interventions except
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Addis 2004 (Continued)
for agoraphobic exposure, in which the fre-
quency of use was low with no differences be-
tween the treatments.“
Al Kubaisy 1992
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 18 and 60 years, agora-, social or specific phobic disorder
on ICD-10 criteria for at least a year, mean 4-phobic-targets score of greater than 20 on
a 0 to 32 scale, written informed consent (patients were told they would be in a research
study about the best way to treat their kind of problem)
Exclusion criteria: severe organic disease; failed exposure treatment in the last year;
more than 2 units of alcohol a day from at least 3 weeks before entering the trial; on
medication or on a stable dose of more than the daily equivalent of 5 mg of diazepam,
100 mg imipramine or 10 mg propranolol, taken only at night, for at least 4 months (by
when it was unlikely to have any further effect, so this minority was retained to boost
cell size)
Characteristic of the sample (agoraphobia sub-sample):
• Age: not specified
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified
Interventions Participants (n = 34) were randomly assigned to either:
1) Daily live self exposure homework + clinician accompanied live exposure (clas-
sified as BT, n = 13)
• Therapy format: not stated
• Duration of each session: 150 minutes
• Mean number of sessions: 6
• Duration of intervention: 6 weeks
2) Daily live self exposure homework with six negotiation and monitoring sessions
(classified as BT, n = 11)
• Therapy format: not stated
• Duration of each session: 150 minutes
• Mean number of sessions: 6
• Duration of intervention: 6 weeks
3) Daily self relaxation homework with six negotiation and monitoring sessions
(classified as PT, n = 10)
• Therapy format: not stated
• Duration of each session: 150 minutes
• Mean number of sessions: 6
• Duration of intervention: 6 weeks
Outcomes Time points for assessment: baseline, 8 weeks, 14 weeks, 26 weeks
Measures: Fear Questionnaire (FQ), panic frequency, Beck Depression Inventory (BDI)
,HamiltonDepression (HAM-D),Global Improvement (CGI-I), Global Severity (CGI-
S)
The following outcomes were used for quantitative analyses:
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Al Kubaisy 1992 (Continued)
ST-Remission: not measured (imputed from continuous scale)
ST- Response: not measured for agoraphobia sub-sample (imputed from continuous
scale)
ST-Dropouts: refusers and dropouts before week 8
Continuous scale: although measured (CGI) detailed data are not reported
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Low risk ST-Remission not measured: imputed
from CGI-S, which was rated by ”an asses-
sor (psychiatrists, psychologists and nurse ther-
apists) kept blind to the treatment condition.
“
Incomplete outcome data (attrition bias)
Short-term
High risk 29% of randomised patients (agorapho-
bia sub-sample) did not receive/complete
the assigned intervention.Dropouts imbal-
anced in number across the 3 arms. Re-
fusers and dropouts data not reported
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk ”Both Ee and e patients had the rationale of
exposure explained at the 1st session, and were
asked to read the self-help chapter fromLiving
With Fear (Marks IM, 1980) and to follow
its guidelines“.Marks IM is among the study
authors.
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Other bias Unclear risk Modification of the original sample with
replacements. Number and randomisation
of replacements not specified
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Arch 2012
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-IV diagnosis of one or more anxiety disorders, including
panic disorder with or without agoraphobia (PD/A), social anxiety disorder (SAD), spe-
cific phobia (SP), obsessive-compulsive disorder (OCD), or generalised anxiety disorder
(GAD)
Exclusion criteria: none
Characteristic of the sample (agoraphobia sub-sample):
• Age: not specified
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified
Interventions Participants (n = unclear) were randomly assigned to either:
1) Acceptance and commitment therapy (classified as 3W, n = unclear)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
2) Cognitive behaviour therapy (classified as CBT, n = unclear)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
Outcomes Time points for assessment: pre-treatment, post-treatment, 6 months follow-up, 12
months follow-up
Measures: Anxiety Disorders Interview Schedule-IV (ADIS-IV), Anxiety Sensitivity In-
dex (ASI), Penn State Worry Questionnaire (PSWQ), Fear Questionnaire (FQ), Main
Target Phobia Scale (a single-item avoidance rating for each participant’s ”main phobia“)
, Quality of Life Inventory (QOLI), Acceptance and Action Questionnaire-16 (AAQ)
The following outcomes were used for quantitative analyses:
ST-Remission: although reported (Clinical Severity Rating on ADIS-IV lower than 4)
, ST-Remission could not be calculated following an ITT principle (number of PD/A
patients randomised to each arm not specified)
ST- Response: not measured
ST-Dropouts: not measured
Continuous scale: ASI at pre- and post-treatment
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Randomization sequences were produced by
http://www.randomizer.org“
97Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Arch 2012 (Continued)
Allocation concealment (selection bias) Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
High risk ”One hundred and forty-three participants [.
..] were randomized to ACT (n=65) or CBT
(n=78). All participants who began treatment
(n=128) were included in the intent-to-treat
(ITT) sample (n 57=ACT, n=71 CBT)“.
Data for randomised patients who did not
begin treatment unavailable
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Unclear risk ”CBT for anxiety disorders followed a protocol
authored by Craske“; ”ACT for anxiety dis-
orders followed a manual authored by Eifert
and Forsyth“.
Both CraskeMG and EifertGH are among
the study authors: although possible, the
direction of a researcher allegiance bias
would be unclear
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”All sessions were videotaped for supervision
purposes with a hidden video camera; ses-
sions were also audiotaped for therapy adher-
ence purposes with a discrete digital recorder.
Videos were generally played in supervision
sessions or watched beforehand by supervisors.
“
Arntz 2002
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 17 and 70 years, primary DSM-III-R diagnosis of panic
disorder with no or mild agoraphobic avoidance, panic disorder for at least 3 months, at
least one panic attack during the previous 4 weeks, asking for treatment of panic disorder.
No use of serotonergic antidepressants or benzodiazepines (for at least 4 weeks; patients
using this medication were, if they agreed, taken off medication), or if unwilling to stop
medication, keeping this medication at a constant level during treatment or stopping it
during treatment
Exclusion criteria: depressive disorder preceding the current episode of panic disorder
or requiring immediate treatment; behaviour therapy received for panic disorder; evi-
dence of organic mental disorders, mental retardation, psychotic disorders, alcohol or
drug dependence, cardiovascular disease, asthma, epilepsy; medical contraindication for
exposure, behavioural experiments or hyperventilation
Characteristic of the sample:
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Arntz 2002 (Continued)
• Age: 34.8 years (range 20 to 65)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: 27.5%
• Percentage of patients with major depression: not specified (mood disorder 33.
3%)
Interventions Participants (n = 69) were randomly assigned to either:
1) Cognitive therapy (classified as CT, n = unclear)
• Therapy format: individual/group
• Duration of each session: 60 minutes (individual sessions)/105 minutes (group
sessions)
• Mean number of sessions: 16
• Duration of intervention: 14 weeks (plus 2 sessions after 1 and 6 months)
2) Interoceptive exposure (classified as BT, n = unclear)
• Therapy format: individual/group
• Duration of each session: 60 minutes (individual sessions)/105 minutes (group
sessions)
• Mean number of sessions: 16
• Duration of intervention: 14 weeks (plus 2 sessions after 1 and 6 months)
Outcomes Time points for assessment: baseline, post-treatment (16 weeks), 1-month follow-up,
6 months follow-up
Measures: panic diary, Fear of Fear Questionnaire, Fear Questionnaire (FQ), State-Trait
Anxiety Inventory (STAI), Symptom Check List (SCL-90)
The following outcomes were used for quantitative analyses:
ST-Remission: although measured (panic-free at post-treatment), data cannot be used
to calculate remission following an ITT principle (n randomised for each arm is unclear)
ST- Response: not measured
ST-Dropouts: detailed data are not reported
Continuous scale: although measured, detailed data are not reported
LT-Remission/Response: although measured (panic-free at 6 months follow-up) de-
tailed data are not reported
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Selective reporting (reporting bias) High risk Study protocol unavailable. Pre-planned
measures are not reported with sufficient
details
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Arntz 2002 (Continued)
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”There were weekly supervisions, during
which each case was presented in detail and
adherence to the protocol was checked. Care
was taken to exclude cognitive techniques
from the IE treatment, and exposure tech-
niques from the CT treatment.“
Barlow 1989
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM III-R diagnosis of panic disorder with mild or no agoraphobic
avoidance. The interviewers rated the severity of the disturbance on a 0 to 8-point scale
(reflecting co-jointly distress and disability from the disorder), and only clients whose
severity rating was at least 4 were included in the study. Finally, only subjects who
reported the presence of at least 1 panic attack in a 2-week period prior to assessment
were included. Subjects on medications or receiving alternative psychotherapies for the
requisite time, and who met suitability criteria, were included under the agreement
that medication regime and psychotherapy contact were maintained at constant levels
throughout
Exclusion criteria: aged below18 or above 65 years; current alcohol or drug dependency/
abuse; primary diagnosis of major depression, and any signs of psychosis or organic brain
syndrome. In addition, clients concurrently involved in other psychotherapy programs
were assessed for suitability only if the alternative therapy was not focused on anxiety
management, and they had been in therapy for at least 6 months. Finally, subjects were
excluded if they had begun benzodiazepines within the past 3months orMAO inhibitors
or tricyclic antidepressants within the past 6 months
Characteristic of the sample:
• Age: not specified for the ITT sample (completers sub-sample mean age 31.7
years, SD 8.3)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified for the ITT sample (25%
in completers sub-sample)
• Percentage of patients with major depression: not specified for the ITT sample
(5% in completers sub-sample)
Interventions Participants (n = 71) were randomly assigned to either:
1) Wait list (classified as WL, n = 16)
• Mean number of sessions: 0
• Duration of intervention: 15 weeks
2) Applied progressive muscle relaxation (classified as PT, n = 15)
• Therapy format: individual
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Barlow 1989 (Continued)
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks
3) Exposure and cognitive restructuring (classified as CBT, n = 16)
• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks
4) Relaxation combined exposure and cognitive restructuring (classified as CBT, n =
24)
• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks
Outcomes Time points for assessment: assessments were conducted at pre-treatment and post-
treatment. Active treatment group subjects were also assessed 3 months, 6 months, 12
months and 24 months after treatment completion
Measures: Anxiety Disorder Interview Schedule-Revised (ADIS-R), Trait Scale of the
State-Trait Anxiety Inventory (STAI-T), Cognitive-Somatic AnxietyQuestionnaire, Fear
Questionnaire (FQ), Beck Depression Inventory (BDI), Psychosomatic Rating Scale,
Subjective Symptom Scale, self monitoring records (regarding daily fluctuations in anx-
iety and depression and occurrence of panic attacks), composite criteria for treatment
responder (20% improvement in at least 3 of the following 4 measures: (1) clinical rating
of severity (at least 2 points); (2) client’s self rating from the Fear Questionnaire (at least
2 points); (3) number of panic attacks per week, and (4) Subjective Symptom Scale total
score (at least 8 points) and End-State Functioning (applied only to treatment respon-
ders. At least three of the following five criteria had to be obtained for high end-state
status: (1) score of 2 or less on the clinician’s rating of severity; (2) score of 2 or less for
the client’s self rating; (3) 0 panic attack per week; (4) score of 2 or less for the mean
anxiety rating, and (5) score of 10 or less for the Subjective Symptom Scale total score)
The following outcomes were used for quantitative analyses:
ST-Remission: high end-state functioning* at post-treatment
ST- Response: treatment responder as defined by composite criteria
ST-Dropouts: subjects who did not complete assigned treatment
Continuous scale: Fear Questionnaire (FQ)
LT-Remission/Response: reported data were not included in the analyses because of
high level of dropouts (see Secondary outcomes): ”data were available for 23 subjects at
the 6-month follow-up period (R n=9; E&C n=8; COMB n=6)“
Notes * ”At least three of the following five criteria had to be obtained for high end state status:
(1) score of 2 or less on the clinician’s rating of severity; (2) score of 2 or less for the client’s
selfrating; (3) zero panic attack per week; (4) score of 2 or less for the mean anxiety rating,
and (5) score of 10 or less for the Subjective Symptom Scale total score. End state functioning
was determined if data from only three different measures were present but all three reflected
positive or negative responding. End state status could not be determined if more than two of
the five measures were missing.“
Risk of bias
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Barlow 1989 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Unclear risk At least 3 out of 5 criteria had to be obtained
for high end-state status. Although assessor
was a ”blind, independent rater“, only one
of those 5 criteria was assessor-rated, so it
was possible for a patient to fall into the
end-state category on the basis of self rated
measures only
Incomplete outcome data (attrition bias)
Short-term
High risk ”The percentage of dropouts for each condi-
tion were 6%, 33%, 6%, and 17%. For
the study completers, data were missing at
post-test for several variables due to non-com-
pliance. The number of missing data points
ranged from 1 to 4 variables within each
group. Missing data were not replaced by av-
erages.“
Incomplete outcome data (attrition bias)
Long-term
High risk ”data were available for 23 subjects at
the 6-month follow-up period (R n=9; E&
C n=8; COMB n=6).“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk Barlow DH and Craske MG are authors of
a CBT manual (see Barlow 2000b)
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”Treatment delivery was examined by means
of ratings of the content of therapy sessions
from periodic spot checks of audiotapes (all
therapy sessions were audiotaped to avoid the
possibility of response bias in the therapists ver-
bal behavior during spot checking). Thirty-
five tapes were randomly selected, with the
stipulation that each therapist and each treat-
ment phase of each treatment condition were
represented in the sample. Two randomly se-
lected fiveminute segments (excluding the first
and last fiveminutes of the session and includ-
ing at least three minutes of therapist talk)
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were rated from each tape. In all cases, raters
identified correctly the treatment condition
represented by the sample. Judgments of the
treatment phase from which the sample came
were correct in 31 of the 35 cases; two mis-
judgements were from the E & C condition
and two from the R condition. There were
only two instances of inappropriate material;
both of which referred to nontargeted prob-
lem areas and not to inappropriate treatment
technique.“
Beck 1987
Methods Study design: randomised controlled trial
Participants Inclusion criteria: not specified, probably DSM-III diagnosis of panic disorder (as in
another previous study by Ottaviani and Beck described in the book)
Exclusion criteria: not specified
Characteristic of the sample:
• Age: not specified
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified
Interventions Participants (n = 29) were randomly assigned to either:
1) Cognitive therapy (classified as CBT, n = 13)
• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
2) Brief supportive therapy (classified as APP, n = 16)
• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 8
• Duration of intervention: 8 weeks
Outcomes Time points for assessment: baseline, 4 weeks, 8 weeks, 12 weeks (only for cognitive
therapy group)
Measures: panic frequency
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (not imputed because of skewed distribution of available
continuous scale)
ST- Response: not measured (not imputed because of skewed distribution of available
continuous scale)
ST-Dropouts: non-completers
Continuous scale: although measured (panic frequency), detailed data are not reported
LT-Remission/Response: not measured
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Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
Low risk ”There were no dropouts in either group“.
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk Beck AT is involved in conceptualisation
of cognitive therapy (see Description of the
intervention)
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Beck 1992
Methods Study design: randomised controlled trial, cross-over design
Participants Inclusion criteria: age between 18 and 65 years, DSM-III diagnosis of panic disorder
or agoraphobia with panic disorder
Exclusion criteria: none
Characteristic of the sample:
• Age: not specified
• Percentage of agoraphobic patients: 18%
• Percentage of patients on drug therapy: 52%
• Percentage of patients with major depression: not specified (35% according to
imputation from BDI)
Interventions Participants (n = 33) were randomly assigned to either:
1) Focused cognitive therapy (classified as CT, n = 17)
• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
2) Brief supportive psychotherapy (classified as WL*, n = 16)
• Therapy format: not specified
• Duration of each session: 30 minutes
• Mean number of sessions: 8
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• Duration of intervention: 8 weeks
Outcomes Time points for assessment: baseline, 4 weeks, 8 weeks, 12 weeks (only for focused
cognitive therapy group)
Measures: panic frequency, Mobility Inventory for Agoraphobia (MI), Beck Depression
Inventory (BDI), Beck Anxiety Inventory (BAI), Specific Fear Inventory, end-state func-
tioning (only for focused cognitive therapy group)
The following outcomes were used for quantitative analyses:
ST-Remission: absence of panic attacks (clinician rating, before cross-over)
ST- Response: not measured (not imputed)
ST-Dropouts: non-completers (before cross-over)
Continuous scale: not extracted (number of assessed patients unclear: ”Ns varied across
analyses from 14 to 17 patients in the cognitive therapy group and 15 to 16 patients in the
brief supportive psychotherapy group“)
LT-Remission/Response: not measured
Notes *Brief supportive psychotherapy arm was classified as WL (wait list) because: 1) patients
received ”8 weeks of supportive contact“, apparently different from a proper supportive
therapy (which therefore cannot be classified as an active treatment, but rather as a
comparator intervention); 2) although this study is presented as having a cross-over
design, only patients in supportive psychotherapy group (all of them) actually did cross-
over
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Unclear risk ”At each assessment interval, independent
clinical raters reviewed patients’ daily logs
of panic frequency to determine whether the
recorded panic attacks actually met the DSM-
III criteria for panic“.
It is unclear whether raters were blind to
patients’ allocation
Incomplete outcome data (attrition bias)
Short-term
High risk ”Because of missing values for some variables,
Ns varied across analyses from 14 to 17 pa-
tients in the cognitive therapy group and 15 to
16 patients in the brief supportive psychother-
apy group“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
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Researcher allegiance High risk Beck AT is involved in conceptualisation
of cognitive therapy (see Description of the
intervention)
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Beck 1994
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age 18 to 65 years, DSM-III primary diagnosis of panic disorder. Pa-
tients who reported use of psychotropic medication were withdrawn from these regimes,
with at least a 2-week drug clearance before taking the ADIS-R
Exclusion criteria: severe agoraphobia, primary diagnosis of an alternate Axis I diagnosis,
current involvement in psychotherapy, alcohol or substance abuse within the previous 6
months, psychotic symptoms, evidence of organic impairment
Characteristic of the sample:
• Age: not specified for the randomised sample (n = 64) but only for the initially
selected sample (n = 70, mean age 37.5 years, SD 9.7)
• Percentage of agoraphobic patients: not specified for the randomised sample (n
= 64) but only for the initially selected sample (n = 70, 87% being moderately or
mildly agoraphobic)
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified for the randomised
sample (n = 64) but only for the initially selected sample. Depression percentage among
randomised sample was 23% according to imputation based on HAM-D-17 score)
Interventions Participants (n = 64) were randomly assigned to either:
1) Cognitive therapy (classified as CT, n = 22)
• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks
2) Relaxation training (classified as PT, n = 20)
• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks
3) Minimal contact control (classified as NT, n = 22)
• Therapy format: weekly telephone contact
• Duration of each session: not specified
• Mean number of sessions: 0
• Duration of intervention: 10 weeks
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Outcomes Time points for assessment: baseline, 5 weeks, 10 weeks. Subjects in the 2 intervention
groups were asked to return for 1-, 3- and 6-months follow-up visits
Measures: panic frequency, Anxiety Disorders Interview Schedule-Revised (ADIS-R),
Anxiety Sensitivity Index (ASI), Body Sensations Questionnaire (BSQ), Agoraphobic
Cognitions Questionnaire (ACQ), State-Trait Anxiety Inventory (STAI), FearQuestion-
naire (FQ), Hamilton Anxiety and Depression Scales (HAM-A, HAM-D), composite
index of treatment response (based on 4 variables: global PD severity, number of panic
attacks in the previous month, average ACQ and BSQ score, FQ-Ag score)
The following outcomes were used for quantitative analyses:
ST-Remission: panic-free at post-test (10 weeks)
ST- Response: at least mild improvement on composite index of treatment response*
ST-Dropouts: non-completers
Continuous scale: Anxiety Sensitivity Index (ASI)
LT-Remission/Response: panic-free at 6 months follow-up
Notes * ”A composite index of treatment response was derived, using guidelines established by Hi-
madi, Boice, and Barlow (1986) and Barlow et al. (1989). This measure quantified treat-
ment response based on four variables: global PD severity, number of panic attacks in the
previous month, an average of ACQ and BSQ scores, and FQ-Ag score“.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
High risk ”Six subjects dropped out, with 5 (23%) from
the CT condition, 1 (5%) from the RT con-
dition, and none (0%) from the MCC con-
dition“.
Incomplete outcome data (attrition bias)
Long-term
High risk ”Of the 17 subjects who completed CT, 16
(94%) were assessed at all three follow-up
points, with 1 subject not assessed at 3 and 6
months. All 19 RT subjects were evaluated at
each follow-up assessment“.
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
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the psychological therapies under study
(note that first author is Beck JG, not Beck
AT)
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”We provided weekly clinical supervision for
each session to ensure treatment competence.
All sessions were videotaped, with 24% (n=
34) selected randomly for treatment integrity
monitoring“
Beutel 2013
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age 18 to 60 years, primary panic disorder with or without agora-
phobia according to DSM-IV criteria, fluency in the German language, living in the
proximity of Mainz. Psychotropic medication, if present, had to be held constant
Exclusion criteria: psychosis, bipolar disorder, borderline or antisocial personality dis-
order, active substance abuse, severe medical or neurological disease precluding exposure
therapy and ongoing psychotherapy
Characteristic of the sample:
• Age: 36.22 years (SD 10.8)
• Percentage of agoraphobic patients: 74.1%
• Percentage of patients on drug therapy: 22.2%
• Percentage of patients with major depression: 22.2%
Interventions Participants (n = 54) were randomly assigned to either:
1) Panic focused psychodynamic therapy (classified as PD, n = 36)
• Therapy format: not specified
• Duration of each session: 50 minutes
• Mean number of sessions: 24
• Duration of intervention: 12 weeks
2) Cognitive behaviour therapy (classified as CBT, n = 18)
• Therapy format: not specified
• Duration of each session: 50 minutes
• Mean number of sessions: 24
• Duration of intervention: 12 weeks
Outcomes Time points for assessment: baseline, treatment termination, 6 months follow-up
Measures: Structured Clinical Interview for DSM-IV (SCID-I and II), Panic Disorder
Severity Scale (PDSS), Clinical Global Impression scale (CGI), Hamilton Depression
Rating Scale (HAM-D), Symptom Checklist (SCL-90R), Beck Depression Inventory
(BDI), Levels of Emotional Awareness Scale (LEAS)
The following outcomes were used for quantitative analyses:
ST-Remission: PDSS score < 5 in PD or < 7 in PDA at termination
ST- Response: at least 40% reduction of PDSS
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ST-Dropouts: non-completers
Continuous scale: Panic Disorder Severity Scale (PDSS)
LT-Remission/Response: PDSS score < 5 in PD or < 7 in PDA at 6 months follow-up
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”subjects were allocated by an a priori com-
puter-generated list in a 2: 1 randomization
ratio either to Panic Focused Psychodynamic
Psychotherapy or to manualized cognitive be-
havioral therapy plus exposure.“
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Low risk ”Independent, experi-
enced evaluators, blinded to subject condition
and therapist orientation, assessed subjects at
baseline, at treatment termination and at 6
months follow-up.“
Incomplete outcome data (attrition bias)
Short-term
High risk Patients analysed at post-treatment:
PFPP n = 28
CBT n = 14
Incomplete outcome data (attrition bias)
Long-term
High risk Patients analysed at follow-up:
PFPP n = 25
CBT n = 13
Selective reporting (reporting bias) High risk Study protocol available (registered retro-
spectively). Reported primary outcome is
one among other primary outcomes cited
in the protocol: ”Principal outcome crite-
rion is the reduction of panic-related symp-
toms at the follow-up 6-months after treat-
ment. Panic-related symptoms are measured
with standardized questionnaires and inter-
views, e. g. the AKV-MI/BSQ/ACQquestion-
naires, the Hamilton Anxiety Scale, HAMA,
and the Panic Disorder Severity scale, PDSS.
“
Researcher allegiance High risk Milrod B is co-author of PFPPmanual (see
Milrod 1997)
Therapist allegiance Unclear risk Insufficient information provided
109Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Beutel 2013 (Continued)
Treatment fidelity Low risk ”All treatments were videotaped as a basis for
supervision and for later independent assess-
ment of treatment adherence“
Botella 2004
Methods Study design: randomised controlled trial
Participants Inclusion criteria: 18 years of age or older, met DSM-IV (American Psychiatric Associ-
ation, 2000) criteria for the diagnosis of PDA as principal diagnosis and, in the case of
taking medication for PDA, did not increase or modify the kind of medication during
the study
Exclusion criteria: psychosis, severe organic illness or substance abuse or dependence
Characteristic of the sample:
• Age: mean 34.7 years (SD 12.31)
• Percentage of agoraphobic patients: 82.9%
• Percentage of patients on drug therapy: 66.6%
• Percentage of patients with major depression: not reported (29.7% according
to imputation from BDI)
Interventions Participants (n = 37) were randomly assigned to either:
1) In vivo exposure (classified as CBT, n = 12)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 9
• Duration of intervention: 9 weeks
2) Virtual reality exposure (classified as CBT, n = 12)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 9
• Duration of intervention: 9 weeks
3) Wait list (classified as WL, n = 13)
• Mean number of sessions: 0
• Duration of intervention: 9 weeks
Outcomes Time points for assessment: pre-treatment, post treatment, 12 months follow-up
Measures: Anxiety Diagnostic Interview Schedule IV (ADIS-IV), Fear and Avoidance
Scales, panic attack record, Panic Disorder Severity Scale (PDSS), Anxiety Sensitivity
Index (ASI), Agoraphobia Subscale of the Fear Questionnaire (FQ-Ag), Beck Depression
Inventory (BDI), Maladjustment Scale (MS), Clinician Global Impression (CGI)
The following outcomes were used for quantitative analyses:
ST-Remission: ASI score < 27
ST- Response: panic-free OR a 50% reduction in panic frequency
ST-Dropouts: non-completers
Continuous scale: Panic Disorder Severity Scale (PDSS)
LT-Remission/Response: not entered in the analyses (reported LT data refer to the 2
treatment arms, both classified as CBT in this review: comparison not feasible)
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Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table was used (personal
communication)
Allocation concealment (selection bias) Low risk Randomisation was performed by an ex-
perimenter who did not participate in the
study (personal communication)
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk Assessors were blind to the conditions
(personal communication). However, ASI
(used to determine ST-Remission) is a self
administered scale
Incomplete outcome data (attrition bias)
Short-term
Low risk ”All participants in the treatment conditions
were assessed at post treatment 1 week after
the treatment completion“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk Authors involved in the developing of vir-
tual reality exposure treatment for panic
disorder (”This finding has encouraged us to
design a VRE treatment for PDA. Our VR
programme for PDA includes several VR sce-
narios“)
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”The therapists were well trained in CBT
programmes for PDA. Treatment adherence
across the therapists was ensured by a specific
training in the treatment programmes. Also,
the complete team held weekly meetings to su-
pervise the ongoing treatment of all patients“
Brown 1997
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 18 and 65 years, DSM-III-R diagnosis of panic disorder
with or without agoraphobia, at least 1 panic attack in the month preceding the intake
evaluation
Exclusion criteria: actively psychotic, immediate suicidal or homicidal risk, current
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abuse of any substance, brain-damage, in the manic phase of a bipolar disorder without
medication
Characteristic of the sample:
• Age: not specified for ITT sample (among the 40 completers, mean age was 33
years, SD 9.8, range 19 to 56)
• Percentage of agoraphobic patients: not specified for ITT sample (75% among
the 40 completers)
• Percentage of patients on drug therapy: not specified for ITT sample (52.5%
among the 40 completers)
• Percentage of patients with major depression: not specified
Interventions Participants (n = 48) were randomly assigned to either:
1) Focused cognitive therapy (classified as CBT, n = unclear)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 14
• Duration of intervention: 14 weeks
2) Standard cognitive therapy (classified as CT, n = unclear)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 14
• Duration of intervention: 14 weeks
Outcomes Time points for assessment: baseline, termination, 6 months follow-up, 12 months
follow-up
Measures: panic frequency, Hamilton Anxiety Rating Scale-Revised (HARS-R), Hamil-
ton Rating Scale for Depression-Revised (HRSD-R), Beck Anxiety Inventory (BAI),
BeckDepression Inventory (BDI), Agoraphobic Cognition Questionnaire (ACQ), Panic
Belief Questionnaire (PBQ)
The following outcomes were used for quantitative analyses:
ST-Remission: although reported (panic-free at termination), ST-Remission could not
be calculated following an ITT principle (number of patients randomised to each arm
not specified)
ST- Response: not measured (not imputed)
ST-Dropouts: not measured
Continuous scale: panic frequency
LT-Remission/Response: although reported (panic-free at 12 months follow-up), ST-
Remission could not be calculated following an ITT principle (number of patients
randomised to each arm not specified)
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
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Allocation concealment (selection bias) Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
High risk ”Forty-eight subjects initially agreed to par-
ticipate in the study and 40 patients suc-
cessfully completed the study through the l-
year follow-up period. Of eight patients who
dropped out of the study, one patient was
hospitalized for medical reasons after receiv-
ing five SCT sessions, one patient failed to
complete a significant portion of the outcome
measures at several assessment points, one pa-
tient decided to pursue pharmacotherapy ex-
clusively for panic disorder, three patients de-
cided to pursue alternative psychotherapy in-
terventions, and two patients dropped out of
the study for unknown reasons.“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk ”Focused cognitive therapy for panic disor-
der was developed from a theoretical model
of panic disorder (Beck, Emery, & Greenberg,
1985; Clark, 1986).“
Beck AT is among the study authors.
Therapist allegiance Unclear risk No information provided
Treatment fidelity High risk ”Results of tape ratings indicated that all ther-
apists addressed catastrophic interpretations
according to protocol for the 21 patients in
the FCT group. However, protocol violations
were noted for 8 of the 19 patients who re-
ceived SCT.“
Burke 1997
Methods Study design: randomised controlled trial
Participants Inclusion criteria: females, primary DSM-III diagnosis of agoraphobia. Patients were
instructed not to change their medication during the trial
Exclusion criteria: none
Characteristic of the sample:
• Age: in exposure group, mean age was 40 years, SD 8.9; in CBT group, mean age
was 40.1, SD 11.08
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified for ITT sample (53.8%
among the 26 completers)
• Percentage of patients with major depression: not specified
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Interventions Participants (n = 39) were randomly assigned to either:
1) Exposure (classified as BT, n = 20)
• Therapy format: individual
• Duration of each session: 150 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks
2) Cognitive behaviour therapy (classified as CBT, n = 19)
• Therapy format: individual
• Duration of each session: 180 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks
Outcomes Time points for assessment: baseline, post-treatment, 6 months follow-up
Measures: FearQuestionnaire (FQ), Agoraphobia Questionnaire, Spielberger Trait Anx-
iety Inventory (STAI), Beck Depression Inventory (BDI), behavioural test, Agoraphobic
Cognitions Questionnaire (ACQ), Anxiety Scale of the Cognitions Checklist (CCLAS)
, Probability Questionnaire (PQ), Evaluation Questionnaire (EQ)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (imputed from continuous scale)
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk ACQ (used to determine ST-Remission) is
a self administered scale
Incomplete outcome data (attrition bias)
Short-term
High risk ”Thirteen participants dropped out of treat-
ment.“ Reported data refer to treatment
completers.
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapies under study
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Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”CBT session and a tape of an Exp session
from each therapist to send to an independent
assessor not involved in the trial. The assessor
had been trained to teach CT at the Center
for Cognitive Therapy, Philadelphia and she
teaches a specialist training course in CT in
theUK.’ A table of random numbers was used
to select which of each therapist’s CBT and
Exp tapes were sent to the assessor. The total
sample of tapes came to 18 (10CBT and eight
Exp).“
Carter 2003
Methods Study design: randomised controlled trial
Participants Inclusion criteria: African American population, DSM-IV diagnosis of panic disorder
with agoraphobia
Exclusion criteria: any psychotic disorder, current substance abuse or dependence, sig-
nificant suicidal ideation/gestures, any comorbid condition receiving a clinical severity
rating equal to or greater than that assigned the panic disorder diagnosis
Characteristic of the sample:
• Age: not specified for ITT sample (among the 25 completers, mean age was 42.36
years, SD 6.7, for treatment group; mean age was 4.55 years, SD 5.5, for wait list)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified for ITT sample
(among the 25 completers, 84.5% had comorbid depression)
Interventions Participants (n = 32) were randomly assigned to either:
1) Panic control treatment (classified as CBT, n = 17)
• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 11
• Duration of intervention: 11 weeks
2) Wait-list control(classified as WL, n = 15)
• Mean number of sessions: 0
• Duration of intervention: 11
Outcomes Time points for assessment: baseline, post-treatment
Measures: Structured Clinical Interview for DSM-IV Axis I Disorders (ADIS-IV), Anx-
iety Sensitivity Index (ASI), State-Trait Anxiety Inventory (STAI), Beck Depression In-
ventory (BDI), Beck Depression Inventory (BDI), The Hyperventilation Questionnaire
- Cognitive Subscale (HQC), The Mobility Inventory (MI), African American Accul-
turation Scale - Short Form (AAAS), Attitude Toward Treatment Questionnaire (ATQ)
The following outcomes were used for quantitative analyses:
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ST-Remission: recovery (based on ASI)*
ST- Response: improvement + recovery (based on ASI)*
ST-Dropouts: non-completers
Continuous scale: Anxiety Sensitivity Index (ASI)
LT-Remission/Response: not measured
Notes * ”To assess clinically significant change, the method described by Jacobson and Truax (1991)
was employed. For each dependent variable (except the HQC) for which there were established
cutoff scores and test-retest reliability statistics, the level of functioning following therapy for
each patient was examined and judged whether it was closer to the mean of a functional
population than it was to the dysfunctional population. As suggested by Jacobson and Truax
(1991), a reliable change (RC) index was computed for each group to assess whether fluc-
tuations were likely the result of imprecise measurement. Each patient was categorized as
recovered (score closer to the mean of the functional than dysfunctional group and RC greater
than 1.96), improved but not recovered (score closer to the mean of the functional group, but
the change noted did not exceed the RC cutoff of 1.96), or unimproved.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk ASI (used to determine ST-Remission) is a
self administered scale
Incomplete outcome data (attrition bias)
Short-term
High risk ”Three of the 17 treatment patients were clas-
sified as non-completers. Of the 15 assigned
to the wait-list condition, 4 did not return
for the second evaluation (26.6% attrition).
We report the data from the remaining 25 pa-
tients who completed either treatment or the
wait-list assessment.“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk ”The lead therapist for all groups was a li-
censed clinical psychologist who is an African
Americanmale with 15 years experience with
cognitive behavioral therapy for anxiety dis-
orders.“
116Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Carter 2003 (Continued)
Treatment fidelity Unclear risk No information provided
Clark 1994
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age 18 to 60 years, DSM-III-R diagnosis of panic disorder with no,
mild or moderate agoraphobic avoidance, current episode duration at least 6 months
(this criterion was intended tominimise spontaneous remission, at least 3 panic attacks in
the last 3 weeks, consider panic their main problem, willing to accept random allocation
Exclusion criteria: depressive disorder severe enough to require immediate psychiatric
treatment; cognitive therapy, applied relaxation or imipramine in the current episode;
evidence of organic mental disorder, schizophrenia, alcohol or drug dependence, cardio-
vascular disease, asthma, epilepsy; pregnancy or intention to become pregnant. Concur-
rent Axis II personality disorder was not a reason for excluding patients unless personality
disorder was clearly the primary problem
Characteristic of the sample:
• Age: not specified for ITT sample (among the 64 completers, mean age was 34.6
years, SD 9.2)
• Percentage of agoraphobic patients: not specified for ITT sample (among the
64 completers, 81% had mild or moderate agoraphobic avoidance)
• Percentage of patients on drug therapy: unclear
• Percentage of patients with major depression: not specified
Interventions Participants (n = 72) were randomly assigned to either:
1) Cognitive therapy + in vivo exposure (classified as CBT, n = 17, n = 21 after re-
randomisation of WL patients)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 15
• Duration of intervention: 24 weeks
2) Applied relaxation + in vivo exposure (classified as BT, n = 17, n = 21 after re-
randomisation of WL patients)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 15
• Duration of intervention: 24 weeks
3) Imipramine + in vivo exposure (not included in this review, n = 22, n = 26 after re-
randomisation of WL patients)
• Therapy format: not specified
• Duration of each session: 25 minutes
• Mean number of sessions: 15
• Duration of intervention: 24 weeks
4)Wait list (classified asWL, n= 16; afterwaiting period, 12 patients were re-randomised
to 1 of the 3 active treatments)
• Mean number of sessions: 0
• Duration of intervention: 12 weeks
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Clark 1994 (Continued)
Outcomes Time points for assessment: baseline, 3 months follow-up, 6 months follow-up, 15
months follow-up
Measures: panic frequency, panic-related distress/disability, Beck Anxiety Inventory
(BAI), Hamilton Anxiety Rating Scale (HARS), Fear Questionnaire (FQ), Bodily Sen-
sations Questionnaire (BSQ), Body Sensations Interpretation Questionnaire (BSIQ),
Agoraphobic Cognitions Questionnaire (ACQ), Beck Depression Inventory (BDI)
The following outcomes were used for quantitative analyses:
ST-Remission: high end-state functioning* at 3 months (original sample + re-ran-
domised WL patients)
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers (< 3 sessions) at 3 months (original sample)
Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ), measured on origi-
nal sample + re-randomised WL patients
LT-Remission/Response: high end-state functioning* at 15 months (original sample +
re-randomised WL patients)
Notes *High end-state function was defined as panic-free and an assessor panic-related distress/
disability rating equal or below 2 (’slight’)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Low risk ”Assessments, which included ratings com-
pleted by an assessor who was blind to treat-
ment allocation, were at pre-treatment/wait-
ing-list, 3, 6, and 15 months.“
Incomplete outcome data (attrition bias)
Short-term
Low risk ”Of 72 patients meeting acceptance criteria,
3 dropped out (1per treatment). Five who
agreed initially to random allocation refused
to take imipramine when allocated to that
condition. Drop-outs and refusers after ran-
domisation were replaced and not included in
the data analysis.To be classified as a drop-
out, patients had to start treatment but at-
tend no more than two sessions. Patients who
attended at least three sessions were considered
completers and included in all analyses.“
For this review we are not considering the
imipramine arm, therefore dropouts (CBT
n = 1; BT n = 1; WL n = 0) were low in
number and evenly distributed. Therefore,
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the proportion of missing outcomes is not
enough to have a clinically relevant impact
on the intervention effect estimate
Incomplete outcome data (attrition bias)
Long-term
Low risk (See above)
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk ”Cognitive therapy (CT) was based on the
cognitive theory of panic. Several cognitive
and behavioural techniques (see Clark, 1989;
Salkovskis & Clark, 1991) were used to help
patients identify and change misinterpreta-
tions of bodily sensations.“ Both Clark DM
and Salkovskis PM are among the study au-
thors
Therapist allegiance Unclear risk Insufficient information provided
Treatment fidelity Low risk ”To check therapists’ adherence to the treat-
ment protocol ten audiotapes per treatment
(each from a different patient) were randomly
selected and rated for the presence/absence of
features which should be unique to that treat-
ment and for time spent on procedures which
should be common to all treatments. There
were no protocol violations and the treatments
did not differ in times spent on the common
procedures.“
Clark 1999
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age 18 to 60 years, DSM-III-R diagnosis of panic disorder with no,
mild or moderate agoraphobic avoidance, current episode duration at least 6 months
(this criterion was intended tominimise spontaneous remission, at least 3 panic attacks in
the last 3 weeks, consider panic their main problem, willing to accept random allocation,
no use of medication (or, if taking psychotropic medication, on a stable dose for at least
3 months with an agreement not to change dosage), record of at least one panic attack
while keeping a daily panic diary during a post-interview 2-week baseline period
Exclusion criteria: depressive disorder severe enough to require immediate psychiatric
treatment; previous treatment with cognitive therapy or exposure therapy for panic
disorder; evidence of organicmental disorder, schizophrenia, alcohol or drugdependence,
cardiovascular disease, asthma, epilepsy; pregnancy or intention to become pregnant
Characteristic of the sample:
• Age: mean age 34 years (SD 11.1)
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• Percentage of agoraphobic patients: 85%
• Percentage of patients on drug therapy: 12%
• Percentage of patients with major depression: not specified (30.2% imputed
from BDI)
Interventions Participants (n = 43) were randomly assigned to either:
1) Full cognitive therapy (classified as CBT, n = 15)
• Therapy format: not specified
• Duration of each session: 66 minutes (average)
• Mean number of sessions: 15
• Duration of intervention: 24 weeks
2) Brief cognitive therapy (classified as CBT, n = 14)
• Therapy format: not specified
• Duration of each session: 71.25 (average)
• Mean number of sessions: 8
• Duration of intervention: 24 weeks
3) Wait list (classified as WL, n = 14)
• Mean number of sessions: 0
• Duration of intervention: 12 weeks
Outcomes Time points for assessment: baseline, post-treatment/wait list, 3months post-treatment
follow-up, 12 months post-treatment follow-up
Measures: panic-anxiety composite measure, panic frequency, panic-related distress/dis-
ability, Beck Anxiety Inventory (BAI), Hamilton Anxiety Rating Scale (HARS), Fear
Questionnaire (FQ), Body Sensations Interpretation Questionnaire (BSIQ), Agorapho-
bic Cognitions Questionnaire (ACQ), Beck Depression Inventory (BDI)
The following outcomes were used for quantitative analyses:
ST-Remission: high end-state functioning*
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)
LT-Remission/Response: although measured (high end-state functioning*), data could
not be extracted because the comparison was between the 2 active treatment arms, both
classified as CBT (comparison not feasible)
Notes * ”We defined high end-state functioning as panic free and as an assessor-scored panic-related
distress-disability rating of 2 or less (’slight’)“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
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Blinding of outcome assessment (detection
bias)
ST-Remission
Low risk ”Assessments, which included ratings com-
pleted by an independent assessor who was
unaware of treatment allocation, were at pre-
treatment/wait list, post-treatment/wait list,
3-month post-treatment follow-up, and 12-
month post-treatment follow-up.“
Incomplete outcome data (attrition bias)
Short-term
Low risk ”43 patients were randomized. One patient
(allocated to FCT) dropped out after one ses-
sion, having indicated that she was much im-
proved and could not arrange time off work
for further sessions. All other patients com-
pleted treatment“ (and assessments).
The proportion of missing outcomes is not
enough to have a clinically relevant impact
on the intervention effect estimate
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk ”During the 1980s, several effective cognitive-
behavioral treatments for panic disorder were
developed. The two that have been most ex-
tensively evaluated are the panic control treat-
ment (PCT) developed by Barlow, Craske,
and colleagues and the cognitive therapy pro-
gram developed by Clark, Salkovskis, Beck,
and colleagues.“
”To maximize the amount of change achieved
in each therapy session, we developed a set of
self-study modules covering the main aspects
of therapy and asked patients to complete the
modules prior to therapy sessions.“
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk ”Regular individual supervisionwas provided
throughout the trial.“ Insufficient informa-
tion provided
Cottraux 2009
Methods Study design: Randomised controlled trial
Participants Inclusion criteria: DSM-IV diagnosis of panic disorder with agoraphobia. Eligible pa-
tients were not allowed to take any psychotropic medication, with the exception of low
doses hypnotics, and could not receive psychotherapy during the study
Exclusion criteria: current major depression, or a score greater than 18 on theHamilton
rating scale for depression; bipolar disorder, schizophrenia or other psychotic disorders;
121Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cottraux 2009 (Continued)
alcoholism, or street drugs use; history of CBT for PDA, or a current psychotherapy;
treatment with antidepressants, neuroleptics, anxiolytics or mood stabilisers within the
2 weeks preceding the entry
Characteristic of the sample:
• Age: VRET group mean age 37.7 years (SD 7.3); CBT mean age 36.6 years (SD
10.6); WL mean age 37 (SD 11.3)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: 0%
Interventions Participants (n = 92) were randomly assigned to either:
1) Virtual reality exposure therapy (classified as BT, n = 29; n = 43 after re-randomi-
sation of WL patients)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
2) Cognitive behaviour treatment (classified as CBT, n = 31; n = 44 after re-randomi-
sation of WL patients)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
3) Wait list (classified as WL, n = 32)
• Mean number of sessions: 0
• Duration of intervention: 12 weeks
Outcomes Time points for assessment: baseline, post-treatment/WL (3months), 6months follow-
up, 12 months follow-up
Measures: Fear Questionnaire (FQ), Panic Disorder Severity Scale (PDSS), Chambless
Agoraphobic Cognitions scale (ACQ), Panic, Phobia and Generalized Anxiety Scale
(PPGAS), State and Trait Anxiety questionnaire (STAI), Hamilton Anxiety Rating Scale
(HARS), 21-item Beck Depression Inventory (BDI), Sheehan Disability Scale (SDS),
Global Assessment of Functioning scale (GAF), Dissociative Experience Scale (DES),
Work and Social Adjustment scale (WSA)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (imputed from continuous scale)
ST-Response: at least 50% reduction of FQ-Ag score (original sample) at post-treatment
ST-Dropouts: non-completers (original sample)
Continuous scale: Panic Disorder Severity Scale (PDSS; measured on original + re-
randomised sample)
LT-Remission/Response: although measured (at least 50% reduction of FQ-Ag score at
12 months follow-up) data were not entered in the analyses because dropouts exceeded
30% of originally randomised sample (see Secondary outcomes).
Notes None
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Low risk ”Randomizationwas kept secret and delivered
by the biostatistics department of the CHU of
Lyon through a phone call to the secretary of
each center“
Blinding of outcome assessment (detection
bias)
ST-Remission
Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
High risk At post-treatment, 63 patients (on 92 orig-
inally randomised) were assessed (see study
flow chart)
Incomplete outcome data (attrition bias)
Long-term
High risk At 12months follow-up, 51 patients (on 87
randomised) were assessed (see study flow
chart)
Selective reporting (reporting bias) Low risk Study protocol available. All of the study’s
pre-specified (primary and secondary) out-
comes that are of interest in the review have
been reported in the pre-specified way
Researcher allegiance Unclear risk Insufficient information provided
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Craske 1995
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 18 and 65 years, principal diagnosis of panic disorder
with or without agoraphobia according to DSM-III-R criteria, willingness to random
assignment to 17 weeks of either placebo or varying dosage regimes of a psychoactive
medication, successful withdrawal frompsychotropicmedications for at least 7 days prior
to initial diagnostic evaluation
Exclusion criteria: hypersensitivity to benzodiazepines; diagnoses of organic disorders,
obsessive-compulsive disorder, psychoses, bipolar disorder, adjustment disorder and cur-
rent (within the last 6 months) substance abuse/dependence; suicidality; serious medical
conditions
Characteristic of the sample:
• Age: 36.1 years (SD 11, range 21 to 57)
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• Percentage of agoraphobic patients: 67%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified
Interventions Participants (n = 30) were randomly assigned to either:
1) Cognitive behaviour therapy (classified as CBT, n = 16)
• Therapy format: individual
• Duration of each session: 75 minutes
• Mean number of sessions: 4
• Duration of intervention: 4 weeks
2) Nondirective supportive therapy (classified as SP, n = 14)
• Therapy format: individual
• Duration of each session: 75 minutes
• Mean number of sessions: 4
• Duration of intervention: 4 weeks
Outcomes Time points for assessment: baseline, post-treatment
Measures: panic disorder and agoraphobia sections of the ADIS-R, Anxiety Sensitivity
Index (ASI), Fear Questionnaire (FQ), Four Dimensional Anxiety, Subjective Symptoms
Scale
The following outcomes were used for quantitative analyses:
ST-Remission: ASI reduced from baseline and < 28 at post-treatment
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Anxiety Sensitivity Index (ASI)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk ASI is a self rated measure
Incomplete outcome data (attrition bias)
Short-term
Unclear risk ”Sixteen subjects were assigned randomly to
CBT, and 14 to NST. One subject dropped
out from NST, none dropped out from CBT.
“
The proportion of missing outcomes is not
enough to have a clinically relevant impact
on the intervention effect estimate
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Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk CraskeMG is author of a CBTmanual (see
Barlow 2000b)
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk ”Treatment integrity was addressed via man-
ualized treatments, and ongoing therapy su-
pervision, with review and feedback of ap-
proximately 25% of audiotapes of treatment
sessions by the principal author.“
It is unclear whether all sessions were
recorded and selection of audiotapes was
randomised
Craske 2005a
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-IV principal diagnosis of panic disorder with or without ago-
raphobia. Those who were medicated at the time of the initial diagnostic evaluation were
withdrawn from psychotropic medications over a minimum of 4 weeks and washed out
for at least 2 weeks prior to a repeat diagnostic evaluation to re-determine study eligibility
Exclusion criteria: history of bipolar disorder, psychosis, posttraumatic stress disorder
or current substance abuse/dependence
Characteristic of the sample:
• Age: not specified for randomised sample
• Percentage of agoraphobic patients: 29.2%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: 30.3%
Interventions Participants (n = 43) were randomly assigned to either:
1) Cognitive behaviour therapy (classified as CBT, n = 27)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 11
• Duration of intervention: 10 weeks
2) Wait list (classified as WL, n = 16)
• Mean number of sessions: 0
• Duration of intervention: 10 weeks
Outcomes Time points for assessment: baseline, post-treatment, 12 months (after commence-
ment) follow-up
Measures:panic disorder severity (ADIS-IV), Anxiety Sensitivity Index (ASI), FearQues-
tionnaire-Agoraphobia subscale (FQ-Ag), Beck Depression Inventory (BDI), Beck Anx-
iety Inventory (BAI), Subjective Symptoms Scale (SSS)
The following outcomes were used for quantitative analyses:
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Craske 2005a (Continued)
ST-Remission: high end-state functioning*
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Anxiety Sensitivity Index (ASI)
LT-Remission/Response: not measured
Notes * ”Defined as zero daytime and zero nocturnal panic attacks per week over last 2 weeks, panic
disorder severity of 3 or less, and no/mild agoraphobia“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
Unclear risk ”Of 43 participants, 27were assigned toCBT;
3 (11.1%) withdrew during treatment. Six-
teen were assigned to WL; none withdrew
during WL, but 3 (18.8%) withdrew before
(n = 2) or during (n = 1) delayed CBT. Rea-
sons for withdrawal are not known.“
It is unclear whether non-completers were
assessed at post-treatment (probably so)
Incomplete outcome data (attrition bias)
Long-term
Unclear risk Number of assessed patients at 12 months
follow-up is not reported
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk CraskeMG is author of a CBTmanual (see
Barlow 2000b)
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”Each treatment session was audiotaped and
25% (n = 112) were selected randomly for
independent adherence ratings of each content
item of each session (1 = none, 7 = complete
adherence) 2 and percent of off-task discus-
sion. [...] Average adherence ratings ranged
from 4.95 (SD = 0.77) to 6.01 (SD = 1.00)
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, with a total average of 5.64 (SD -- 0.96),
indicating good adherence overall.“
Creager Berger 2001
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age 18 to 60 years, DSM-IV diagnosis of panic disorder
Exclusion criteria: exhibiting characteristics of, or currently diagnosed with schizophre-
nia or any personality disorder; evidence of organic brain syndrome or mental retarda-
tion; any change in psychotropic or other medications or currently taking a medication
for less than 2 weeks; medical conditions that would interfere with the diagnosis and/
or treatment of panic disorder not due to a medical condition; report or exhibition of
characteristics of present substance abuse that would meet DSM-IV criteria; unwilling-
ness or inability to give informed consent; experiencing less than 3 panic attacks within
a 4-week period
Characteristic of the sample:
• Age: not specified for ITT sample (among completers, mean age was 35.3 years,
SD 10.14)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified on ITT sample (90%
among completers)
• Percentage of patients with major depression: not specified
Interventions Participants (n = unclear) were randomly assigned to either:
1) Breathing retraining (classified as PT, n = unclear)
• Therapy format: group/individual
• Duration of each session: 45 minutes
• Mean number of sessions: 6
• Duration of intervention: 6 weeks
2) Cognitive therapy (classified as CBT, n = unclear)
• Therapy format: group/individual
• Duration of each session: 67.5 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks
Outcomes Time points for assessment: pre-treatment, baseline (first session), termination (last
session), 4 weeks after termination
Measures: panic diary, Beck Depression Inventory (BDI), Panic Disorder Severity Scale
(PDSS), end tidal carbon dioxide level (ETCO ), respiratory rate
The following outcomes were used for quantitative analyses:
ST-Remission: although reported (panic-free at termination), ST-Remission could not
be calculated following an ITT principle (number of patients randomised to each arm
not specified)
ST- Response: not measured (not imputed)
ST-Dropouts: not reported
Continuous scale: Panic Disorder Severity Scale (PDSS) at pre-treatment and at 4 weeks
after termination
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LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Random assignment occurred by using the
random number table from a Sharp scientific
calculator“
Allocation concealment (selection bias) Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
High risk ”Of those accepted into the study, one became
ineligible after beginning antidepressants af-
ter session 3 of the cognitive therapy group, one
failed to attend her 6th breathing retraining
session and could not be reached by phone, one
dropped out of the cognitive behavioral ther-
apy after session 6, five people failed to show
up for the first session and could not be reached
by phone, three people stated that they were
too busy or not interested in beginning the
study, and four people did not return phone
calls after the initial screening.“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”The primary investigator of the study trained
each of the therapists andmet with each thera-
pist for 2 hours per week during the treatment
phase to review the previous session and pre-
view the following session. Additionally, the
CBT therapists brought a script into each ses-
sion with them in order to ensure thorough
deliverance of the treatment.“
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De Ruiter 1989
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-III-R diagnosis of Panic Disorder with Agoraphobia. Only
patients who recognised the symptoms induced by voluntary hyperventilation as similar
to their panic attacks were included in the study
Exclusion criteria: psychotic symptoms; substance abuse
Characteristic of the sample:
• Age: mean 34 years (SD 9.2, range 22 to 60). These data probably refer to the
completers sub-sample.
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified for ITT sample (49%
among completers)
• Percentage of patients with major depression: not specified
Interventions Participants (n = 49) were randomly assigned to either:
1) Breathing retraining/cognitive restructuring (classified as CBT, n = 17)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks
2) Exposure therapy (classified as BT, n = 17)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks
3)Breathing retraining/cognitive restructuring + exposure therapy (classified asCBT,
n = 15)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks
Outcomes Time points for assessment: baseline (4 weeks prior to treatment), pre-treatment, post-
treatment
Measures: Fear Surrey Schedule-III (FSS-IZZ), phobic anxiety and avoidance scales,
panic attack diary, Bodily Sensations Questionnaire (BSQ), Symptom CheckIist-90
(SCL-90), respiratory rate (RR) and end tidal carbon dioxide pressure (pC0 )
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (imputed from continuous scale)
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Bodily Sensations Questionnaire (BSQ)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk BSQ (used to impute ST-Remission) is a
self rated measure
Incomplete outcome data (attrition bias)
Short-term
High risk ”Of the 49 patients who entered treatment, 40
completed the program. Attrition rates were 4
(24%) for BRCR, 4 (24%) for EXP and 1
(6%) for BRCR + EXP“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk ”Supervision by a senior clinical psychologist
(the second author) was provided on a weekly
basis.“ Unclear whether all sessions for all
patients were supervised
Dow 2000
Methods Study design: randomised controlled trial
Participants Inclusion criteria: between 18 and 60 years of age; DSM-IV diagnosis of panic disorder,
with or without agoraphobia; current episode duration of at least 3 months; consider
panic the main problem; willing to accept random allocation, including the wait list
condition. All patients taking medication at the time of entry must have been on a stable
dose for 3 months and must have been willing and able to remain on a stable regime for
3 months during the course of treatment
Exclusion criteria: depressive disorder severe enough to require urgent treatment; un-
dergoing CBT for the current episode; evidence of organic mental disorder, schizophre-
nia, alcohol or drug dependence, cardiovascular disease, asthma, epilepsy, or pregnancy
or intention to become pregnant during the course of the study. Concurrent Axis II
personality disorder was not a reason for exclusion unless the personality disorder was
clearly the primary problem
Characteristic of the sample:
• Age: mean age 36.8 years (SD 10)
• Percentage of agoraphobic patients: 76.1%
• Percentage of patients on drug therapy: not specified for ITT sample (among
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completers: 46.4% of Australian patients and 14.1% of Scottish patients)
• Percentage of patients with major depression: not specified
Interventions Participants (n = 186) were randomly assigned to either:
1) CBT - 12 sessions - therapist delivered (classified as CBT, n = 45)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
2) CBT - 6 sessions - therapist delivered (classified as CBT, n = 45)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 6
• Duration of intervention: 6 weeks
3) CBT - 6 sessions - computer augmented (classified as CBT, n = 50)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 6
• Duration of intervention: 6 weeks
4) Wait list (classified as WL, n = 46)
• Mean number of sessions: 0
• Duration of intervention: unclear
Outcomes Time points for assessment: baseline, post-treatment, 6 months follow-up
Measures: panic frequency, panic-related distress/disability, Fear Questionnaire (FQ),
Mobility Inventory for Agoraphobia (MI), Body Sensations Questionnaire (BSQ), Ago-
raphobic Cognitions Questionnaire (ACQ), State-Trait Anxiety Inventory, Trait subscale
(STAI-T), Beck Depression Inventory (BDI), Medical Outcomes Survey Short Form 36
(SF-36)
The following outcomes were used for quantitative analyses:
ST-Remission: panic-free at post-treatment
ST- Response: not measured (not imputed)
ST-Dropouts: not measured (the number of non-completers for each arm is not speci-
fied)
Continuous scale: although measured, data cannot be used because number of assessed
patients is not reported
LT-Remission/Response: although measured (panic-free at follow-up), data cannot be
used because re-randomisation of WL patients leaves only 3 arms, all classified as CBT
(comparison not feasible)
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
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Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
High risk ”In total, 186 patients met entry criteria and
were offered and accepted a place in the study.
Of these, 163 patients (87.6%) commenced
treatment (wait list, n=41; CBT6, n=39;
CBT6-CA, n=41; CBT12, n=42). Twenty-
three patients (14.1%) failed to receive at
least three sessions of their respective course of
treatment or to provide adequate data and
were classified as dropouts.“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”All sessions for all treatment conditions were
tape-recorded, and a random selection (20%)
of tapes were exchanged between sites and
rated by Justin A. Kenardy andMichael G. T.
Dow to ensure adherence to treatment proto-
cols and therapeutic competence. There were
no significant effects for site, treatment, or Site
Treatment on protocol adherence or therapeu-
tic adequacy. Therapists also completed a sepa-
rate checklist for each therapy session to evalu-
ate adherence to the protocol. The correlation
between therapist-rated and externally rated
protocol adherence was 0.92 (p .001). No sig-
nificant differences were found on therapist-
rated treatment protocol compliance across site
or treatment or for Site Treatment. Overall,
there was 97.1% protocol adherence.“
Other bias Unclear risk Modification of the original sample with
replacements. Number and randomisation
of replacements not specified
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Dreessen 1994
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 17 and 70 years, primary DSM-III-R diagnosis of panic
disorder with no or mild agoraphobic avoidance, panic disorder for at least 12months, at
least a mean of 1 panic attack per week during the previous 4 weeks, asking for treatment
of panic disorder, no use of serotonergic antidepressants or benzodiazepines (for at least
4 weeks)
Exclusion criteria: depressive disorder preceding the current episode of panic disorder or
requiring immediate treatment; behaviour therapy received for panic disorder; evidence
of organic mental disorders, psychotic disorders, alcohol or drug dependence, cardio-
vascular disease, asthma, epilepsy; medical contraindication for exposure, behavioural
experiments or hyperventilation
Characteristic of the sample:
• Age: not specified for ITT sample (among completers, mean age was 34.1 years,
range 21 to 52)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified (mood disorder
11% among completers)
Interventions Participants (n = 37) were randomly assigned to either:
1) Cognitive therapy (classified as CT, n = unclear)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 15
• Duration of intervention: 13 weeks (plus 2 sessions after 1 and 6 months)
2) Applied relaxation (classified as PT, n = unclear)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 15
• Duration of intervention: 13 weeks (plus 2 sessions after 1 and 6 months)
Note that ”after the last patient entered the study, a waiting-list control group was formed.
The first 11 men and 7 women meeting the same criteria as used for the treatment group were
drawn from the waiting-list to form a control group.“ This control group is not considered
for this review because it is not randomised
Outcomes Time points for assessment: baseline, post-treatment (13 weeks), 1-month follow-up,
6-month follow-up
Measures: panic diary, Fear of Fear Questionnaire, Fear Questionnaire (FQ), State-Trait
Anxiety Inventory (STAI), Depressive Symptoms Inventory (DSI), SymptomCheck List
(SCL-90)
The following outcomes were used for quantitative analyses:
ST-Remission: although measured (panic-free at post-treatment) detailed data are not
reported
ST- Response: not measured
ST-Dropouts: detailed data are not reported
Continuous scale: although measured, detailed data are not reported
LT-Remission/Response: although measured (panic-free at 6 months follow-up) de-
tailed data are not reported
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Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Selective reporting (reporting bias) High risk Study protocol unavailable. Pre-planned
measures are not reported with sufficient
details
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk ”Weekly supervision was given by the first au-
thor during the whole treatment.“ It is un-
clear whether all sessions for all patients
were supervised
Emmelkamp 1986
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-III diagnosis of agoraphobia
Exclusion criteria: none
Characteristic of the sample:
• Age: not specified for ITT sample (among completers, mean age was 36 years, SD
18 to 56)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified for ITT sample (34.8%
among completers)
• Percentage of patients with major depression: not specified
Interventions In a first phase of the study, participants (n = 51) were randomly assigned to either:
1) Exposure in vivo (classified as BT, n = unclear)
• Therapy format: group
• Duration of each session: 150 minutes
• Mean number of sessions: 6
• Duration of intervention: 3 weeks (1st phase)
2) Rational emotive therapy (classified as CT, n = unclear)
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• Therapy format: group
• Duration of each session: 150 minutes
• Mean number of sessions: 6
• Duration of intervention: 3 weeks (1st phase)
3) Self instructional training (classified as CT, n = unclear)
• Therapy format: group
• Duration of each session: 150 minutes
• Mean number of sessions: 6
• Duration of intervention: 3 weeks (1st phase)
In a second phase of the study, all patents received 6 group sessions (150 minutes each)
of exposure in vivo
Outcomes Time points for assessment: baseline, post-test
Measures: behavioural walk, phobic anxiety and avoidance scales, Fear Questionnaire
(FQ), Irrational Belief Test (IBT), Symptom Check List (SCL-90)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured
ST- Response: not measured
ST-Dropouts: not reported
Continuous scale: although measured, detailed data are not reported
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Selective reporting (reporting bias) High risk Study protocol unavailable. Pre-planned
measures are not reported with sufficient
details
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk ”Therapists received a special training for the
research project and extensive manuals were
used. Therapists were supervised by the senior
author.“ It is unclear whether all sessions for
all patients were supervised
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Erickson 2003
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-IV diagnosis of either panic disorder with or without ago-
raphobia, OCD, social phobia, generalised anxiety disorder, specific phobia or PTSD.
There were no limitations on past or concurrent treatments
Exclusion criteria: active substance abuse or dependence or psychosis
Characteristic of the sample (PDA sub-sample):
• Age: not specified for PDA sub-sample
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified for PDA sub-sample
• Percentage of patients with major depression: not specified for PDA sub-sample
Interventions Participants (PDA sub-sample, n = 36) were randomly assigned to either:
1) Cognitive behaviour therapy (classified as CBT, n = unclear)
• Therapy format: group
• Duration of each session: 120 minutes
• Mean number of sessions: 11
• Duration of intervention: 11 weeks
2) Wait list (classified as WL, n = unclear)
• Mean number of sessions: 0
• Duration of intervention: 11 weeks
Outcomes Time points for assessment: baseline, post-treatment
Measures: Beck Anxiety Inventory (BAI)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured
ST- Response: although measured (40% reduction in BAI score), data for the PDA sub-
sample are not reported
ST-Dropouts: not reported for PDA sub-sample
Continuous scale: the only available measure (BAI) is not considered among outcomes
of interest for this review (see Secondary outcomes)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
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Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”We assessed clinicians’ adherence to the pro-
tocol by asking independent raters to listen to
audiotapes of a random sample of sessions (33
tapes, or one of every four sessions). Overall,
the ratings indicated that group leaders ad-
hered closely to the intended protocol and that
quality of implementation was midway be-
tween good and very good.“
Gloster 2010
Methods Study design: multicentre randomised controlled trial
Participants Inclusion criteria: 18 to 65 years old (see protocol), DSM-IV-TR diagnosis of panic
disorder with agoraphobia, score of 18 or more on the Hamilton Anxiety Scale (HAM-
A), score of 4 or more on the Clinical Global Impression (CGI). Patients had to agree
to discontinue all psychopharmacological medication and were not allowed to have any
concomitant psychotherapy. Patients on psychopharmacological medication underwent
a washout period prior to baseline
Exclusion criteria: unable to comply with the study schedule or requirements; clinically
significant suicidal intent; DSM-IV-TR diagnosis of any psychotic or bipolar disorder,
borderline personality disorder, or current alcohol dependence; medical condition that
could explain symptoms. Other current comorbid diagnoses, including unipolar depres-
sion and other anxiety disorders, were allowed unless they were of primary clinical con-
cern
Characteristic of the sample:
• Age: in the 3 groups age mean (SD) were respectively: 35.5 (SD 11); 35.5 (SD
10.4); 35.6 (SD 11.2)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: 43.2%
Interventions Participants (n = 369) were randomly assigned to either:
1) CBT variant with therapist-guided exposure outside the therapy room (classified
as BT, n = 163)
• Therapy format: individual
• Duration of each session: 100 minutes
• Mean number of sessions: 14
• Duration of intervention: unclear (12 sessions over 6 weeks + 2 booster sessions
at unspecified time)
2) CBT variant with non-therapist-guided exposure outside the therapy room (clas-
sified as BT, n = 138)
• Therapy format: individual
• Duration of each session: 100 minutes
• Mean number of sessions: 14
• Duration of intervention: unclear (12 sessions over 6 weeks + 2 booster sessions
137Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gloster 2010 (Continued)
at unspecified time)
3) Wait list (classified as WL, n = 68)
• Mean number of sessions: 0
• Duration of intervention: not specified
Outcomes Time points for assessment: baseline, intermediate (after the 4th session), post-treat-
ment, 6 months follow-up
Measures: Structured Interview Guide for theHamilton Anxiety Scale (HAM-A/SIGH-
A), Clinical Global Impression (CGI), Panic Agoraphobia Scale (PAS), Mobility Inven-
tory - Agoraphobia subscale (MI-Ag)
The following outcomes were used for quantitative analyses:
ST-Remission: PAS score ≤ 8 at post-treatment
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Panic Agoraphobia Scale (PAS)
LT-Remission/Response: although measured (PAS score ≤ 8 at 6 months follow-up),
data cannot be used because re-randomisation of WL patients leaves only 2 arms, both
classified as BT (comparison not feasible)
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Low risk ”The randomization list was generated at the
clinical coordination center (Dresden) by per-
sonnel not associated with patient care. The
study centers were blind to the assignment of
subsequent cases and were informed of treat-
ment status only after a fax documenting the
included patient was sent to the clinical coor-
dination center.More numbers for each center
were drawn than necessary so that treatment
condition of final patients in each study cen-
ter remained unpredictable, thereby ensuring
blinding of the randomization throughout the
study.“
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk The Panic Agoraphobia Scale (PAS, used
to determine ST-Remission) is a self report
questionnaire
Incomplete outcome data (attrition bias)
Short-term
High risk A total of 63 patients (34 + 25 + 4) were
lost at post-treatment assessment (see study
flow chart)
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Selective reporting (reporting bias) High risk Not all of the study’s pre-specified primary
outcomes have been reported (Aggregated
Panic Disorder Scale and Mobility Inven-
tory: PDS-MI score). One reported out-
come was not pre-specified (PAS)
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”All treatment sessions were videotaped, and
a randomly selected sample of almost 18%
was evaluated. All raters were blind to treat-
ment condition and evaluated each tape us-
ing the therapist adherence and competence
rating scale for PD and AG. Adherence
and competence were assessed on the basis
of a 9-point scale from 0 (nonexistent) to
8 (optimal adherence/excellent competence).
Themean overall ratings of therapy adherence
and competence across all sessions were 5.53
(SD 1.29) and 5.73 (SD 1.26), respectively,
indicating that therapists demonstrated good
levels of adherence to the manual and imple-
mented it with good levels of competence.“
Goldstein 2000
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 18 and 65 years, DSM-IV diagnosis of panic disorder
with agoraphobia at least 1 year’s duration, agoraphobic avoidance at least moderately
severe for the prior 6 months. Participants excluded on the basis of recent medication
changes were eligible for reconsideration once medications were stabilised in appropriate
limits
Exclusion criteria: being in therapy elsewhere if not willing to suspend that treatment
until the end of the study; on dosages of alprazolam in excess of 1.5 mg daily (or similar
dosages for other benzodiazepines); taking antidepressant or antianxiety medication for
less than 6months or change of medication within the last 12 weeks; comorbid diagnoses
of thought disorder, major depression, bipolar disorder, or substance dependence; pres-
ence of another anxiety disorder more severe than the PDA; DSM-IV diagnosis of any of
the following Axis II disorders: paranoid, schizoid, schizotypal, antisocial or borderline
Characteristic of the sample:
• Age: mean 38.16 years (range 22 to 63)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: 45.65%
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• Percentage of patients with major depression: 0%
Interventions Participants (n = 46) were randomly assigned to either:
1) EMDR (not included in this review, n = 18)
• Therapy format: not specified
• Duration of each session: 90 minutes
• Mean number of sessions: 6
• Duration of intervention: 4 weeks
2) Association and relaxation therapy (classified as PT, n = 13)
• Therapy format: not specified
• Duration of each session: 90 minutes
• Mean number of sessions: 6
• Duration of intervention: 4 weeks
3) Wait list (classified as WL, n = 15)
• Mean number of sessions: 0
• Duration of intervention: 4 weeks
Outcomes Time points for assessment: baseline, termination, 5 to 6 weeks after termination
Measures: Agoraphobic Cognitions Questionnaire (ACQ), Body Sensations Question-
naire (BSQ), Brief Body Sensations Interpretation Questionnaire (BBSIQ), Panic Ap-
praisal Inventory (PAl), Mobility Inventory (MI), Beck Depression Inventory (BDI)
, Beck Anxiety Inventory (BAI), Brief Symptom Inventory (BSI), Social Adjustment
Scale-Self-Report (SAS-SR), Distress Questionnaire, Panic Disorder Symptom
Severity interview (PDSS), panic/anxiety diary
The following outcomes were used for quantitative analyses:
ST-Remission: not measured
ST- Response: not measured
ST-Dropouts: non-completers
Continuous scale: although measured, data concerning ART group are not reported.
EMDR is not an included treatment, therefore only data on WL patients could be
extracted (comparison not feasible)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
High risk ”Of the 46 participants who entered the study,
4 dropped out prior to the completion of treat-
ment. One dropped out during the waiting
list period before she provided posttest data
or received her treatment condition assign-
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ment. Three participants (one of whom had
previously been in the waiting list condi-
tion) dropped out or were terminated during
EMDR: one because of a marital crisis, an-
other because of deterioration, and a third for
repeated cancellations of appointments.“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable. Data concern-
ing ART group are not reported
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”To ensure that therapists adhered to the treat-
ment protocol, all sessions were audio- Or
videotaped and reviewed by Alan J. Goldstein
prior to supervisionmeetings, which were held
weekly to discuss clinical issues and proper pro-
vision of treatment. Two of the authors, Di-
anne L. Chambless and Kimberly A. Wilson,
and their trained research assistants followed
detailed integrity checklists that assessed ad-
herence to treatment protocol, presence of ther-
apist support and reinforcement, and protocol
violations, which included introducing other
treatments into the session. Adherence checks
were conducted on 31% (n = 80) of all ses-
sions. Of these, 33 were independently rated
by additional coders to assess reliability. Av-
erage percent agreement was 95% for the in-
tegrity items identified a priori to be most im-
portant. The adherence monitoring team was
not otherwise involved in participants’ treat-
ment and was unaware of participants’ treat-
ment outcome.“
Other bias Unclear risk Modification of the original sample with
replacements. Number and randomisation
of replacements not specified
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Methods Study design: randomised controlled trial
Participants Inclusion criteria:DSM-III-R diagnosis of panic disorder with or without agoraphobia.
Subjects were dissuaded from participating in other therapy or self help procedures
during the study. Subjects taking medication for anxiety or depression were allowed
to participate if they had been stabilised on the medication for at least 4 weeks and
continued to have panic symptoms
Exclusion criteria: seizure disorder, kidney disease, stroke, schizophrenia, organic brain
syndrome, emphysema, heart attack, chronic hypertension
Characteristic of the sample:
• Age: not specified for ITT sample (among completers, mean age was 35.7, SD
10.2, range 19 to 59 years)
• Percentage of agoraphobic patients: not specified for ITT sample (94% among
completers)
• Percentage of patients on drug therapy: not specified for ITT sample (16%
among completers)
• Percentage of patients with major depression: not specified
Interventions Participants (n = 33) were randomly assigned to either:
1) Bibliotherapy (not included in this review, n = 12)
• Therapy format: self help
• Duration of each session: 0 minutes
• Mean number of sessions: 0
• Duration of intervention: 4 weeks
2) Guided imaginal coping (classified as CBT, n = 9)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 4 weeks
3) Wait list (classified as WL, n = 12)
• Mean number of sessions: 0
• Duration of intervention: 7 weeks
Outcomes Time points for assessment: baseline, post-treatment
Measures: Daily Panic Attack Records (DPAR), Panic Cognitions Questionnaire
(PACQ), Panic Symptoms Questionnaire (PASQ), Mobility Inventory for Agoraphobia
(MI), Anxiety Sensitivity Index (ASI), Beck Depression Inventory (BDI), Likelihood
of Having a Panic Attack, Your Thoughts During a Panic Attack, Coping with Panic
Attacks, Panic Self-Efficacy Questionnaire
The following outcomes were used for quantitative analyses:
ST-Remission: panic-free
ST- Response: panic-free OR 50% reduction in number of panic attacks, panic symp-
toms
ST-Dropouts: non-completers
Continuous scale: Anxiety Sensitivity Index (ASI). Note that reported SDs are uncom-
monly low, so we considered them as being SEs
LT-Remission/Response: not measured
Notes None
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk Panic frequency (used to determine ST-Re-
mission) was self rated
Incomplete outcome data (attrition bias)
Short-term
Low risk ”Only 2 subjects dropped out: 1 from the WL
group and 1 from the BT group. The subject
from the WL group reported that she had to
move to a different state to seek employment
and could no longer continue in the study.
The subject from the BT condition completed
all the dependent measures of the study, but
was not included in the analyses because she
had failed to read the book.“
For this review we are not considering the
bibliotherapy arm, therefore data are miss-
ing for only one subject (WL) and reasons
for missing outcome data are unlikely to be
related to true outcome
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk In bibliotherapy arm, ”subjects read the
book Coping with Panic (Clum, 1990).“ In
Guided Imaginal Coping arm, ”the proto-
col for each of the eight treatment sessions was
outlined for therapists. These plans were de-
rived primarily frommaterial in Coping with
Panic.“
Clum G is among the study authors.
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”The second author supervised the four thera-
pists weekly in order to ensure the uniformity
of treatment procedures, and the research team
met regularly for discussion. In addition, some
treatment sessions were observed directly, or
videotaped and later observed by the first and
second authors. A random sample of 8 sessions
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was observed to ensure treatment integrity.“
Griegel 1995
Methods Study design: randomised controlled trial
Participants Inclusion criteria:DSM-III-R diagnosis of panic disorder with or without agoraphobia.
Subjects using psychotropic medications were required to maintain a stable dosage for
at least 1 month and throughout treatment and evaluation
Exclusion criteria: comorbid DSM-III-R diagnosis rated as severe as panic disorder;
being in psychotherapy for anxiety (subjects who were in psychotherapy for other psy-
chological difficulties were included if they had been in a stable therapeutic relationship
for at least 3 months)
Characteristic of the sample:
• Age: not specified for ITT sample (among completers, mean age was 36.03 years,
SD 8.02, range 21 to 52)
• Percentage of agoraphobic patients: unclear (data are measured on 36 patients,
not 37. Among these 36 patients, 86% are agoraphobic)
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified
Interventions Participants (n = 37) were randomly assigned to either:
1) Breathing retraining - slow respiration rate (classified as PT, n = 11)
• Therapy format: not specified
• Duration of each session: 42.5 minutes
• Mean number of sessions: 3
• Duration of intervention: 2 weeks
2) Breathing retraining - increase respiration rate (classified as PT, n = 12)
• Therapy format: not specified
• Duration of each session: 42.5 minutes
• Mean number of sessions: 3
• Duration of intervention: 2 weeks
3) Wait list (classified as WL, n = 14)
• Mean number of sessions: 0
• Duration of intervention: 4
Outcomes Time points for assessment: baseline, post-treatment.
Measures: Anxiety Disorders Interview Schedule-R (ADIS-R), Anxiety Sensitivity Index
(ASI), Emotional Control Questionnaire (ECQ), Self-Efficacy Questionnaire (SEQ),
Diagnostic Symptom Questionnaire (DSQ), Interoceptive Exposure Test (IET), respi-
ratory rate
The following outcomes were used for quantitative analyses:
ST-Remission: panic-free
ST- Response: not measured
ST-Dropouts: non-completers
Continuous scale: Anxiety Sensitivity Index (ASI)
LT-Remission/Response: not measured
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Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Low risk Panic frequency was rated by assessors. ”As-
sessors who conducted evaluations at pre- and
post-assessment were blind to the subjects’ ex-
perimental condition.“
Incomplete outcome data (attrition bias)
Short-term
High risk ”The first 37 subjects agreeing to participate
were randomly assigned to one of three groups
to enlist the requisite sample size of 10 subjects
per cell (7 subjects dropped out of the study
before completion of the post-assessment).“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk ”All sessions were audiotaped and 25% of
these tapes were rated by an assessor blind to
the treatment conditions, who was then asked
to identify the treatment condition being con-
ducted. Accurate identification of treatment
protocol was made 93% of the time (14/15)
. One tape was inaudible and could not be
rated.“ It is unclear whether the selection of
tapes to assess was random
Hazen 1996
Methods Study design: randomised controlled trial
Participants Inclusion criteria: 18 years of age or older, primary DSM-III-R diagnosis of panic
disorder with or without agoraphobia, minimum Grade 8 reading and writing ability,
physician agreement regarding participation
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Exclusion criteria: presence of organic disease which might be related to panic disorder
or interfere with participation in the study; presence of other serious psychiatric disor-
ders, specifically psychotic disorders, substance abuse and current major depressive dis-
order; presence of significant suicidal risk; involvement in other psychological treatment;
current pharmacological treatment for panic disorder, with the exception of low doses of
benzodiazepines (equivalent of 20 mg diazepam or less) or stable doses of antidepressants
(i.e. prescribed for at least 6 months and stable dose for at least 3 months)
Characteristic of the sample:
• Age: not specified for ITT sample (among completers, mean age was 37.12 years,
SD 9.57, range 20 to 73 years)
• Percentage of agoraphobic patients: not specified for ITT sample (92.4%
among completers)
• Percentage of patients on drug therapy: not specified for ITT sample (45%
among completers)
• Percentage of patients with major depression: 0%
Interventions Participants (n = 117) were randomly assigned to either:
1) Individual self administration of the self help manual (not included, n = unclear)
• Therapy format: individual
• Mean number of sessions: 0
• Duration of intervention: weeks
2) Use of the manual in a self help treatment group (not included, n = unclear)
• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 13
• Duration of intervention: 14 weeks
3) Use of the manual in a treatment group led by professional therapists (classified
as CBT, n = unclear)
• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 13
• Duration of intervention: 14 weeks
4) Wait list (classified as WL, n = unclear)
• Mean number of sessions: 0
• Duration of intervention: 14 weeks
Outcomes Time points for assessment: baseline, post-treatment
Measures: Anxiety Sensitivity Index (ASI), Fear Questionnaire-Agoraphobia Subscale
(FQ-Ag), Sheehan Patient-Rated Anxiety Scale (SPRAS), Clinical Global Improvement
(CGI)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (not imputed: number of randomised patients for each
arm not specified)
ST- Response: not measured (not imputed: number of randomised patients for each
arm not specified)
ST-Dropouts: not reported by treatment group
Continuous scale: Anxiety Sensitivity Index (ASI)
LT-Remission/Response: not measured
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Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
High risk ”Of the 117 subjects enrolled in the evalua-
tion study, 106 completed the Anxiety Sensi-
tivity Index at pre- and posttreatment. These
subjects comprised the sample for the present
study.“ No further detail about these 11
dropouts is reported.
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Hendriks 2010
Methods Study design: randomised controlled trial
Participants Inclusion criteria: adults aged over 60 years, principal DSM-IV diagnosis of panic dis-
order with or without agoraphobia. Co-morbidity with other anxiety disorders, depres-
sion or dysthymia was allowed as long as PD(A) was the principal diagnosis. Participants
using benzodiazepines were asked to adhere to a fixed daily dose for the duration of the
study
Exclusion criteria: presence of severe psychiatric disorders (e.g. psychotic disorder, bipo-
lar disorder), severe somatic condition that would hinder appropriate application of CBT
(e.g. severe cardiovascular disease), contraindication for paroxetine, current use of an an-
tidepressant in an adequate dose, current and adequate psychological treatment, failure
of paroxetine or CBT in the past, abuse of or dependency on alcohol or psychoactive
substances, dementia and a score of 23 or less on the Mini-Mental State Examination
Characteristic of the sample:
• Age: mean age 68.6 years (SD 4.6)
• Percentage of agoraphobic patients: 48%
• Percentage of patients on drug therapy: 22%
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• Percentage of patients with major depression: not specified (mood disorder 12.
2%)
Interventions Participants (n = 49) were randomly assigned to either:
1) Cognitive behaviour therapy (classified as CBT, n = 20)
• Therapy format: individual
• Duration of each session: 50 minutes
• Mean number of sessions: 14
• Duration of intervention: 14 weeks
2) Paroxetine (not included, n = 17)
• Therapy format: individual
• Duration of each session: 30 minutes
• Mean number of sessions: 9
• Duration of intervention: 14 weeks
3) Wait list (classified as WL, n = 12)
• Mean number of sessions: 0
• Duration of intervention: 14 weeks
Outcomes Time points for assessment: baseline, 8 weeks, 14 weeks (termination), 26 weeks (3
months follow-up)
Measures: Agoraphobic Cognitions Questionnaire (ACQ), Mobility Inventory (MI),
Symptom Checklist (SCL-90)
The following outcomes were used for quantitative analyses:
ST-Remission: panic-free (zero panic attacks in the preceding week) at termination
ST- Response: improvement > 30% on one of the primary outcome scales
ST-Dropouts: non-completers
Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)
LT-Remission/Response: although measured (panic-free at 26 weeks), details are not
reported and anyway refer to the comparison paroxetine versus CBT
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”A sealed envelope was randomly selected from
an initial total of 75 envelopes containing the
treatment assignments, with 30 being labelled
as CBT, 30 as paroxetine and 15 as waiting
list.“
Allocation concealment (selection bias) Unclear risk See above. It is unclear whether envelopes
were opaque and sequentially numbered
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk ”All assessments were administered by trained,
independent psychologists who were blind to
the study and treatments delivered.“ How-
ever, panic frequency was rated through
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MI, which is a self rated measure
Incomplete outcome data (attrition bias)
Short-term
Low risk ”Five patients (10.2%) failed to complete the
14-week treatment protocol: three dropped
out in the paroxetine condition (side-effects, n
= 1; protocol violation, n = 1; broken hip, n
= 1), one in the CBT condition (protocol vi-
olation) and one in the WL condition (severe
somatic illness.“We are not considering the
paroxetine group for this review, therefore
the proportion of missing outcomes com-
pared with the observed event risk is not
enough to have a clinically relevant impact
on the intervention effect estimate
Selective reporting (reporting bias) Low risk Study protocol available. All primary out-
comes coincide (however, note that BDI, a
secondary outcome, is not reported)
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk ”Throughout the study, they were weekly su-
pervised by a registered supervisor (a mem-
ber of the Dutch Association of Behavioural
and Cognitive Therapy). Per session, the ther-
apists recordedwhich specificCBT component
they had applied and any deviations from the
treatment manual were discussed.“ It is un-
clear whether all sessions for all patients
were supervised; no detail is reported about
supervisor assessments
Other bias Unclear risk This study has been funded byGlaxo Smith
Kline, so a sponsorship bias is possible.
However, because the Paroxetine arm is
not considered for this review, it is unclear
whether the comparison CBT versus WL
can be affected by this possible source of
bias
149Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hoffart 1995
Methods Study design: randomised controlled trial, inpatient setting
Participants Inclusion criteria: age from 20 to 65 years, DSM-III-R diagnosis of panic disorder
with agoraphobia, DSM-III-R agoraphobia severity rated as moderate or severe, patients
considered the symptoms of agoraphobia (that is avoidance behaviour and situational
panic or symptom attacks and not spontaneous panics or other mental problems) as
their main problem. A plan for the reduction or discontinuation of medication before
hospital admission was agreed upon and patients were informed that use of psychotropic
medication was prohibited during the 6-week inpatient treatment period
Exclusion criteria: none
Characteristic of the sample:
• Age: not specified for ITT sample (among completers, mean age was 40.1 years,
SD 9.3)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified for ITT sample
(63% among completers)
Interventions Participants (n = 52) were randomly assigned to either:
1) Cognitive therapy (classified as CBT, n = 26)
• Therapy format: group
• Duration of each session: unclear
• Mean number of sessions: unclear
• Duration of intervention: 6 weeks
2) Guided mastery therapy (classified as BT, n = 26)
• Therapy format: group
• Duration of each session: unclear
• Mean number of sessions: unclear
• Duration of intervention: 6 weeks
Outcomes Time points for assessment: precare (before hospital admission), pre-treatment (1week)
, post-intensive period (4 weeks), post-treatment (6 weeks), 1 year follow-up
Measures: Behavioral Avoidance Tests (BATs), Structured Clinical Interview for the
DSM-III-R (SCID-I), Phobic Avoidance Rating Scale (PARS), Body Sensations Ques-
tionnaire (BSQ), Agoraphobic Cognitions Questionnaire (ACQ), Mobility Inventory
for Agoraphobia (M), Self-Efficacy Scales for Agoraphobia (SESA), State-Trait Anxiety
Inventory (STAI), Beck Depression Inventory (BDI), panic diary
The following outcomes were used for quantitative analyses:
ST-Remission: high end-state functioning* at post-treatment
ST- Response: improvement > 50% on PARS separation avoidance sub-scale
ST-Dropouts: non-completers
Continuous scale: Body Sensations Questionnaire (BSQ)
LT-Remission/Response: high end-state functioning* at 1 year follow-up
Notes * ”It was decided a priori to give a status of high endstate functioning to those who at
posttreatment (l) had a score of 1.5 or lower at the PARS separation avoidance subscale,
implying that at least half of the six situations of this subscale were approached regularly
without use of safety signals (e.g. medication); (2) had a score of 3--“symptoms interfere with
work or social activity only in minor ways”--or less in interviewer rated global severity; and
(3) were free of spontaneous panic attacks in the two weeks after discharge.“
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Low risk ”A symptom rating interview was performed
by a psychiatrist who worked in another in-
stitution and was blind to the treatment con-
dition of the patients. The interview included
the 0 to 4 point Phobic Avoidance Rating
Scale (PARS).“
Incomplete outcome data (attrition bias)
Short-term
Unclear risk ”Six of the 52 patients, 3 in each condition,
dropped out from the study. Four patients
dropped out before or within the first 24 hours
after admission to the hospital: 2 because of
problematic family circumstances, 1 was not
allowed financial coverage for the hospital stay
from her home country, and 1withdrew as she
experienced overwhelming fantasies of being
locked in forever in amental hospital. Two pa-
tients, 1 in each condition, withdrew just after
the discontinuation of anxiolytics because they
could not tolerate being without them.“Miss-
ing outcome data are balanced in num-
bers across intervention groups, with simi-
lar reasons for missing data across groups.
However, it is unclear whether the propor-
tion of missing outcomes is enough to have
a clinically relevant impact on the interven-
tion effect estimate
Incomplete outcome data (attrition bias)
Long-term
Unclear risk All treatment completers (n =46, see above)
were assessed at 1-year follow-up
Selective reporting (reporting bias) High risk Study protocol unavailable. Results of
ACQ measurements are not reported
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
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Hoffart 1995 (Continued)
Treatment fidelity Unclear risk ”The two psychologists alternated between be-
ing supervisor and being the primary thera-
pist, responsible for the overall treatment and
for conducting the group sessions together with
a co-therapist, in the 6 groups. In the intensive
three-week period, the supervising psycholo-
gist conducted two 45 min supervision ses-
sions per week, addressing immediate treat-
ment problems and questions about adherence
to the manuals. In addition, the supervisor
listened to audiotapes of therapy sessions and
gave written feedback to the therapists.“ It is
unclear whether all therapy sessions were
assessed.
Karekla 2004
Methods Study design: randomised controlled trial
Participants Inclusion criteria: primary DSM-IV diagnosis of panic disorder with or without ago-
raphobia
Exclusion criteria: psychosis, substance abuse, suicidal ideation or intent
Characteristic of the sample:
• Age: not specified for ITT sample (among those who attended at least the first
treatment session, mean age was 34.95, SD 11.07, range 20 to 67)
• Percentage of agoraphobic patients: not specified for ITT sample (78.3%
among those who attended at least the first treatment session)
• Percentage of patients on drug therapy: not specified for ITT sample (72.7%
among those who attended at least the first treatment session)
• Percentage of patients with major depression: not specified for ITT sample
(34.8% among those who attended at least the first treatment session)
Interventions Participants (n = 28) were randomly assigned to either:
1) Panic control treatment (classified as CBT, n = 14)
• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks
2) Acceptance-enhanced panic control treatment (classified as 3W, n = 14)
• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks
Outcomes Time points for assessment: pre-treatment, mid-treatment, post-treatment, 6 months
follow-up
Measures: State-Trait Anxiety Inventory (STAI), Acceptance and Action Questionnaire
(AAQ), Automatic Thoughts Questionnaire (ATQ), Beck Depression Inventory (BDI),
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Anxiety Sensitivity Index (ASI), Agoraphobic Cognitions Questionnaire (ACQ), Panic
and Agoraphobia Scale (PAS), Panic Disorder Severity Scale (PDSS), quality of life (SF-
36), Valued Living Questionnaire (VLQ), White Bear Suppression Inventory (WBSI),
Subjective Units of Distress Scale (SUDS), Diagnostic Symptoms Questionnaire (DSQ)
, Anxiety and Willingness Scale (AWS)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured
ST- Response: not measured
ST-Dropouts: non-completers (including early dropouts)
Continuous scale: although measured, data cannot be used because number of assessed
patients is not reported
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
High risk ”Twenty-eight individuals met inclusion cri-
teria and were scheduled for treatment. Of
those, 22 attended at least the first session.
Fourteen participants completed the full 10
weeks of treatment. The cases of participants
who prematurely dropped out of treatment are
dropped out from further analyses.“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
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Klosko 1988
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 18 and 65 years, DSM-III-R primary diagnosis of panic
disorder with a clinician’s severity rating of at least 4 on a 0 to 8 scale (moderate severity)
, at least 1 panic attack in the week before starting treatment
Exclusion criteria: pharmacotherapy or psychotherapy begun in the past 6 months; ei-
ther in drug or psychotherapeutic treatment more than 6 months (unless subjects agreed
to stop such treatment for the duration of the study); on 4 mg or more of alprazolam for
any 3-week period and were non-responders; evidence of benzodiazepine hypersensitiv-
ity; undergone cognitive behaviour therapy for anxiety at any time; females who were
pregnant or lactating or at risk to become pregnant; significant medical problems, as de-
termined by history, medical report and laboratory values; history of psychotic disorder
or dementia; history of alcohol or other substance abuse within the last 6months; current
or past bipolar disorder. Subjects with major depression were excluded only if depression
predominated over panic disorder at the time of presentation and if depression preceded
panic disorder chronologically. Subjects with acute suicidal ideation were excluded
Characteristic of the sample:
• Age: not specified for ITT sample (among completers, mean age was 37, SD 11.
04)
• Percentage of agoraphobic patients: not specified for ITT sample (79% among
completers)
• Percentage of patients on drug therapy: not specified for ITT sample (59.6%
among completers)
• Percentage of patients with major depression: not specified
Interventions Participants (n = 69) were randomly assigned to either:
1) Alprazolam (not included, n = 17)
• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks
2) Placebo (not included, n = 18)
• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks
3) Behaviour therapy (classified as CBT, n = 18)
• Therapy format: individual
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks
4) Wait list (classified as WL, n = 16)
• Mean number of sessions: 0
• Duration of intervention: 15 weeks
Outcomes Time points for assessment: baseline, post-treatment.
Measures: daily self monitoring, Anxiety Disorders Interview Schedule - R (ADIS-R)
, Hamilton Anxiety Rating Scale (HAM-A), Hamilton Rating Scale for Depression
(HAM-D)
The following outcomes were used for quantitative analyses:
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ST-Remission: ADIS-IV severity < 4
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Anxiety Disorders Interview Schedule - R (ADIS-R)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Low risk ”Posttreatment clinical assessment measures
were gathered through administration of a
short form of the ADIS-R. The ADISR ad-
ministrators were blind to group assignment“
Incomplete outcome data (attrition bias)
Short-term
High risk ”Out of 69 initial subjects, 57 subjects com-
pleted the study, and 12 subjects dropped out.
A higher rate of dropout was observed in the
placebo group compared with the other three
groups. One subject out of 17 (5.9%) dropped
from the alprazolam group, 7 out of 18 (38.
9%) from the placebo group, 3 out of 18 (16.
7%) from the PCT group, and 1 out of 16
(6.3%) from the waiting-list group.“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk BarlowDH is author of a CBTmanual (see
Barlow 2000b)
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”All therapy sessions were tape-recorded and
checked for treatment integrity.“
Other bias High risk Performance bias: in contrast with patients
in the CBT group, patients in theWLwere
not asked to withdraw medications
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Korrelboom 2013
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age 18 to 65 years, DSM-IV-TR clinical diagnosis of panic disorder
with or without agoraphobia, being able to read, speak and understand Dutch well
enough to participate in the treatment groups and to fill in all assessments. Use of
psychotropic medication was permitted only if the medication dose was stable during
the study and had been stable for at least 2 months prior to study inclusion. Patients who
changed their medication during treatment were considered to be dropouts, patients
who started (a new) medication less than 2 months before inclusion had to wait for
participation until they had fulfilled this 2-month criterion
Exclusion criteria: severe co-morbid psychopathology, such as psychosis; addiction;
being suicidal; mental retardation; concurrent psychological treatments, or cognitive
behavioural treatments in the past 6 months
Characteristic of the sample:
• Age: mean age 36.1 years (SD 11.9)
• Percentage of agoraphobic patients: 79%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified
Interventions Participants (n = 143) were randomly assigned to either:
1) Competitive memory training for panic (classified as CBT, n = 70)
• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 7
• Duration of intervention: 7 weeks
2) Applied relaxation (classified as PT, n = 73)
• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 7
• Duration of intervention: 7 weeks
Outcomes Time points for assessment: baseline, post-treatment, 6 months follow-up
Measures: Panic Appraisal Inventory (PAI), Mobility Inventory (MI)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (imputed from continuous scale)
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Mobility Inventory for agoraphobia when alone (MI-A)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
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Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk MI is a self rated scale
Incomplete outcome data (attrition bias)
Short-term
Low risk ”During treatment, a total of 24 patients
(17%) dropped out (13 in AR and 11 in
COMET). Analyses were on an intention-to-
treat basis. First, in a binary logistic regression
analysis, it was checked whether dropout was
predicted by age, diagnosis, gender or any of
the outcome measures at M-pre. Then miss-
ing values were imputed with the SPSS 20
multiple imputation algorithm.“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk It seems that authors are involved in con-
ceptualisation of COMET-panic: ”Since
this COMET-panic protocol appeared to be
effective in two pilot studies in routine clini-
cal settings (Korrelboom et al. 2008; Peeters
et al. 2005), it was decided to put the new
protocol to the test in a randomized controlled
trial versus an evidence-based anti-panic pro-
cedure, in this case AR.“
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”Both panic management techniques were
available inwritten form (amanual) for ther-
apists and patients. In regular meetings thera-
pists and researchers discussed adherence to the
treatment protocols. As an additional check on
treatment integrity, patients filled in a check-
list containing specific questions about the na-
ture of the treatments they had just received.
This checklist contained statements about spe-
cific differential identifying elements of both
therapies. If both treatments had been de-
livered properly, AR patients should identify
more AR ingredients in the treatment they
had received and few/none of the COMET
elements, and vice versa for the COMET pa-
tients. In the AR condition the mean score for
‘AR ingredients’ was 36.7 (SD = 3.1) whereas
the highest possible score was 40, while the
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mean score for ‘COMET ingredients’ in this
condition was only 16.6 (SD = 9.5) whereas
the lowest possible score was 4. On the other
hand, in the COMET condition these figures
were 34.0 (SD = 5.7) for ‘COMET ingredi-
ents’ (possible maximum of 40) and 15.2 (SD
=7.6) for ‘AR ingredients’ (possible minimum
of 4).“
Lidren 1994
Methods Study design: randomised controlled trial
Participants Inclusion criteria:DSM-III-R diagnosis of panic disorder with or without agoraphobia.
Individuals taking medication for anxiety could participate if they were still suffering
from panic symptoms after 6 weeks of stabilisation on medication, if they maintained
the same dosages throughout treatment, and if they recorded both the type and amount
of medication usage throughout the study
Exclusion criteria: seizure disorder, kidney disorder, stroke, myocardial infarction,
chronic hypertension, emphysema, organic brain syndrome, chronic use of alcohol, drug
dependence, major depressive disorder, psychotic disorders, involvement in any type of
therapy focusing on anxiety management
Characteristic of the sample:
• Age: 33.7 years (SD 11.8)
• Percentage of agoraphobic patients: 83.3%
• Percentage of patients on drug therapy: 39%
• Percentage of patients with major depression: 0%
Interventions Participants (n = 36) were randomly assigned to either:
1) Bibliotherapy (not included, n = 12)
• Therapy format: self help
• Mean number of sessions: 0
• Duration of intervention: 8 weeks
2) Group therapy (classified as CBT, n = 12)
• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks
3) Wait list (classified as WL, n = 12)
• Mean number of sessions: 0
• Duration of intervention: 8 weeks
Outcomes Time points for assessment: baseline, post-treatment, 3 months follow-up, 6 months
follow-up
Measures: panic frequency and severity, Panic Attack Symptom Questionnaire (PASQ)
, Panic Attack Cognition Questionnaire (PACQ), Mobility Inventory (MI), Panic Self-
Efficacy Questionnaire (PSEQ), Beck Depression Inventory (BDI)
The following outcomes were used for quantitative analyses:
ST-Remission: Mobility Inventory (MI) score < 32 at post-treatment
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ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Mobility Inventory for agoraphobia when alone (MI-A)
LT-Remission/Response: Mobility Inventory (MI) score < 32 at 6 months follow-up
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk Mobility Inventory (MI) is a self ratedmea-
sure
Incomplete outcome data (attrition bias)
Short-term
Low risk ”Attrition rates were zero for all three condi-
tions“
Incomplete outcome data (attrition bias)
Long-term
Low risk (see above)
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk ”The BT condition used Clum’s (1990) Cop-
ing with panic book. Subjects in the GT con-
dition also used Clum’s (1990) Coping with
panic text.“ Glum GA is among the study
authors.
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”We videotaped all sessions, with the faculty
member on the research team viewing these
tapes for treatment integrity.“
Malbos 2011
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-IV diagnosis of panic disorder with agoraphobia
Exclusion criteria: epilepsy, dissociative or non-dissociative chronic psychosis, recent
discontinuation of psychotropic drugs, substance dependence
Characteristic of the sample:
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• Age: mean age 44.11 years (SD 13.79, range 24 to 72)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: 23.5%
Interventions Participants (n = 17) were randomly assigned to either:
1) Virtual reality exposure only (classified as BT, n = 9)
• Therapy format: not specified
• Duration of each session: 90 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks
2) Virtual reality exposure + cognitive therapy (classified as CBT, n = 8)
• Therapy format: not specified
• Duration of each session: 90 minutes
• Mean number of sessions: 10
• Duration of intervention: 10 weeks
Outcomes Time points for assessment: baseline, post-treatment, 3 months follow-up
Measures: Presence Questionnaire (PQ v3.0), Subjective Units of Discomfort (SUD)
, Depression Anxiety Stress Scales (DASS 21), Anxiety Sensitivity Index (ASI), Agora-
phobia Cognitions Questionnaire (ACQ), Mobility Inventory for Agoraphobia (MI),
Simulation Sickness Questionnaire (SSQ), Behavioural Avoidance Test (BAT), heart rate
(HR) and heart rate variability (HRV)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (imputed from continuous scale)
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Anxiety Sensitivity Index (ASI)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The allocation to each group was done using
a randomisation table generated by a comput-
erised sequence generator.“
Allocation concealment (selection bias) Low risk ”It was impossible to foresee the assignment of
the next patient entering the study“ (personal
communication)
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk ASI is a self rated measure
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Incomplete outcome data (attrition bias)
Short-term
Low risk ”One participant (VRO)dropped out at an
early stage due to a severe myopia.“ The pro-
portion of missing outcomes is not enough
to have a clinically relevant impact on the
intervention effect estimate
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Unclear risk ”In the present study we designed all required
VEs for the VRET of agoraphobia within a
game level editor.“ Although possible, the
extent to which this source of bias may af-
fect the results is unclear, because both arms
are administered the same VEs
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Marchione 1987
Methods Study design: randomised controlled trial
Participants Inclusion criteria:DSM-III diagnosis of agoraphobiawith panic attacks, other inclusion
criteria are mentioned but not reported
Exclusion criteria: none reported
Characteristic of the sample:
• Age: not specified for ITT sample (among completers, mean age was 38.1 years,
SD 11.8, range 25 to 65)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified
Interventions Participants (n = 19) were randomly assigned to either:
1) Cognitive therapy + graduated exposure (classified as CBT, n = unclear)
• Therapy format: group
• Duration of each session: 120 minutes (first 2 sessions), 60 minutes (following
14 sessions)
• Mean number of sessions: 16
• Duration of intervention: not specified
2) Progressive deep muscle relaxation + graduated exposure (classified as BT, n =
unclear)
• Therapy format: group
• Duration of each session: 120 minutes (first 2 sessions), 60 minutes (following
14 sessions)
• Mean number of sessions: 16
• Duration of intervention: not specified
3) Graduated exposure alone (classified as BT, n = unclear)
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• Therapy format: group
• Duration of each session: 120 minutes (first 2 sessions), 90 minutes (following
14 sessions)
• Mean number of sessions: 16
• Duration of intervention: not specified
Outcomes Time points for assessment: baseline, mid-treatment, post-treatment
Measures: Global Assessment of Severity, Self-Rating of Severity, Phobic Anxiety and
Avoidance Scale, Fear Survey Schedule, Fear Questionnaire (FQ), Taylor Manifest Anxi-
ety Scale, Panic Scale, Beck Depression Inventory (BDI), Hopkins Symptom Checklist,
Subjective Symptom Checklist, Standardised Behavioral Avoidance Course (S-BAC),
heart rate
The following outcomes were used for quantitative analyses:
ST-Remission: although measured (high end-state functioning*) detailed data are not
reported
ST- Response: not measured
ST-Dropouts: detailed data are not reported
Continuous scale: although measured, detailed data are not reported
LT-Remission/Response: not measured
Notes * ”Five criteria were used to classify subjects’ level of Endstate (low-medium-high) functioning.
Subjects were assigned 1 point for each of the following scores: (a)≤2 on the Global Assessment
of Severity; (b)≤2 on the Self-Rating of Severity; (c)≤3 on the Phobic Anxiety and Avoidance
Scale; (d) Completing the Standardized-Behavioral Avoidance Course; and, (e) ≤3 SUDS
(in vivo anxiety). Subjects with 0-1 points = low Endstate functioning; 2-3 points = medium
Endstate functioning, and those with 4-5 points were classified as having high Endstate
functioning.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Selective reporting (reporting bias) High risk Study protocol unavailable. Pre-planned
measures are not reported with sufficient
detail
Researcher allegiance High risk ”The cognitive therapy was developed by
Michelson (1984), adapted from Antaki and
Brewin (1982), Beck and Emery (1979)
, Bums (1980), Mckay, Davis and Fan-
ning (1981), and Sank and Shaffer (1984).
“Michelson L is among the study authors.
Therapist allegiance Unclear risk No information provided
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Treatment fidelity Low risk ”To ensure the treatment procedures were ad-
ministered consistently, weekly meetings were
held to discuss and review all treatment ses-
sions. Treatment integrity probes were ran-
domly conducted on 25% of the sessions and
revealed consistently high (100%) levels of fi-
delity.“
Meulenbeek 2008
Methods Study design: multicentre randomised controlled trial
Participants Inclusion criteria: over 18 years of age, subthreshold or mild panic disorder with or
without agoraphobia (DSM-IV), defined as having symptoms of panic disorder falling
below the cut-off of 13 on the Panic Disorder Severity Scale-Self Report (PDSS-SR)
. If a participant used medication for anxiety or depression (e.g. benzodiazepines or
antidepressants) it was agreed to keep medication use stable during the study period
Exclusion criteria: severe panic disorder (PDSS-SR > 12), current psychological treat-
ment for panic disorder-related complaints, presence of other severe mental or social
problems, suicidal intention warranting treatment or likely to interfere with participa-
tion in the group course as assessed by an experienced psychologist during intake
Characteristic of the sample:
• Age: not specified for clinical sub-sample (among all participants, mean age was
42 years, SD 12.4, range 20 to 75)
• Percentage of agoraphobic patients: not specified for clinical sub-sample (62%
among all participants)
• Percentage of patients on drug therapy: not specified for clinical sub-sample
(38.7% among all participants)
• Percentage of patients with major depression: not specified
Interventions Participants (clinical sub-sample, n = 100) were randomly assigned to either:
1) ”Don’t Panic“ intervention (classified as CBT, n = 50)
• Therapy format: group
• Duration of each session: 120 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks
2) Wait list (classified as WL, n = 50)
• Mean number of sessions: 0
• Duration of intervention: 12
Outcomes Time points for assessment: baseline, post-intervention, 6 months follow-up
Measures: Panic Disorder Severity Scale-Self Report (PDSS-SR), Mini International
Neuropsychiatric Interview-Plus (MINI-Plus), Mobility Inventory (MI), sub-scale for
anxiety of theHospital Anxiety andDepression Scale (HADS-Anxiety), BeckDepression
Inventory (BDI-II)
The following outcomes were used for quantitative analyses:
ST-Remission: PDSS at post-treatment < 1 SD compared to baseline mean and below
4 (cut-off value)
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ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: not reported for clinical sub-sample
Continuous scale: Panic Disorder Severity Scale-Self Report (PDSS-SR, data for clinical
sub-sample available on personal communication)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”A blocked randomisation scheme was used,
stratified by mental health centre, subthresh-
old panic disorder v. mild panic disorder, and
by presence v. absence of co-occurring agora-
phobia.“
Allocation concealment (selection bias) Low risk ”The randomisation took place after admin-
istration of the Mini International Neuropsy-
chiatric Interview-Plus (MINI-Plus)8 and
was carried out centrally by an independent
third party.“
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk ST-Remission is calculated from the Self
Report of Panic Disorder Severity Scale
Incomplete outcome data (attrition bias)
Short-term
Low risk All randomised patients (clinical sub-sam-
ple) were assessed with PDSS-SR at post-
treatment (personal communication)
Selective reporting (reporting bias) High risk Study protocol available: declared primary
outcome is ”incidence of DSM-IV panic dis-
order.“ In published report: ”we used the
PDSS-SR and the MINI-Plus as the primary
outcome measures.“
Researcher allegiance High risk ”We developed an early intervention for panic
symptoms, called the ‘Don’t Panic’ course“
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Other bias High risk Performance bias: WL patients are free to
make use of other interventions
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Meuret 2008
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 18 and 60 years, principal DSM-IV diagnosis of panic
disorder with or without agoraphobia, no additional psychological treatment until after
the 2-month follow-up. If on psychotropic medications, on stable doses for at least 3
months prior to treatment with an agreement not to change dosage at least until after
the 2-month follow-up
Exclusion criteria: evidence of organic mental disorder, suicidality, schizophrenia, al-
cohol or drug dependence, cardiovascular disease, pulmonary disease, epilepsy or preg-
nancy
Characteristic of the sample:
• Age: not specified for ITT sample (among completers, mean age was 41 years, SD
8.9)
• Percentage of agoraphobic patients: not specified for ITT sample (83.8%
among completers)
• Percentage of patients on drug therapy: not specified for ITT sample (32.4%
among completers)
• Percentage of patients with major depression: not specified
Interventions Participants (n = 43) were randomly assigned to either:
1) Breathing training therapy (classified as PT, n = 24)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 5
• Duration of intervention: 4 weeks
2) Wait list (classified as WL, n = 19)
• Mean number of sessions: 0
• Duration of intervention: 4 weeks
Outcomes Time points for assessment: baseline, post-treatment (week 4), 2 months follow-up
(week 12), 12 months follow-up
Measures:PanicDisorder Severity Scale (PDSS), Clinical Global Impression Scale (CGI)
, Anxiety Sensitivity Index (ASI), Sheehan Disability Scale (SDS), Mobility Inventory
for Agoraphobia (MI-AAL), Beck Depression Inventory (BDI), week-by-week changes
in end-tidal pCO (mm Hg) and RR (breaths/minute)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (imputed from continuous scale)
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Panic Disorder Severity Scale (PDSS)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
165Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Meuret 2008 (Continued)
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Unclear risk ”An assessment battery was administered at
baseline (week 0), post-treatment (week 4), 2-
month follow-up (week 12), and 12-month
follow-up (week 53). It included the PDSS
(Shear et al., 1997), a clinician-rated scale of
PD severity and the Clinical Global Impres-
sion Scale (CGI; Guy, 1976) (both assessed by
independent raters).“ It is unclear whether
raters were blind to treatment allocation
Incomplete outcome data (attrition bias)
Short-term
High risk 35 patients were analysed at post-treatment
(see study flow chart)
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk ”We devised a capnometry-assisted breathing
training therapy (BRT) that uses immediate
feedback to teach patients how to raise their
pCO over a series of training and practice
sessions.“
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Meuret 2010
Methods Study design: 2-site, randomised controlled trial
Participants Inclusion criteria: minimum age of 18 years, current principal DSM-IV diagnosis (i.e.
the disorder presently associated with the greatest life interference) of panic disorder with
agoraphobia, being on a stable dose of psychotropic medication for at least 3 months
before study initiation (if applicable) and agreement to continue this dose through the 2-
month follow-up appointment, agreement not to initiate additional therapy until after
the final follow-up appointment
Exclusion criteria: indication of a history of bipolar disorder, psychotic disorder or
suicidal intention, or current substance abuse or dependence, organic mental disorder,
serious unstable medical disease, respiratory illness or seizures
Characteristic of the sample:
• Age: not reported for ITT sample (among initiators, mean age was 33.2 years, SD
9.9, range 20 to 57)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not reported for ITT sample (62.2%
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among initiators)
• Percentage of patients with major depression: not reported for ITT sample
(mood disorders 3.3% among initiators)
Interventions In a first phase of the study, participants (n = 47) were randomly assigned to 5 weekly
sessions of either capnometry-assisted breathing training (n = 24) or cognitive training
(n = 23)
In a second phase of the study, participants of both groups underwent 3 weekly sessions
of in vivo exposure plus a 4th session at 2-month follow-up, therefore:
1) Capnometry-assisted breathing training + in vivo exposure (classified as BT, n =
24)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 9
• Duration of intervention: 16 weeks
2) Cognitive training + in vivo exposure (classified as CBT, n = 23)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 9
• Duration of intervention: 16 weeks
Outcomes Time points for assessment: baseline, pre-phase 1, post-phase 1/pre-exposure (begin-
ning of phase 2), post-exposure (after the 3weekly sessions of in vivo exposure), 2months
follow-up (last exposure session)
Measures: Panic Disorder Severity Scale (PDSS), Body Sensations Questionnaire (BSQ)
, Anxiety Sensitivity Index (ASI), combined measure of symptom appraisal (ASI/BSQ),
Mobility Inventory for Agoraphobia (MI), Anxiety Control Questionnaire (ACQ), end-
tidal pCO , respiration rate (RR)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured
ST- Response: not measured
ST-Dropouts: non-completers at termination (last exposure session)
Continuous scale: although measured, detailed data are not reported
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Randomization software was used to assign
patients to condition.“
Allocation concealment (selection bias) Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
High risk In the CT + exposure arm, a total of 12
patients (out of 23 randomised) completed
all sessions; in the CART + exposure arm, a
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Meuret 2010 (Continued)
total of 16 patients (out of 24 randomised)
completed all sessions
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk ”CART is based on the theory that sus-
tained levels of hypocapnia contribute to
symptom development and maintenance of
PD (Meuret 2008).“
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”All sessions were audio- or video-taped and
discussed in the weekly supervision meetings
by expert clinicians to ensure that therapists
adhered to the treatment protocol. A random
sample of 10% of all recorded treatment ses-
sions (10 CART and 10 CT sessions) was
evaluated blindly for protocol adherence by
two independent, experienced master’s-level
clinicians. In addition, 50% of the rated ses-
sions (5 CART and 5 CT) were randomly
selected and rated by another master’s-level
and one doctoral-level clinician to assess inter-
rater reliability. Adherence to the givenmodel/
protocol was rated high for both conditions
(CART: M 6.25, SD 0.92; CT: M 5.50, SD
1.20), and ratings were not significantly dif-
ferent between conditions. Interrater agree-
ment was calculated with intraclass correla-
tion coefficients. The results suggest that coders
showed high agreement (intraclass correlation
[2, 1] 0.85; Shrout & Fleiss, 1979).“
Meyerbroker 2011
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between18 and65years,DSM-IV-TRdiagnosis of panic disorder
with agoraphobia
Exclusion criteria: presence of a medical condition (pregnancy, seizure disorder, pace-
maker), current use of tranquillisers or not on a stable dose of antidepressants, current
substance dependence, current depression with suicidal ideation, bipolar disorder, bor-
derline or antisocial personality disorder, history of psychosis, severe cognitive impair-
ment
Characteristic of the sample:
• Age: not specified
• Percentage of agoraphobic patients: 100%
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• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified
Interventions Participants (n = 55) were randomly assigned to either:
1) CBT + virtual reality exposure (classified as CBT, n = 19)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 10
• Duration of intervention: not specified
2) CBT + in vivo exposure (classified as CBT, n = 18)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 10
• Duration of intervention: not specified
3) Wait list (classified as WL, n = 18)
• Mean number of sessions: 0
• Duration of intervention: 8 weeks
Outcomes Time points for assessment: baseline, post-treatment.
Measures: Panic Disorder Severity Scale (PDSS), Mobility Inventory (MI), Bodily Sen-
sation Questionnaire (BSQ), Agoraphobic Cognitions Questionnaire (ACQ), Panic Ap-
praisal Inventory (PAI), Avoidance Scale of Watson and Marks
The following outcomes were used for quantitative analyses:
ST-Remission: not measured
ST- Response: not measured
ST-Dropouts: non-completers
Continuous scale: althoughmeasured, data cannot be used (n,mean andSDare reported
only for the comparison VRET versus IVExp, both classified as CBT: comparison not
feasible)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Patients were randomized with randomly
permuted blocks“ (personal communica-
tion)
Allocation concealment (selection bias) Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
High risk ”After randomization, 9 of the 55 patients
declined to start the treatment. During treat-
ment 15 patients dropped out for various rea-
sons: medical issues (n = 2), acute crisis 2),
could not experience the virtual environment
as real (n = 2), had no further complaints
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(n = 3) and personal circumstances (n = 1)
. Completer analyses included the remaining
sample of 31 patients who completed all treat-
ment sessions (n = 29) or at least 80% of
the sessions (n = 2). Intent-to-treat analyses
were done with multiple imputation on the
full sample (n = 46) who started at least 1
treatment session“
Selective reporting (reporting bias) High risk Study protocol available: declared primary
outcomes are PDSS and MI (plus Be-
havioural Avoidance Test, added subse-
quently). Primary outcomes are not speci-
fied in published report
Researcher allegiance Low risk ”None of the authors has any conflict of inter-
est“
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Milrod 2006a
Methods Study design: randomised controlled trial
Participants Inclusion criteria: diagnosis with primary DSM-IV panic disorder with or without ago-
raphobia, minimum severity score of 5 on the 0- to 8-point Anxiety Disorders Interview
Schedule for DSM-IV (ADIS-IV-Lifetime Version), minimum of 1 weekly panic attack.
Patients were included whether or not they were taking anti-panic medication: subjects
meeting study entrance criteria while taking stable doses of medication agreed to keep
medication type and dose constant throughout the study. Patients discontinued ongoing
psychotherapy to gain study entrance. Patients with comorbid major depression, per-
sonality disorders and severe agoraphobia were included
Exclusion criteria: psychosis, bipolar disorder and active substance abuse (6 months
remission necessary for inclusion)
Characteristic of the sample:
• Age by treatment group: PFPP group mean age 33.4 (SD 9.6); ART group mean
age 33.5 (SD 8.5)
• Percentage of agoraphobic patients: PFPP group 69%; ART group 86%
• Percentage of patients on drug therapy: PFPP group 19%; ART group 17%
• Percentage of patients with major depression: PFPP group 19%; ART group
26%
Interventions Participants (n = 49) were randomly assigned to either:
1) Panic focused psychodynamic psychotherapy (classified as PD, n = 26)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 24
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• Duration of intervention: 12 weeks
2) Applied relaxation training (classified as PT, n = 23)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 24
• Duration of intervention: 12 weeks
Outcomes Time points for assessment: baseline, termination, 2 months follow-up, 4 months
follow-up, 6 months follow-up, 12 months follow-up
Measures:PanicDisorder Severity Scale (PDSS), SheehanDisability Scale (SDS),Hamil-
ton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (imputed from continuous scale)
ST- Response: 40% reduction in PDSS at termination
ST-Dropouts: non-completers
Continuous scale: Panic Disorder Severity Scale (PDSS)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Subjects were randomly assigned using a
computer generated treatment assignment list
that was stratified by presence or absence of 1)
comorbid current DSM-IV major depression
and 2) stable doses of antipanic medication.“
Allocation concealment (selection bias) Low risk ”All study staff was blinded“ (personal com-
munication)
Blinding of outcome assessment (detection
bias)
ST-Remission
Low risk ”Independent evaluators, blinded to subject
condition and therapist orientation, assessed
subjects at baseline, treatment termination,
and at 2, 4, 6, and 12 months posttreatment
termination“
Incomplete outcome data (attrition bias)
Short-term
High risk ”Rates of dropout from the 12-week random-
ized controlled clinical trial differed signifi-
cantly between the randomly assigned treat-
ment groups: two out of 26 (7%) panic-fo-
cused psychodynamic psychotherapy subjects
and eight out of 23 (34%) applied relax-
ation training subjects dropped out. The anal-
yses described above adhered to the inten-
tion-to-treat principle using last observation
forward to impute missing data for the pri-
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mary outcome and three continuous secondary
outcomes.“ Although a LOCF method was
used, LOCF cases are many and unbal-
anced between arms
Selective reporting (reporting bias) Low risk Study protocol available. All of the study’s
pre-specified (primary and secondary) out-
comes have been reported in the pre-spec-
ified way
Researcher allegiance High risk Milrod B and Busch F are co-authors of
PFPP manual (see Milrod 1997)
Therapist allegiance Unclear risk Insufficient information provided
Treatment fidelity Unclear risk ”Therapists in both modalities met monthly
for group supervision and received individ-
ual supervision as needed. Therapists in both
modalities were monitored for adherence to
treatment protocol by adherence raters in each
modality with equal frequency. Three video-
tapes were rated for adherence per individual
treatment. All therapists met predetermined
adherence standards.“ It is unclear whether
all sessions for both therapies were recorded
and if the 3 videotapes monitored for ad-
herence where chosen randomly
Muncy 1991
Methods Study design: randomised controlled trial
Participants Inclusion criteria:DSM-III-R diagnosis of panic disorder with or without agoraphobia,
drug-free, in reasonably good health, not currently in therapy (or, in this case, able to
arrange with the therapist to work within the structure of the project)
Exclusion criteria: none
Characteristic of the sample:
• Age: not specified
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified (68.4% imputed
from BDI in the 3 arms considered for this review)
Interventions Participants (n = 26) were randomly assigned to either:
1) Rational emotive therapy (classified as CT, n = 7)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 6
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• Duration of intervention: 6 weeks
2) Rational emotive therapy + biofeedback (classified as CT, n = 8)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 6
• Duration of intervention: 6 weeks
3) Imipramine (not included, n = 7)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: not specified
• Duration of intervention: 6 weeks
4) Wait list (classified as WL, n = 4)
• Mean number of sessions: 0
• Duration of intervention: 6 weeks
Outcomes Time points for assessment: baseline, mid-treatment (3 weeks after commencement),
termination (6 weeks after commencement)
Measures:Minnesota Multiphasic Personality Inventory (MMPI), Millon Clinical Mul-
tiaxial Inventory (MCMI), Beck Depression Inventory (BDI), State-Trait Anxiety In-
ventory (STAI)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured
ST- Response: not measured
ST-Dropouts: non-completers
Continuous scale: not measured (none of the available measures meets our inclusion
criteria, see Secondary outcomes)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
Low risk ”Two subjects from G3 (Imipramine arm)
abandoned the study in the first three weeks
of the treatment due to their inability to tol-
erate the side-effects of imipramine. Thus,
the number of observations was reduced to
24 [...].“ Since we are not considering the
imipramine arm for this review, the num-
ber of dropouts is 0
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
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Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Ost 1993
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 20 and 60 years, DSM-III-R diagnosis of panic disorder
with agoraphobia, express a willingness to participate in the study for a period of 3
months. If any medication was used the intake was to be held constant during the study;
participants had to agree not to receive any other kind of psychiatric or psychological
treatment except for any ongoing medication during the treatment
Exclusion criteria: any other psychiatric complaint in need of immediate treatment;
psychotic or organic symptoms
Characteristic of the sample:
• Age: not reported for ITT sample (among completers, mean age was 37.42 years,
SD 8.38, range 23 to 56)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not reported for ITT sample (51%
among completers)
• Percentage of patients with major depression: not reported for ITT sample
(38% among completers)
Interventions Participants (n = 46) were randomly assigned to either:
1) Applied relaxation (classified as PT, n = 15)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
2) Exposure in vivo (classified as BT, n = 16)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
3) Cognitive treatment (classified as CBT, n = 15)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
Outcomes Time points for assessment: baseline, post-treatment, 1 year follow-up
Measures: Agoraphobia Scale, Fear Questionnaire (FQ), Mobility Inventory for Ago-
raphobia (MI), Agoraphobic Cognitions Questionnaire (ACQ), Body Sensations Ques-
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tionnaire (BSQ), Hamilton Anxiety Scale (HAM-A), State-Trait Anxiety Inventory
(STAI), Hamilton Depression Scale (HAM-D), Beck Depression Inventory (BDI), Be-
havior Test (BAT), Autonomic Perception Questionnaire (APQ)
The following outcomes were used for quantitative analyses:
ST-Remission: clinically significant improvement* (Agoraphobia Scale criteria) at post-
treatment
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)
LT-Remission/Response: clinically significant improvement* (Agoraphobia Scale cri-
teria) at 1 year follow-up
Notes * ”To assess the degree of clinically significant improvement achieved by the patients the method
described by Jacobson, Follette and Revenstorf (1984) was used. On any single measure a
patient’s post-treatment or follow-up score must be outside the range of the patient group’s pre-
treatment scores, or inside a normal group’s range, in the direction of functionality, defined
as Mean ±1.96 x SD . Besides, the change must be statistically reliable. For this study we
chose to apply two criteria; percentage of situations completed in the BAT, and score on the
avoidance part of Agoraphobic Scale. The respective cutoff scores were:
BAT: Mean 23.23, SD 14.57, criterion: 22.23 + 1.96(14.57) = 51.79, i.e. 52.
Agoraphobia Scale-Avoidance: Mean 20.56, SD 6.76, criterion 20.56 - 1.96(6.76) = 7.31.
“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk The Agoraphobia Scale (used to determine
ST-Remission) is a self report measure
Incomplete outcome data (attrition bias)
Short-term
Low risk ”One patient from the Exposure group
dropped out after 2 sessions and was replaced.
All the AR- and CT-patients completed the
study. At follow-up I patient (in the AR-
group) had died, I refused participation in the
assessment (E-group), and 1 (AR-group) had
moved and was unreachable by mail or tele-
phone. Thus, follow-up assessment was done
on 42 (93.3%) of the original patients.“
Incomplete outcome data (attrition bias)
Long-term
Low risk (See above). Missing outcome data bal-
anced in numbers across intervention
groups; the proportion of missing out-
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comes compared with the observed event
risk is not enough to have a clinically rele-
vant impact on the intervention effect esti-
mate
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk Ost LG is involved in conceptualisation of
Applied Relaxation (see Ost 1987)
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Other bias Unclear risk Modification of the original sample with
one replacement
Ost 1995
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 18 and 60 years, DSM-III-R diagnosis of panic disorder
with mild or no agoraphobic avoidance, duration of the panic disorder of at least 1 year,
at least 3 panic attacks during the 3 weeks baseline, panic disorder seen as the patient’s
primary problem, agreeing to take part in the study for 18 weeks, including pre- and
post-assessment, and 1 year follow-up, and be willing to accept random allocation. If
on prescribed drugs for panic disorder: (a) the dosage had to be constant for 3 months
before the start of the treatment; and (b) the patient had to agree to keep the dosage
constant throughout the study
Exclusion criteria: primary depression (i.e. onset before the start of the panic disorder)
, any other psychiatric disorder in immediate need of treatment
Characteristic of the sample:
• Age: not reported for ITT sample (among completers, mean age was 32.6 years,
SD 7.1, range 23 to 45)
• Percentage of agoraphobic patients: 21.05%
• Percentage of patients on drug therapy: not reported for ITT sample (72%
among completers)
• Percentage of patients with major depression: not specified
Interventions Participants (n = 38) were randomly assigned to either:
1) Applied relaxation (classified as PT, n = 19)
• Therapy format: individual
• Duration of each session: 55 minutes
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
2) Cognitive therapy (classified as CBT, n = 19)
• Therapy format: individual
• Duration of each session: 55 minutes
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• Mean number of sessions: 12
• Duration of intervention: 12 weeks
Outcomes Time points for assessment: baseline, post-treatment, 1 year follow-up.
Measures: Anxiety Disorders Interview Schedule-Revised (ADIS-R), Hamilton Anxiety
Scale (HAM-A), Hamilton Depression Scale (HAM-D), panic diary, Panic Attack Scale
(PAS), Beck Anxiety Inventory (BAI), State-Trait Anxiety Inventory (STAI), Self-Rating
of Anxiety Scale (SAS), Beck Depression Inventory (BDI), Body Sensations Question-
naire (BSQ), Agoraphobic Cognitions Questionnaire (ACQ), Bodily Sensations Inter-
pretations Questionnaire
The following outcomes were used for quantitative analyses:
ST-Remission: high end-state functioning* at post-treatment
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Body Sensations Questionnaire (BSQ)
LT-Remission/Response: high end-state functioning* at 1 year follow-up
Notes * ”High end-state functioning (HEF) was defined as being panic-free and having an inde-
pendent assessor rating of severity of the panic disorder of ≤2 (i.e. ’slight’) on the (ADIS-R)
0-8 scale.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information reported
Allocation concealment (selection bias) Unclear risk No information reported
Blinding of outcome assessment (detection
bias)
ST-Remission
Unclear risk ”High end-state functioning (HEF) was de-
fined as being panic-free and having an inde-
pendent assessor rating of severity of the panic
disorder of ≤2 (i.e. ’slight’) on the (ADIS-R)
0-8 scale.“ It is unclear whether the assessor
was blind to treatment allocation
Incomplete outcome data (attrition bias)
Short-term
Low risk 2 patients, both in the AR group, dropped
out at an early stage of treatment due to
scheduling difficulties. All 36 patients that
completed the study were followed up 1
year later. The proportion of missing out-
comes compared with the observed event
risk is not enough to have a clinically rele-
vant impact on the intervention effect esti-
mate
Incomplete outcome data (attrition bias)
Long-term
Low risk (see above)
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Selective reporting (reporting bias) High risk Study protocol unavailable. Agoraphobic
Cognitions Questionnaire (ACQ) results
are not reported, although this should be an
administered scale according to the meth-
ods section
Researcher allegiance High risk Ost LG is involved in conceptualisation of
Applied Relaxation (see Ost 1987)
Therapist allegiance Unclear risk No information reported
Treatment fidelity Unclear risk No information reported
Ost 2004
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 18 and 60 years, primary DSM-IV diagnosis of panic
disorder with agoraphobia, severity of at least 4 on the ADIS-IV 0 to 8 scale, minimum
of 1 year duration of the phobia. If on psychotropic medication: have been on a constant
dose for at least 4 months and accept to keep the dosage constant throughout therapy
Exclusion criteria: primarymajor depression (i.e. onset before the PDA), current alcohol
or substance abuse, psychotic or organic symptoms, ongoing psychotherapy
Characteristic of the sample:
• Age: mean 36.1 years (SD 10.3, range 18 to 58)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: 52%
• Percentage of patients with major depression: 12.3%
Interventions Participants (n = 73) were randomly assigned to either:
1) Exposure in vivo (classified as BT, n = 25; after re-randomisation of WL n = 35)
• Therapy format: individual
• Duration of each session: 67.5 minutes
• Mean number of sessions: 14 (12 to 16)
• Duration of intervention: 14 (12 to 16) weeks
2) Cognitive behaviour therapy (classified as CBT, n = 26; after re-randomisation of
WL n = 36)
• Therapy format: individual
• Duration of each session: 67.5 minutes
• Mean number of sessions: 14 (12 to 16)
• Duration of intervention: 14 (12 to 16) weeks
3) Wait list (classified as WL, n = 22)
• Mean number of sessions: 0
• Duration of intervention: 16
Outcomes Time points for assessment: baseline, post-treatment, 1 year follow-up.
Measures: Anxiety Disorders Interview Schedule-IV (ADIS-IV), Hamilton Anxiety
Scale (HAM-A), Hamilton Depression Scale (HAM-D), Agoraphobia Scale, Mobility
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Ost 2004 (Continued)
Inventory (MI), Fear Questionnaire (FQ), Panic Attack Scale (PAS), Anxiety Sensitiv-
ity Index (ASI), Body Sensations Questionnaire (BSQ), Agoraphobic Cognitions Ques-
tionnaire (ACQ), Beck Anxiety Inventory (BAI), State-Trait Anxiety Inventory (STAI)
, Beck Depression Inventory (BDI), Quality of Life Inventory panic diary, behavioural
approach tests
The following outcomes were used for quantitative analyses:
ST-Remission: no longer meet DSM-IV criteria for PDA at post-treatment (original
sample)
ST-Response:notmeasured (imputed from the continuous scale for the original sample)
ST-Dropouts: non-completers (original sample)
Continuous scale: Anxiety Sensitivity Index (ASI) measured on the original sample
(SDs are not reported but could be borrowed from other studies using ASI)
LT-Remission/Response: no longer meet DSM-IV criteria for PDA at 1 year follow-
up (original + re-randomised sample)
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
Unclear risk ”An independent research assistant not in-
volved with the treatment performed all the
diagnostic interviews and ratings.“ It is un-
clearwhether the assessorwas blind to treat-
ment allocation
Incomplete outcome data (attrition bias)
Short-term
Low risk ”Seven patients dropped out of treatment be-
fore completion; 3 (13%) in the E-group,
2 (8%) in the CBT-group, and 2 (9%)
in the WLC-group, a non-significant differ-
ence.“ Missing outcome data balanced in
numbers across intervention groups. The
proportion of missing outcomes compared
with the observed event risk is not enough
to have a clinically relevant impact on the
intervention effect estimate
Incomplete outcome data (attrition bias)
Long-term
High risk ”After the post-assessment of the waiting list
two patients dropped out and the remain-
ing were randomized to the two treatment
conditions with 10 in each. When the for-
mer WLC-patients were treated 3 of the 10
randomized to the E-group, but none in the
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CBT-group, dropped out.“ Reason for miss-
ing outcome data likely to be related to true
outcome, with imbalance in numbers for
missing data across intervention groups
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”The therapy sessions were audiotaped and
upon completion, three sessions were randomly
selected for every patient, one from each third
of the therapy, for analysis. Three licensed psy-
chotherapists with long experience of CBT
and blind to the allocation of the patients lis-
tened to the tapes and classified the sessions as
either an exposure or aCBT-session. They also
rated the competency of the therapists using a
modified version of the Cognitive therapy scale
(Young&Beck, 1980), consisting of nine spe-
cific items and a general item (rated on a 0-
6 scale). Which treatment the patient was re-
ceiving was correctly identified in 96.7% of
the sessions rated by the experts, indicating a
satisfying degree of treatment integrity.“
Petterson 1996
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-III-R diagnosis of panic disorder
Exclusion criteria: none
Characteristic of the sample:
• Age: range 20 to 63 years
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified
Interventions Participants (n = 27*) were randomly assigned to either:
1) Cognitive behaviour treatment (classified as CBT, n = 14?)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 6
• Duration of intervention: 6 weeks
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2) No treatment (classified as NT, n = 13?)
• Mean number of sessions: 0
• Duration of intervention: 6 weeks
Outcomes Time points for assessment: baseline, post-treatment
Measures: Anxiety Sensitivity Index (ASI), State-Trait Anxiety Inventory (STAI), Panic
Attack Record, physiologic measures (blood pressure, pulse rate, finger temperature)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (not imputed because number of randomised patients is
unclear)
ST- Response: not measured (not imputed because number of randomised patients is
unclear)
ST-Dropouts: unclear
Continuous scale: Anxiety Sensitivity Index (ASI). SDs are not reported but could be
borrowed from other studies using ASI
LT-Remission/Response: not measured
Notes *It is unclear whether the reported number participants (n = 27) refers to the ITT sample
or to treatment completers (”Twenty-seven adults completed the study. [...] The subjects
were randomly assigned to either the Treatment (n = 14) or Control (n = 13) conditions“).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
Unclear risk No information provided
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
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Rees 1999
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-III diagnosis of panic disorder with little or no agoraphobic
avoidance
Exclusion criteria: secondary diagnosis with an overall severity rating less than 2 points
away from the panic disorder severity rating on the clinician’s 9-point rating scale inADIS;
any medical condition such as asthma, angina, emphysema that might have complicated
the panic disorder
Characteristic of the sample:
• Age: not specified
• Percentage of agoraphobic patients: 82.5%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: 11.1%
Interventions Participants (n = 40) were randomly assigned to either:
1) Information giving + self monitoring (classified as PE, n = 20)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 2
• Duration of intervention: 2 weeks
2) Self monitoring alone (classified as APP, n = 20)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 2
• Duration of intervention: 2 weeks
Outcomes Time points for assessment: baseline, post-treatment.
Measures: daily records of panic, anxiety, depression and anticipatory fear of panic
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (not imputed because of skewed distribution of available
continuous scale)
ST- Response: not measured (not imputed because of skewed distribution of available
continuous scale)
ST-Dropouts: non-completers
Continuous scale: panic frequency
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
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Incomplete outcome data (attrition bias)
Short-term
Low risk No dropouts
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Reinecke 2013
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-IV diagnosis of panic disorder with or without agoraphobia,
naive to exposure-based CBT; at least moderate agoraphobic avoidance, panic-related
safety behaviours (e.g. medication, or standing close to an escape exit to prevent panic
attacks) and catastrophic panic cognitions (e.g. ”If I stay here my heart will beat even
faster, and I will suffer a heart attack“), assessed with a structured panic assessment
interview. Occasional medication with benzodiazepines
or β-blockers as needed was not an exclusion criterion; however, patients were required
to be medication-free 48 hours before the test sessions to avoid any interference with
experimental testing and CBT
Exclusion criteria: lifetime history of epilepsy, psychotic disorders, bipolar disorder or
substance abuse, primary depressive disorder, insufficient English skills, psychopharma-
cological or psychotherapeutic treatment during the last 6 months
Characteristic of the sample:
• Age by group: treatment group mean age 36 (SD 14.7); wait list group mean age
35.1 (SD 14.1)
• Percentage of agoraphobic patients: treatment group 100%; wait list group 85.
7%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: 7.14%
Interventions Participants (n = 28) were randomly assigned to either:
1) Single session exposure-based CBT (classified as CBT, n = 14)
• Therapy format: not specified
• Duration of each session: 30 minutes
• Mean number of sessions: 1
• Duration of intervention: not applicable (single session)
2) Wait list (classified as WL, n = 14)
• Mean number of sessions: 0
• Duration of intervention: 4 weeks
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Outcomes Time points for assessment: baseline (day 1), post-treatment (day 2), follow-up (4
weeks)
Measures: Hospital Anxiety and Depression Scale, Body Sensations Questionnaire
(BSQ), Agoraphobic Cognitions Questionnaire (ACQ), Mobility Inventory (MI), Faces
Dot Probe Task, Stress Test
The following outcomes were used for quantitative analyses:
ST-Remission:MI-Ag score fallingwithin the range reported for healthy control subjects
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk Mobility Inventory (used to determine ST-
Remission) is a self rated measure
Incomplete outcome data (attrition bias)
Short-term
Low risk All patients were assessed at 4 weeks follow-
up.
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk ”Our single-session treatment was a very con-
densed version of psychological intervention
recommended for delivery in routine clinical
care“
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
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Salkovskis 1999
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-III-R diagnosis of panic disorder with moderate or severe
avoidance, at least 2 panic attacks occurring in the 4 weeks prior to assessment, a score of
9 or more on the modified Fear Questionnaire, agoraphobic avoidance sub-scale (FQ-
Ag), being unable to complete the penultimate step of a pre-determined standardised
behavioural avoidance test course conducted prior to the experimental procedure, it was
possible to identify both catastrophic thoughts which occurred during panic attacks, and
safety-seeking behaviours which the patients said they carried out during the attacks to
prevent the feared catastrophes. In addition, it was required that the patient rated an
increase of anxiety from baseline of at least 20 points on a 100 point visual analogue
scale when entering the 5-minute individualised behaviour test
Exclusion criteria: none
Characteristic of the sample:
• Age by group: decreased safety behaviours group mean age 42.11 (SD 13.5);
exposure only group mean age 33.6 (SD 11.7)
• Percentage of agoraphobic patients: 100%
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified (44% according to
imputation from BDI)
Interventions Participants (n = 18) were randomly assigned to either:
1) Cognitive behaviour therapy (classified as CBT, n = 9)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 4
• Duration of intervention: 8 days
2) Habituation-based exposure therapy (classified as BT, n = 9)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 4
• Duration of intervention: 8 days
Outcomes Time points for assessment: baseline, post-treatment.
Measures: Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), panic
frequency, Fear Questionnaire (FQ), Agoraphobic Cognitions Questionnaire (ACQ),
standardised behavioural walk (BW), individualised behavioural test (BT)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (imputed from continuous scale)
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk ”Randomisation was on the basis of sampling
without replacement, using sealed envelopes
opened on completion of the initial assess-
ments“
Allocation concealment (selection bias) Unclear risk It is unclearwhether envelopeswere opaque
and sequentially numbered
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk Agoraphobic Cognitions Questionnaire
(ACQ), used to impute ST-remission, is a
self rated measure
Incomplete outcome data (attrition bias)
Short-term
Unclear risk Missing outcome data balanced in num-
bers across intervention groups (1 dropout
from each arm), it is unclear whether the
proportion of missing outcomes compared
with the observed event risk is enough to
have a clinically relevant impact on the in-
tervention effect estimate
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk Both Salkovskis PM and Clark DM are au-
thors of a manual for CBT in panic disor-
der (see Clark 1986b)
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Schmidt 1997a
Methods Study design: randomised controlled trial
Participants Inclusion criteria: principal DSM-IV diagnosis of panic disorder
Exclusion criteria: change inmedication type or dose during the 8weeks preceding entry,
evidence of serious suicide intent, current substance abuse, current or past schizophrenia,
bipolar disorder, organic mental disorder
Characteristic of the sample:
• Age: not specified
• Percentage of agoraphobic patients: 58%
• Percentage of patients on drug therapy: 59%
• Percentage of patients with major depression: not specified (16.6% according
to imputation from BDI)
Interventions Participants (n = 54) were randomly assigned to either:
1) Cognitive behaviour therapy + respiratory training (classified as CBT, n = 18)
• Therapy format: group
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• Duration of each session: not specified
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
2) Cognitive behaviour therapy (classified as CBT, n = 20)
• Therapy format: group
• Duration of each session: not specified
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
3) Wait list (classified as WL, n = 16)
• Mean number of sessions: 0
• Duration of intervention: 12 weeks
Outcomes Time points for assessment: baseline, post-treatment (12 weeks)
Measures: Clinical Global Impression - Severity (CGI-S), panic diary, Shehan Patient-
Rated Scale (SPRAS), Fear Questionnaire (FQ), Anxiety Sensitivity Inde (ASI), Panic
Appraisal Inventory (PAI), Beck Depression Inventory (BDI), Shehan Disability Scale
(SDS), Acute Panic Inventory (API), physiological measures (vital capacity, CO in-
take volume), psychophysiological measures (heart rate, systolic blood pressure, diastolic
blood pressure)
The following outcomes were used for quantitative analyses:
ST-Remission: high end-state functioning* at post-treatment
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Anxiety Sensitivity Inde (ASI)
LT-Remission/Response: not measured
Notes * High end-state functioning: ”A patient was classified as recovered when scores on each of
three clinical dimensions (i.e. panic frequency, anxiety and phobic avoidance) fell within the
normal range. Recovery criteria for the SPRAS and FQ are based on established cutoff scores
reported in the literature. The recovery criterion for panic attacks was zero.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk The 3measures used to assess the high end-
state functioning status (panic frequency,
SPRAS score, FQ score) are all self reported
Incomplete outcome data (attrition bias)
Short-term
High risk ”Of those patients assigned to the treatment
conditions (n=54), 34 were assessed at post-
treatment.“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
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Researcher allegiance High risk ”Treatment integrity was maintained by us-
ing a structured and manualized treatment
protocol (Schmidt 1994) that described spe-
cific goals and strategies for each session.“
Schmidt NB is among the study authors.
Therapist allegiance Unclear risk No information provided
Treatment fidelity High risk ”Treatment integrity was maintained by us-
ing a structured and manualized treatment
protocol that described specific goals and
strategies for each session.“
Schmidt 1997b
Methods Study design: randomised controlled trial
Participants Inclusion criteria: principal DSM-IV diagnosis of panic disorder with or without ago-
raphobia (active duty military sample)
Exclusion criteria: change inmedication type or dose during the 8weeks preceding entry,
evidence of serious suicide intent, current substance abuse, current or past schizophrenia,
bipolar disorder, organic mental disorder
Characteristic of the sample:
• Age: mean 31.8 years (SD 9.7)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified (20% according to
imputation based on BDI)
Interventions Participants (n = 37) were randomly assigned to either:
1) Cognitive behaviour treatment (classified as CBT, n = 25)
• Therapy format: group
• Duration of each session: not specified
• Mean number of sessions: 12
• Duration of intervention: 12 weeks
2) Wait list (classified as WL, n = 12)
• Mean number of sessions: 0
• Duration of intervention: 12 weeks
Outcomes Time points for assessment: baseline (week 0), post-treatment (week 9), 3 months
follow-up (week 21)
Measures: Texas Panic Attack Record Form, Shehan Patient-Rated Scale (SPRAS), Fear
Questionnaire (FQ), Shehan Disability Scale (SDS), Beck Depression Inventory (BDI)
The following outcomes were used for quantitative analyses:
ST-Remission: high end-state functioning* at post-treatment
ST- Response: not measured
ST-Dropouts: non-completers
Continuous scale: not measured
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LT-Remission/Response: not measured
Notes * High end-state functioning: ”A patient was classified as recovered when scores on each of
three clinical dimensions (i.e. panic frequency, anxiety and phobic avoidance) fell within the
normal range. Recovery criteria for the SPRAS and FQ are based on established cutoff scores
reported in the literature. The recovery criterion for panic attacks was set at zero.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk The 3measures used to assess the high end-
state functioning status (panic frequency,
SPRAS score, FQ score) are all self reported
Incomplete outcome data (attrition bias)
Short-term
High risk ”Of those patients assigned to a treatment con-
dition (n=37), 29 were assessed at post-treat-
ment. Dropouts were similar across condi-
tions, with 20% of patients in the immediate
treatment condition (n=5) and 25% of pa-
tients in the delayed treatment condition (n=
3) discontinuing their participation.“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk ”Treatment integrity was maintained by uti-
lizing a structured and manualized treat-
ment protocol (Schmidt 1994) that described
specific goals and strategies for each session.“
Schmidt NB is among the study authors.
Therapist allegiance Unclear risk No information provided
Treatment fidelity High risk ”Treatment integrity was maintained by uti-
lizing a structured and manualized treat-
ment protocol that described specific goals and
strategies for each session.“
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Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-III-R diagnosis of generalised anxiety disorder, panic disorder
with or without agoraphobia and major depression
Exclusion criteria: none
Characteristic of the sample (panic disorder sub-sample):
• Age: not specified
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified
Interventions Participants (panic disorder sub-sample, n = 21) were randomly assigned to either:
1) Cognitive behaviour therapy (classified as CBT, n = 15)
• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 7
• Duration of intervention: 7 weeks
2) Wait list (classified as WL, n = 6)
• Mean number of sessions: 0
• Duration of intervention: 7 weeks
Outcomes Time points for assessment: baseline, start of treatment, termination, 6 weeks follow-
up, 3 months follow-up, 6 months follow-up, 12 months follow-up
Measures: Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured
ST- Response: not measured
ST-Dropouts: non-completers
Continuous scale: not measured
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Incomplete outcome data (attrition bias)
Short-term
Low risk No dropouts
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
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the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Sharp 2004
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 18 and 70 years, DSM-IV diagnosis of panic disorder
with or without agoraphobia, score a minimum of 15 on the Hamilton Anxiety Scale,
score a maximum of 20 on theMontgomery Asberg Depression Rating Scale, symptoms
lasting at least 3 months. Patients taking concurrent psychotropic medications were not
excluded from the study, but were required to continue taking these medications as
prescribed throughout the study period
Exclusion criteria: having received a psychological treatment for panic disorder and
agoraphobia in the past 6 months
Characteristic of the sample:
• Age: not specified for ITT sample (among completers, mean age ranged from 34.
6 to 41.7 depending on group)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified for ITT sample (50%
among completers)
• Percentage of patients with major depression: not specified
Interventions Participants (n = 97) were randomly assigned to either:
1) Group CBT (classified as CBT, n = 38)
• Therapy format: group
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 12 weeks
2) Individual CBT (classified as CBT, n = 37)
• Therapy format: group
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 12 weeks
3) Wait list (classified as WL, n = 22)
• Mean number of sessions: 0
• Duration of intervention: 12 weeks
Outcomes Time points for assessment: baseline, post-treatment, 3 months follow-up
Measures: Hamilton Anxiety Scale (HAM-A), Symptom Rating Test (SRT), Mont-
gomery Asberg Depression Rating Scale (MADRS), Fear Questionnaire - agoraphobia
sub-scale (FQ-Ag), panic diary
The following outcomes were used for quantitative analyses:
ST-Remission: FQ-Ag below 10 at post-treatment
ST- Response: not measured (imputed from continuous scale)
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Sharp 2004 (Continued)
ST-Dropouts: non-completers
Continuous scale: Fear Questionnaire - agoraphobia sub-scale (FQ-Ag)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk Although assessor was blind to treatment
allocation, FQ (used to extract ST-Remis-
sion), is a self rated measure
Incomplete outcome data (attrition bias)
Short-term
High risk ”A total of n = 27 patients dropped out of
treatment early failing to complete five ses-
sions of study treatment. Group treatment had
a significantly higher drop-out rate (n=18,
47%), than either individual treatment (n=
6, 16%), or waiting list (n=3, 14%).“
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Unclear risk ”For the two treatment groups all patients re-
ceived the same CBT and all received identi-
cal treatment instructions with the samewrit-
ten treatment manual being supplied to all
patients.“ It is unclear whether authors were
involved in writing the administered man-
ual
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Shear 1994
Methods Study design: randomised controlled trial
Participants Inclusion criteria:DSM-III-R diagnosis of panic disorder with or without agoraphobia.
All subjects were required to discontinue psychotropic medication for at least 2 weeks
before study entry and to refrain from using medication or any other psychotherapeutic
treatment during the study
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Shear 1994 (Continued)
Exclusion criteria: none
Characteristic of the sample:
• Age: not specified for ITT sample (among completers, mean age was 34.7 years,
SD 9.7)
• Percentage of agoraphobic patients: 92%
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified (18.2% according
to imputation from BDI)
Interventions Participants (n = 66) were randomly assigned to either:
1) Cognitive behaviour treatment (classified as CBT, n = 37)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks
2) Non-prescriptive treatment (classified as SP, n = 29)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 15
• Duration of intervention: 15 weeks
Outcomes Time points for assessment: baseline, post-treatment, 6 months follow-up
Measures: Anxiety Disorders Interview Schedule-R (ADIS-R), panic diary, Brief Fear
Questionnaire, Mobility Inventory (MI), Beck Depression Inventory (BDI), Hopkin’s
Symptom Checklist (SCL-90), Sheehan Disability Scale (SDS), Hamilton Rating Scale
for Anxiety (HAM-A), Hamilton Rating Scale for Depression (HAM-D), State-Trait
Anxiety Inventory (STAI), Anxiety Sensitivity Index (ASI), Body Sensations Question-
naire (BSQ), Agoraphobic Cognitions Questionnaire (ACQ)
The following outcomes were used for quantitative analyses:
ST-Remission: panic-free at post-treatment
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Anxiety Sensitivity Index (ASI)
LT-Remission/Response: although measured (panic-free at 6 months follow-up) data
were not entered in the analyses because dropouts exceeded 30% of the originally ran-
domised sample (see Secondary outcomes).
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
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Shear 1994 (Continued)
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk ”Most pretreatment and all posttreatment and
follow-up interviewswere conducted by an in-
dependent evaluator who was “blind” to the
treatment condition, study aims, and meth-
ods.“ However, ST-remission is defined as
being panic-free, a self rated measure
Incomplete outcome data (attrition bias)
Short-term
High risk ”Pretreatment data were obtained on 45 sub-
jects (CBT=24,NPT=21). Forty-one subjects
completed posttreatment assessments (CBT=
20, NPT=21).“
Incomplete outcome data (attrition bias)
Long-term
High risk ”43 subjects completed the follow-up assess-
ments (CBT=23, NPT=20).“
Selective reporting (reporting bias) High risk Study protocol unavailable. The results of
somemeasures planned in themethods sec-
tion are not reported (e.g. ACQ, BSQ)
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”All treatments were supervised by one of us
(MKS) in weekly meetings. The CBT ses-
sions were rated for treatment adherence by
Michelle Craske, PhD, and Karla Moras,
PhD, from the Albany Stress and Anxiety
Clinic. The NPT sessions were rated for ab-
sence of CBT material. The CBT interven-
tion was rated separately for protocol adher-
ence, general skill, and specific skill on a scale
of 0 through 8. The NPT intervention was
screened for absence of CBT. Thirty audio-
tapes were randomly selected from each con-
dition. The mean adherence ratings for CBT
sessions was 4.5 on a scale of 0 through 8. [...
] There was no indication that NPT sessions
3 through 16 included CBT techniques. The
NPT intervention was not rated for adher-
ence or skill in this study.“
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Taylor 1982
Methods Study design: randomised controlled trial, cross-over design
Participants Inclusion criteria: DSM-III diagnosis of panic disorder, at least 1 panic attack in the
last 3 weeks, agreement to discontinue all psychotropic medications except as prescribed
in the study
Exclusion criteria: none
Characteristic of the sample:
• Age: mean 34.9 years (range 18 to 25)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: not specified
Interventions In the first phase of the treatment (before cross-over), participants (n = unclear) were
randomly assigned to either:
1) Relaxation (classified as, n = unclear)
• Therapy format: not specified
• Duration of each session: 30 minutes
• Mean number of sessions: up to 5
• Duration of intervention: not specified
2) Diazepam (not included, n = unclear)
• Therapy format: not specified
• Duration of each session: 30 minutes
• Mean number of sessions: 4 to 5
• Duration of intervention: not specified
3) Placebo (not included, n = unclear)
• Therapy format: not specified
• Duration of each session: 30 minutes
• Mean number of sessions: 4 to 5
• Duration of intervention: not specified
4) No treatment (classified as WL, n = unclear)
• Mean number of sessions: 0
• Duration of intervention: not specified
Outcomes Time points for assessment: baseline, post-treatment
Measures: self report diary (anxiety,mood), State-Trait Anxiety Inventory (STAI), Profile
of Mood States, physiological measures (heart rate, skin conductance)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured
ST- Response: not measured
ST-Dropouts: detailed data are not reported
Continuous scale: the only available measure (STAI) is not considered among the
outcomes of interest for this review (see Secondary outcomes). Furthermore, detailed
data are not reported.
LT-Remission/Response: not measured
Notes
Risk of bias
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Taylor 1982 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Unclear risk It is unclear whether the researchers in-
volved have a vested interest for or against
the psychological therapy under study (ref.
1 of study report)
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Telch 1993
Methods Study design: randomised controlled trial
Participants Inclusion criteria: age between 18 and 65 years, principal DSM-III-R diagnosis of panic
disorder with or without agoraphobia, at least 1 panic attack during the past 30 days
Exclusion criteria: recent change in psychotropicmedications; current psychosis, bipolar
disorder or substance abuse disorder
Characteristic of the sample:
• Age: mean 34.6 years (SD 10.3)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: 61.2%
• Percentage of patients with major depression: not specified (34.3% according
to imputation from BDI)
Interventions Participants (n = 67) were randomly assigned to either:
1) Panic inoculation training (classified as CBT, n = 34)
• Therapy format: group
• Duration of each session: 90 minutes
• Mean number of sessions: 12
• Duration of intervention: 8 weeks
2) Wait list (classified as WL, n = 33)
• Mean number of sessions: 0
• Duration of intervention: 8 weeks
Outcomes Time points for assessment: baseline, post-treatment (week 9), 6 months follow-up
Measures: Sheehan Patient-Rated Anxiety Scale (SPRAS), Agoraphobia scale of the Fear
Questionnaire (FQ-Ag), Beck Depression Inventory (BDI), Anxiety Sensitivity Index
(ASI), panic diary
The following outcomes were used for quantitative analyses:
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Telch 1993 (Continued)
ST-Remission: recovery* at post-treatment
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Anxiety Sensitivity Index (ASI)
LT-Remission/Response: not measured
Notes * ”The two groups were compared on a composite index of recovery defined as the proportion
of patients attaining normal levels of functioning on all three major facets of the disorder (i.
e. panic attacks, anxiety and panic-related avoidance).“ Recovery criterion for panic attack
was set at 0, for anxiety it was SPRAS score < 30, for avoidance it was FQ-Ag < 12
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk The 3measures used to assess the high end-
state functioning status (panic frequency,
SPRAS score, FQ score) are all self reported
Incomplete outcome data (attrition bias)
Short-term
Low risk No dropout in either group
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk ”A 65-page treatment manual (Telch 1990)
describes the specific goals and strategies for
each session.“
Therapist allegiance High risk ”All sessions were conducted by one pri-
mary therapist (MJT, JL or NBS) and
a graduate student assistant.“ As noted
above,MJTelch andNBSchmidtmay have
a vested interested in the success of their
active treatment
Treatment fidelity Low risk ”To help protect the integrity of the treatment,
therapists and their assistants followed a pro-
cedural outline for each therapy session. In ad-
dition, all treatment sessions were videotaped
and randomly selected segments were rated for
consistency with the written treatment proto-
col.“
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Tyrer 1988
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-III diagnosis of generalised anxiety disorder, panic disorder or
dysthymic disorder; currently receiving no psychotropic drugs (and had not been taking
benzodiazepines, neuroleptic drugs or antidepressants in regular dosage for at least 4
weeks before entry to the study); willing to enter the study, in which they understood
that they would receive either drug or psychological treatments for up to 10 weeks
Exclusion criteria: major depressive episode or other psychiatric disorders that take
diagnostic precedence over the 3 diagnoses above in the DSM-III classification
Characteristic of the panic disorder sub-sample:
• Age: not specified (in the full sample median age was 35 years, range 17 to 76)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: 0%
• Percentage of patients with major depression: 0%
Interventions Participants (panic disorder sub-sample, n = 74) were randomly assigned to either:
1) Cognitive and behaviour therapy (classified as CT, n = 33)
• Therapy format: not specified
• Duration of each session: 60 minutes
• Mean number of sessions: 5
• Duration of intervention: 6 weeks
2) Self help treatment package (classified as APP, n = 17)
• Therapy format: not specified
• Duration of each session: 15 minutes
• Mean number of sessions: 5
• Duration of intervention: 6 weeks
3) Diazepam (not included, n = 7)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: not specified
• Duration of intervention: 6 weeks
4) Dothiepin (not included, n = 7)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: not specified
• Duration of intervention: 6 weeks
5) Placebo (not included, n = 10)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: not specified
• Duration of intervention: 6 weeks
Outcomes Time points for assessment: baseline, mid-treatment (2, 4, 6 weeks), post-treatment
(10 weeks), 16 weeks follow-up, 32 weeks follow-up, 1 year follow-up, 2 years follow-
up, 5 years follow-up, 12 years follow-up
Measures: Comprehensive Psychopathological Rating Scale (CPRS), Montgomery &
Asberg Depression Rating Scale (MADRS), Brief Anxiety Scale (BAS), Hospital Anxiety
and Depression Scale (HADS), General Neurotic Syndrome Scale (GNSS), Life Events
Schedule, Personality Assessment Schedule (PAS)
The following outcomes were used for quantitative analyses:
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Tyrer 1988 (Continued)
ST-Remission: not measured
ST- Response: not measured
ST-Dropouts: non-completers
Continuous scale: although measured, none of the available scales is considered for this
review (see Secondary outcomes)
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The randomised treatments were indicated
by opening a sealed envelope once patients sat-
isfied the inclusion criteria for the study.“
Allocation concealment (selection bias) Unclear risk It is unclearwhether envelopeswere opaque
and sequentially numbered
Incomplete outcome data (attrition bias)
Short-term
Low risk Considering only panic disorder patients
allocated to either CBT (n = 33) or self
help treatment package (n = 17), 3 pa-
tients were lost at post-treatment assess-
ment (personal communication: 2 patients
in the CBT arm, 1 patient in the self help
arm). Therefore, missing outcome data are
low in number and balanced across inter-
vention groups
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Unclear risk No information provided
Williams 1996
Methods Study design: randomised controlled trial
Participants Inclusion criteria:DSM-III-R diagnosis of panic disorder with or without agoraphobia,
at least 2 DSM-III-R-defined panic attacks per week over a 2-week baseline period.
Subjects were asked to refrain from receiving any other psychological treatment for
panic, phobia or depression during the study until after the 6-week follow-up. Subjects
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Williams 1996 (Continued)
taking regularly prescribed medications were asked not to alter their medication regimen
during the programme, and all subjects were asked to refrain from taking discretionary
medication
Exclusion criteria: none
Characteristic of the sample:
• Age: mean 38 years (range 17 to 76)
• Percentage of agoraphobic patients: 91.67%
• Percentage of patients on drug therapy: 62.5%
• Percentage of patients with major depression: 52.08%
Interventions Participants (n = 48) were randomly assigned to either:
1) Cognitive treatment (classified as CT, n = 14)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks
2) Performance treatment (classified as BT, n = 12)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks
3) Combined treatment (classified as CBT, n = 13)
• Therapy format: individual
• Duration of each session: 60 minutes
• Mean number of sessions: 8
• Duration of intervention: 8 weeks
4) Delayed treatment (classified as WL, n = 9)
• Mean number of sessions: 0
• Duration of intervention: 8 weeks
Outcomes Time points for assessment: baseline, post-treatment, 6 weeks follow-up, 1 to 2 years
follow-up
Measures: panic diary, Self-Efficacy Scales for Agoraphobia (SESA), Fear Questionnaire
(FQ), panic coping self efficacy, Agoraphobic Cognitions Questionnaire (ACQ), Body
Sensations Questionnaire (BSQ), Beck Depression Inventory (BDI)
The following outcomes were used for quantitative analyses:
ST-Remission: panic-free at post-treatment
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Agoraphobic Cognitions Questionnaire (ACQ)
LT-Remission/Response: panic-free at 1 to 2 years follow-up
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
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Williams 1996 (Continued)
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk Panic frequency is a self rated measure
Incomplete outcome data (attrition bias)
Short-term
Low risk ”All Ss completed the treatment program;
there were no dropouts in any treatment con-
dition.“
Incomplete outcome data (attrition bias)
Long-term
Unclear risk Among the 39 subjects allocated to the 3 ac-
tive intervention arm, 34 were assessed at 1
to 2-year follow-up. Dropouts (n = 5) were
2/14 in cognitive treatment group, 2/12 in
the performance treatment group and 1/
13 in the combined treatment group.Miss-
ing outcome data are balanced across inter-
vention groups. It is unclear whether the
proportion of missing outcomes compared
with the observed event risk is enough to
have a clinically relevant impact on the in-
tervention effect estimate
Selective reporting (reporting bias) Unclear risk Study protocol unavailable
Researcher allegiance High risk ”The performance-based treatment was an of-
fice-based adaptation of guidedmastery treat-
ment (Williams 1990; Williams, Dooseman
& Kleifield 1984; Williams & Zane 1989;
Zane & Williams 1993), which emphasizes
the importance of performance successes in
helping people gain a sense of mastery and self-
efficacy.“ Williams SL is among the study
authors.
Therapist allegiance Unclear risk Insufficient information provided
Treatment fidelity Low risk ”All treatment sessions were audiotaped, and
for each treatment condition, one tape from
each therapist was chosen randomly, and all
therapist statements on it were transcribed
and assembled into sets containing five con-
secutive statements. Two assistants trained in
the coding manual independently, coded the
sets of statements, while remaining unaware
of Ss’ assigned treatment condition and of the
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Williams 1996 (Continued)
hypotheses under investigation. Based on the
codes of one randomly chosen coder, in the
performance treatment sessions, 72% of the
sets of therapist statements contained perfor-
mance interventions and 0% cognitive inter-
ventions. Sets of therapist statements in the
cognitive treatment sessions contained 58%
cognitive interventions and 0% performance
interventions. Combined treatment sessions
contained 54% performance interventions
and 29% cognitive interventions.“
Wollburg 2011
Methods Study design: randomised controlled trial
Participants Inclusion criteria: DSM-IV diagnosis of panic disorder with or without agoraphobia,
willing to accept an 8-week treatment delay if assigned to the wait list
Exclusion criteria: history of schizophrenia, bipolar disorder, dementia, alcohol or drug
abuse, current use of medications with pronounced sympathetic, parasympathetic or
respiratory effects, current score on the BDI exceeding 30, current suicidality
Characteristic of the sample:
• Age (by group):mean 43.8 years (SD10.7); mean 43.7 years (SD 14.5); mean
38.3 years (SD 14.4)
• Percentage of agoraphobic patients: not specified
• Percentage of patients on drug therapy: not specified
• Percentage of patients with major depression: not specified (8.1% imputed
from BDI)
Interventions Participants (n = 74) were randomly assigned to either:
1) Lower-CO breathing retraining (classified as PT, n = 19)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 5
• Duration of intervention: 5 weeks
2) Raise-CO breathing retraining (classified as PT, n = 28)
• Therapy format: not specified
• Duration of each session: not specified
• Mean number of sessions: 5
• Duration of intervention: 5 weeks
3) Wait list (classified as WL, n = 27)
• Mean number of sessions: 0
• Duration of intervention: 8 weeks
Outcomes Time points for assessment: baseline, 1-month follow-up (coincides with end of wait
list), 6-month follow-up
Measures: Panic Disorder Severity Scale (PDSS), Anxiety Sensitivity Index (ASI), Beck
Depression Inventory (BDI), Mobility Inventory for Agoraphobia (MI), Agoraphobic
Cognitions Questionnaire (ACQ), Anxiety Control Questionnaire, Beck Anxiety Inven-
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Wollburg 2011 (Continued)
tory (BAI), Body Sensations Questionnaire (BSQ)
The following outcomes were used for quantitative analyses:
ST-Remission: not measured (imputed from continuous scale)
ST- Response: not measured (imputed from continuous scale)
ST-Dropouts: non-completers
Continuous scale: Anxiety Sensitivity Index (ASI). Note that reported SDs are uncom-
monly low, so we considered them as being SEs
LT-Remission/Response: not measured
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
ST-Remission
High risk ASI is a self rated measure
Incomplete outcome data (attrition bias)
Short-term
Low risk No dropouts at 1-month follow-up (see
study flow chart)
Selective reporting (reporting bias) High risk Study protocol available. PDSS scores at
1-month follow-up (primary outcome) are
not reported
Researcher allegiance Low risk To our knowledge, the researchers involved
do not have a vested interest for or against
the psychological therapy under study
Therapist allegiance Unclear risk No information provided
Treatment fidelity Low risk ”All sessions were audiotaped. Of the 50 treat-
ment completers, the session for 20 were ran-
domly selected and rated for therapist compe-
tence and adherence. Overall competence rat-
ings of all therapists ranged from 3 (good) to
5 (excellent). The mean adherence rating as
measured by application of respiratory behav-
ioral techniques was 5.35 (SD 0.67), with
rating of 6 being excellent.“
3W: third-wave
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AAAS: African American Acculturation Scale - Short Form
AAQ: Acceptance and Action Questionnaire
ACQ: Agoraphobic Cognitions Questionnaire
ADIS-IV: Anxiety Disorders Interview Schedule-IV
API: Acute Panic Inventory
APP: attention/psychological placebo
APQ: Autonomic Perception Questionnaire
AR: applied relaxation
ART: applied relaxation training
ASI: Anxiety Sensitivity Index
ATQ: Attitude Toward Treatment Questionnaire/Automatic Thoughts Questionnaire
AWS: Anxiety and Willingness Scale
BAI: Beck Anxiety Inventory
BATs: Behavioral Avoidance Tests
BBSIQ: Brief Body Sensations Interpretation Questionnaire
BDI: Beck Depression Inventory
BSI: Brief Symptom Inventory
BSQ: Body Sensations Questionnaire
BT: behaviour therapy
CART: capnometry-assisted breathing training
CBT: cognitive behaviour therapy
CCLAS: Anxiety Scale of the Cognitions Checklist
CGI: Clinician Global Impression
CT: cognitive training
DPAR: Daily Panic Attack Records
DSI: Depressive Symptoms Inventory
DSM: Diagnostic and Statistical Manual of Mental Disorders
DSQ: Diagnostic Symptom Questionnaire
ECQ: Emotional Control Questionnaire
EMDR: eye movement desensitisation and reprocessing
FQ: Fear Questionnaire
FQ-Ag: Fear Questionnaire-Agoraphobia Subscale
FSS-IZZ: Fear Surrey Schedule-III
GNSS: General Neurotic Syndrome Scale
HAM-D: Hamilton Depression Scale
HARS: Hamilton Anxiety Rating Scale
HARS-R: Hamilton Anxiety Rating Scale - Revised
HEF: high end-state functioning
HR: heart rate
HRV: heart rate variability
IBT: Irrational Belief Test
ICD-10: International Classification of Diseases
IET: Interoceptive Exposure Test
ITT: intention-to-treat
IVExp: in vivo exposure
LEAS: Levels of Emotional Awareness Scale
LOCF: last observation carried forward
LT: long-term
MAO: monoamine oxidase
MCMI: Millon Clinical Multiaxial Inventory
MMPI: Minnesota Multiphasic Personality Inventory
NT: no treatment
OCD: obsessive compulsive disorder
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OQ: Outcome Questionnaire
PACQ: Panic Cognitions Questionnaire
PAI: Panic Appraisal Inventory
PARS: Phobic Avoidance Rating Scale
PAS: Panic Agoraphobia Scale/Personality Assessment Schedule
PASQ: Panic Symptoms Questionnaire
PBQ: Panic Belief Questionnaire
PCT: panic control therapy
PD/A: Panic disorder with or without agoraphobia
PDS-MI: Panic Disorder Scale and Mobility Inventory
PDSS: Panic Disorder Severity Scale
PE: psychoeducation
PFPP: panic focused psychodynamic therapy
PPGAS: Panic, Phobia and Generalized Anxiety Scale
PQ: Presence Questionnaire
PSEQ: Panic Self-Efficacy Questionnaire
PSWQ: Penn State Worry Questionnaire
PT: physiological therapies
PTSD: post-traumatic stress disorder
QOLI: Quality of Life Inventory
RR: respiration rate
SAS-SR: Social Adjustment Scale-Self-Report
SCL: Symptom Check List
SD: standard deviation
SE: standard error
SESA: Self-Efficacy Scales for Agoraphobia
SP: supportive psychotherapy
SPRAS: Sheehan Patient-Rated Anxiety Scale
SSQ: Simulation Sickness Questionnaire
ST: short-term
STAI: State-Trait Anxiety Inventory
SUD: Subjective Units of Discomfort
TAU: treatment as usual
VLQ: Valued Living Questionnaire
VRET: virtual reality exposure therapy
WBSI: White Bear Suppression Inventory
WL: wait list
WSA: Work and Social Adjustment scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andersson 2011 Mixed sample. More than 20% of patients are under 18 (personal communication) [Ongoing study]
Barlow 2000a Drug versus placebo versus CBT versus CBT + drug versus CBT + placebo. In the related study exploring EFT
versus CBT, not all patients in the EFT arm were randomised
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(Continued)
Benecke 2014 All participants are required to have a comorbid personality disorder [Ongoing study]
Borden 1986 Assignment to WL was not randomised
Bélanger 2006 Quasi-randomised design (personal communication)
Elsesser 2002 Quasi-randomised design (personal communication)
Fava 1997 The study focuses on refractory patients
Gloster 2010a The study focuses on refractory patients
Ito 2001 Since data for the intervention arms include data from re-randomised WL patients, data for WL arm cannot be
extracted (double-count): the 3 remaining arms would be BT(I) versus BT(E) versus BT(I+E). Comparison not
feasible. Randomisation probably not respected: ”twenty patients left the trial before week 4 and were replaced“,
”the final sample of 80 patients included 10 of the WL who were re-randomised“. Number of patients originally
randomised to each arm unclear. Assessment of the original arms (without the re-randomised and the substitutes)
not reported
Michelson 1996 Replacements are not evenly distributed and constitute more than 15% of the final sample
Teusch 1996 Replacements constitute 24.5% of the final sample
Zane 1993 The study explicitly focuses on agoraphobia, reporting that only 73% of participants had a comorbid panic
disorder. We considered studies focusing on agoraphobia, rather than panic disorder, when it could be safely
assumed that at least 80% of the participants were suffering from panic disorder
BT: behaviour therapy
CBT: cognitive behaviour therapy
EFT: emotion focused therapy
WL: wait list
Characteristics of studies awaiting assessment [ordered by study ID]
Bressi 2010a
Methods Randomised controlled trial
Participants 35 patients with a diagnosis of panic disorder (DSM IV-TR)
Interventions CBT versus PD versus NT (usual care)
Outcomes • Hamilton Rating Scale for Depression (HAM-D)
• Hamilton Rating Scale for Anxiety (HAM-A)
• Panic and Anticipatory Anxiety Scale (PAAAS)
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Bressi 2010a (Continued)
• Toronto Alexithymia Scale-20 items (TAS-20)
Notes Only abstract available. No reply after trying to contact the author at the available email addresses
Foley 2006
Methods Randomised controlled trial
Participants Mixed sample (diagnosis for depressive and/or anxiety related disorders according the Anxiety Disorders Interview
Schedule)
Interventions CBT versus 3W (each administered in 8 weekly group therapy sessions)
Outcomes • Hamilton Depression Rating Scale
• Depression and Anxiety Stress Scales
• Freiburg Mindfulness Inventory
Notes Only abstract available. No reply after trying to contact the author at the available email addresses
Franklin 1990
Methods Unclear
Participants 56 patients with chronic panic disorder
Interventions BT + SMT (self mastery training) versus BT + APP (imaginal rehearsal)
Outcomes • Anxiety
• Panic frequency
• Phobic avoidance
• Help seeking
• Drug usage
• Composite criterion of clinical improvement
Notes Only abstract available. No reply after trying to contact the author at the available email addresses
Irgens 2009
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: single group assignment
Masking: single-blind (outcomes assessor)
Primary purpose: treatment
Participants 72 patients, age 18 years or older, diagnosis of agoraphobia, score on Mobility Inventory ”Alone“ of 2.5 or more
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Irgens 2009 (Continued)
Interventions TFT (thought field therapy: not included) versus CBT versus WL
Outcomes Change in agoraphobic situation scores in ADIS. Among secondary outcomes: MI, ACQ, BSQ, BDI, BAI
Notes (Personal communication)
Margraf 1991
Methods Unclear
Participants Unclear
Interventions Unclear
Outcomes Unclear
Notes Full report not retrievable. No reply after trying to contact the author at the available email addresses
Milrod 2006b
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: single-blind (outcomes assessor)
Primary purpose: treatment
Participants Age 18 to 70 years, DSM-IV diagnosis criteria for primary PD with or without agoraphobia, history of at least 1
spontaneous panic attack per week within the month prior to study entry
Interventions CBT versus PD versus PT
Outcomes Panic Disorder Severity Scale (PDSS)
Notes Only protocol available. Study completed but not yet published
Richards 1997
Methods Unclear
Participants Unclear
Interventions Unclear
Outcomes Unclear
Notes Full report not retrievable. No reply after trying to contact the author at the available email addresses
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Roache 1998
Methods Randomised controlled trial
Participants 30 patients with generalised anxiety or panic disorder
Interventions CBT versus NT
Outcomes • Self administration of capsules (alprazolam/placebo)
• Level of anxiety (scale used not specified)
Notes Only abstract. No reply after trying to contact the author at the available email addresses
Strauss 1997
Methods Unclear
Participants 58 patients with the DSM-III-R diagnosis of panic disorder with and without agoraphobia
Interventions CBT versus PT versus CBT+Imipramine versus BT + imipramine
Outcomes • Beck Anxiety Inventory
• Fear Questionnaire
• Fear Diary
• HAM-D
• HAM-A
• Global Improvement Scale
• Behaviour test (DBTA)
Notes Only abstract. No reply after trying to contact the author at the available email addresses
Vincelli 2003
Methods Randomised controlled trial
Participants 12 patients with a ”DSM-IV diagnosis of anxiety disorders for a minimum of 6 months as determined by independent
clinicians on clinical interviews.“
Exclusion criteria are: psychotic or bipolar disorders, high suicidal risks, medical illness (i.e. cardiac conduction
disease, vestibular dysfunction), pregnant women
Interventions Experiential-cognitive therapy (ECT) versus CBT versus WL
Outcomes • Beck Depression Inventory (BDI)
• State-Trait Anxiety Inventory (STAI)
• Agoraphobic Cognitions Questionnaire (ACQ)
• Fear Questionnaire (FQ)
Notes The diagnosis of participants is unclear. No reply after trying to contact the author at the available email addresses
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Vincelli 2004
Methods Randomised controlled trial
Participants 36 patients (age 35 to 53) with a diagnosis of panic disorder with agoraphobia
Interventions CBT (12 sessions) versus CBT plus virtual reality exposure (8 sessions) versus WL
Outcomes • Panic frequency
• Level of depression (scale not specified)
• State and trait anxiety (scale not specified)
Notes Only abstract. Maybe continuation of Vincelli 2003a. No reply after trying to contact the author at the available
email addresses
3W: third-wave
ACQ: Agoraphobic Cognitions Questionnaire
ADIS: Anxiety Disorders Interview Schedule
APP: attention/psychological placebo
BAI: Beck Anxiety Inventory
BDI: Beck Depression Inventory
BSQ: Body Sensations Questionnaire
BT: behaviour therapy
CBT: cognitive behaviour therapy
DSM: Diagnostic and Statistical Manual of Mental Disorders
FQ: Fear Questionnaire
HAM-A: Hamilton Anxiety Rating Scale
HAM-D: Hamilton Depression Scale
PAAAS: Panic and Anticipatory Anxiety Scale
PD: psychodynamic therapies
PDSS: Panic Disorder Severity Scale
PT: physiological therapies
MI: Mobility Inventory
NT: no treatment
SMT: self mastery training
STAI: State-Trait Anxiety Inventory
WL: wait list
Characteristics of ongoing studies [ordered by study ID]
Barlow 2010
Trial name or title NCT01243606
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: open-label
Primary purpose: treatment
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Barlow 2010 (Continued)
Participants Age 18 years or older, fluent in the English language, who have a principal DSM-IV diagnosis of SAD, PD/
A, GAD or OCD
Interventions CBT (disorder specific) versus CBT (unified protocol) versus WL
Outcomes • Anxiety Disorders Interview Schedule for DSM-IV-Lifetime Version (ADIS-IV)
• Clinical Global Impression Severity (CGI-S) and Improvement Scales (CGI-I)
• Structured Interview Guide for the Hamilton Anxiety and Depression Rating Scale (SIGH-A and
SIGH-D)
Starting date December 2010
Contact information David H Barlow: dhbarlow@bu.edu
Todd J Farchione: tfarchio@bu.edu
Notes Completion expected by December 2014
Caspi 2012
Trial name or title NCT01677429
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: double-blind (subject, caregiver, outcomes assessor)
Primary purpose: treatment
Participants Age 18 to 45 years, clinical diagnosis of panic disorder, stable on the same drug and dosage for at least 1
month
Interventions BT (with VR balance challenge) versus BT (without VR balance challenge) versus CBT
Outcomes • Hamilton Rating Scale for Anxiety (HAM-A)
• Panic Disorder Severity Scale (PDSS)
• Panic and Agoraphobia Scale (PAS)
Starting date September 2012
Contact information Revital Amiaz: amiazr@gmail.com
Efrat Czerniak: efrat30.3@gmail.com
Notes Completion expected by September 2013
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Gensichen 2012
Trial name or title DRKS00004386
Methods Study type: interventional
Allocation: randomised controlled trial
Blinding: open (masking not used)
Control: active control
Purpose: treatment
Assignment: parallel
Participants Age 18 or older, clinical diagnosis of panic disorder with or without agoraphobia (ICD-10: F.41.0 or F40.
01), positive screening questionnaires, sufficient German language skills, private telephone
Interventions CBT versus NT
Outcomes Severity of anxiety, measured by the Beck Anxiety Inventory (BAI)
Starting date October 2012
Contact information Thomas Hiller: Thomas.Hiller@med.uni-jena.de
Notes Completion expected by Spring 2015
Sandell 2012
Trial name or title NCT01606592
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: factorial assignment
Masking: open-label
Primary purpose: treatment
Participants Age between 18 and 60, DSM-V diagnosis of panic disorder (with or without agoraphobia), willingness to
stop other ongoing psychotherapy treatments and to refrain from non-study treatments during follow-up
Interventions Randomised CBT/PD versus chosen CBT/PD versus WL
Outcomes • Panic Disorder Severity Scale (PDSS)
• Occupational status
• Absence from work due to sickness
Starting date January 2010
Contact information Not specified
Notes Completion expected by 2017
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Teismann 2012
Trial name or title NCT01680237
Methods Allocation: randomised
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: open-label
Primary purpose: treatment
Participants Age between 18 and 65 years, diagnosis of panic disorder with agoraphobia
Interventions CBT versus BT
Outcomes Change (from baseline) in the Mobility Inventory
Starting date October 2011
Contact information Tobias Teismann: tobias.teismann@rub.de
Juergen Margraf: juergen.margraf@rub.de
Notes Completion expected by August 2015
ADIS: Anxiety Disorders Interview Schedule
BAI: Beck Anxiety Inventory
BT: behaviour therapy
CBT: cognitive behaviour therapy
CGI: Clinical Global Impression
DSM: Diagnostic and Statistical Manual of Mental Disorders
GAD: generalised anxiety disorder
HAM-A: Hamilton Rating Scale for Anxiety
ICD-10: International Classification of Diseases
NT: no treatment
OC: obsessive compulsive disorder
PAS: Panic and Agoraphobia Scale
PD: psychodynamic therapies
PD/A panic disorder with/without agoraphobia
PDSS: Panic Disorder Severity Scale
SAD: social anxiety disorder
SIGH-A/SIGH-D: Structured Interview Guide for the Hamilton Anxiety and Depression Rating Scale
VR: virtual reality
WL: wait list
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Short-term remission: pairwise meta-analyses and NMA results
Compar-
ison
(X vs Y)
Pairwise meta-analyses
(common τ = 0.69)
Standard NMA
(τ = 0.64)
NMA adjusted for SSE
(τ = 0.59)
# of stud-
ies
OR CI
(lower)
CI
(upper)
OR CI
(lower)
CI
(upper)
OR CrI
(lower)
CrI (up-
per)
PT vs SP - - - - 0.36 0.11 1.18 0.35 0.10 1.11
BT vs SP - - - - 0.37 0.12 1.15 0.38 0.12 1.19
BT vs PT 2 1.11 0.21 6.00 1.03 0.42 2.28 1.10 0.51 2.50
CT vs SP - - - - 0.47 0.11 2.07 0.44 0.10 1.90
CT vs PT 1 1.22 0.20 7.48 1.33 0.44 4.05 1.27 0.41 3.91
CT vs BT 1 0.95 0.12 7.47 1.29 0.41 4.07 1.15 0.37 3.61
CBT vs
SP
3 0.68 0.24 1.91 0.68 0.25 1.83 0.67 0.25 1.82
CBT vs
PT
4 1.56 0.62 3.94 1.90 0.98 3.69 1.95 1.02 3.97
CBT vs
BT
10 2.09 1.10 3.97 1.84 1.06 3.22 1.77 1.02 3.11
CBT vs
CT
1 1.69 0.21 13.47 1.43 0.48 4.23 1.53 0.52 4.68
WL vs SP - - - - 0.08 0.03 0.26 0.22 0.06 0.78
WLvs PT 4 0.21 0.06 0.70 0.23 0.12 0.48 0.64 0.27 1.65
WL vs
BT
3 0.12 0.04 0.43 0.23 0.12 0.45 0.58 0.25 1.36
WL vs
CT
2 0.12 0.02 0.61 0.18 0.06 0.52 0.50 0.15 1.77
WL vs
CBT
18 0.13 0.07 0.22 0.12 0.07 0.21 0.33 0.16 0.69
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Table 1. Short-term remission: pairwise meta-analyses and NMA results (Continued)
NT vs SP - - - - 0.26 0.04 1.82 0.24 0.03 1.67
NT vs PT 1 0.70 0.11 4.33 0.73 0.14 3.68 0.70 0.14 3.48
NT vs BT - - - - 0.71 0.13 3.96 0.64 0.11 3.51
NT vs
CT
1 0.57 0.09 3.48 0.55 0.11 2.73 0.55 0.11 2.71
NT vs
CBT
- - - - 0.38 0.07 2.05 0.36 0.07 1.85
NT vs
WL
- - - - 3.11 0.58 16.78 1.10 0.18 6.26
PD vs SP - - - - 0.71 0.14 3.52 0.71 0.14 3.42
PD vs PT 1 4.21 0.70 25.49 1.99 0.57 7.02 2.05 0.60 7.38
PD vs BT - - - - 1.94 0.50 7.48 1.88 0.48 7.17
PD vs CT - - - - 1.50 0.30 7.43 1.61 0.33 8.17
PD vs
CBT
1 0.51 0.09 2.99 1.05 0.30 3.68 1.06 0.29 3.66
PD vs
WL
- - - - 8.50 2.27 31.84 3.21 0.75 12.87
PD vs
NT
- - - - 2.73 0.36 20.56 2.91 0.40 22.56
OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less
than one favours treatment Y. Note that in the main text, where necessary, we inverted the values presented in Table 4 for an easier
presentation, in which an OR greater than 1 stands for a higher number of events (short-term remissions) in the intervention group
when compared to the control group. Statistically significant results are written in bold.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CrI: credible interval
CT: cognitive training
NMA: network meta-analysis
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
SSE: small study effects
WL: wait list
215Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Short-term remission: I2 values and their 95% confidence intervals
Comparison I2(%) 95% CI
CBT vs SP 0 0 to 90
WL vs CBT 58 29 to 75
CBT vs BT 5 0 to 64
WL vs BT 34 0 to 78
WL vs PT 56 0 to 85
CBT vs PT 0 0 to 85
This values refer to standard meta-analyses, where each comparison has its own heterogeneity variance.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CT: cognitive training
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list
Table 3. Short-term remission: ranking of treatments
Treatment SUCRA
SP 88
CBT 76
PD 73
CT 50
BT 41
PT 35
NT 25
WL 13
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
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SP: supportive psychotherapy
WL: wait list
Table 4. Short-term response: pairwise meta-analyses and NMA results
Compar-
ison
(X vs Y)
Pairwise meta-analyses
(common τ = 0.55)
Standard NMA
(τ = 0.63)
NMA adjusted for SSE
(τ = 0.65)
# of stud-
ies
OR CI
(lower)
CI
(upper)
OR CI
(lower)
CI
(upper)
OR CrI
(lower)
CrI (up-
per)
PT vs SP - - - - 0.68 0.20 2.31 0.69 0.20 2.41
BT vs SP - - - - 0.589 0.18 1.93 0.69 0.21 2.33
BT vs PT 2 0.90 0.21 3.90 0.87 0.41 1.88 1.00 0.46 2.23
CT vs SP - - - - 0.39 0.07 2.07 0.36 0.07 1.96
CT vs PT 1 0.94 0.18 4.97 0.58 0.16 2.09 0.53 0.14 2.04
CT vs BT 1 0.20 0.03 1.46 0.66 0.18 2.51 0.53 0.13 2.07
CBT vs
SP
3 1.02 0.38 2.73 1.04 0.36 2.99 1.12 0.40 3.26
CBT vs
PT
4 1.23 0.56 2.71 1.54 0.81 2.94 1.62 0.84 3.17
CBT vs
BT
10 1.78 1.00 3.18 1.77 1.02 3.04 1.61 0.92 2.86
CBT vs
CT
1 2.92 0.43 19.98 2.65 0.73 9.62 3.08 0.81 12.26
WL vs SP - - - - 0.17 0.05 0.53 0.45 0.12 1.93
WLvs PT 4 0.15 0.05 0.44 0.25 0.12 0.50 0.65 0.24 1.91
WL vs
BT
4 0.32 0.14 0.73 0.29 0.15 0.54 0.65 0.28 1.68
WL vs
CT
1 0.31 0.02 4.27 0.43 0.12 1.61 1.24 0.26 6.42
WL vs
CBT
17 0.19 0.05 0.31 0.16 0.10 0.26 0.40 0.18 1.00
NT vs SP - - - - 0.16 0.02 1.21 0.15 0.02 1.22
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Table 4. Short-term response: pairwise meta-analyses and NMA results (Continued)
NT vs PT 1 0.31 0.06 1.62 0.24 0.05 1.25 0.22 0.04 1.25
NT vs BT - - - - 0.27 0.05 1.59 0.22 0.03 1.37
NT vs
CT
1 0.33 0.06 1.68 0.41 0.08 2.13 0.42 0.07 2.31
NT vs
CBT
- - - - 0.16 0.03 0.87 0.14 0.02 0.80
NT vs
WL
- - - - 0.96 0.17 5.46 0.33 0.04 2.32
PD vs SP - - - - 1.02 0.20 5.28 1.07 0.20 5.70
PD vs PT 1 4.22 0.84 21.31 1.51 0.42 5.35 1.54 0.42 5.92
PD vs BT - - - - 1.73 0.44 6.70 1.54 0.37 6.41
PD vs CT - - - - 2.59 0.45 14.82 2.94 0.47 18.59
PD vs
CBT
1 0.34 0.07 1.76 0.98 0.27 3.47 0.95 0.25 3.60
PD vs
WL
- - - - 6.02 1.60 22.61 2.37 0.49 10.75
PD vs
NT
- - - - 6.28 0.80 49.20 7.03 0.84 61.98
OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less
than one favours treatment Y. Note that in the main text, where necessary, we inverted the values presented in Table 4 for an easier
presentation, in which an OR greater than 1 stands for a higher number of events (short-term remissions) in the intervention group
when compared to the control group. Statistically significant results are written in bold.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CrI: credible interval
CT: cognitive training
NMA: network meta-analysis
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
SSE: small study effects
WL: wait list
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Table 5. Short-term response: I2 values and their 95% confidence intervals
Comparison I2(%) 95% CI
CBT vs SP 7 0 to 90
WL vs CBT 39 0 to 66
CBT vs BT 22 0 to 62
WL vs BT 26 0 to 72
WL vs PT 14 0 to 87
CBT vs PT 45 0 to 82
This values refer to standard meta-analyses, where each comparison has its own heterogeneity variance.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CT: cognitive training
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list
Table 6. Short-term response: ranking of treatments
Treatment SUCRA
CBT 84
PD 74
SP 72
BT 53
PT 52
WL 31
CT 27
NT 7
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
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SP: supportive psychotherapy
WL: wait list
Table 7. Short-term dropouts: pairwise meta-analyses and NMA results
Comparison Pairwise meta-analysis Network meta-analysis
(τ = 0.33)
# of studies OR CI (lower) CI (upper) OR CI (lower) CI (upper)
PT vs SP - - - - 0.76 0.28 2.08
BT vs SP - - - - 0.92 0.35 2.28
BT vs PT 2 2.19 0.46 10.38 1.20 0.60 2.40
CT vs SP - - - - 1.06 0.20 5.62
CT vs PT 1 5.59 0.59 52.73 1.38 0.33 5.86
CT vs BT - - - - 1.15 0.26 5.20
CBT vs SP 3 0.63 0.21 1.89 0.64 0.28 1.43
CBT vs PT 3 0.56 0.24 1.28 0.83 0.46 1.50
CBT vs BT 10 0.89 0.52 1.51 0.69 0.42 1.15
CBT vs CT - - - - 0.60 0.14 2.60
WL vs SP - - - - 0.48 0.19 1.22
WL vs PT 5 0.74 0.30 1.83 0.63 0.35 1.15
WL vs BT 4 0.34 0.16 0.69 0.52 0.30 0.93
WL vs CT - - - - 0.46 0.11 1.97
WL vs CBT 14 0.70 0.42 1.16 0.76 0.48 1.20
NT vs SP - - - - 0.10 0.00 2.18
NT vs PT 1 0.29 0.01 7.51 0.13 0.01 3.10
NT vs BT - - - - 0.11 0.00 2.69
NT vs CT 1 0.07 0.00 1.37 0.10 0.00 1.93
NT vs CBT - - - - 0.16 0.01 3.80
NT vs WL - - - - 0.21 0.09 5.01
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Table 7. Short-term dropouts: pairwise meta-analyses and NMA results (Continued)
PD vs SP - - - - 0.33 0.08 1.46
PD vs PT 1 0.16 0.03 0.84 0.44 0.12 1.52
PD vs BT - - - - 0.36 0.10 1.35
PD vs CT - - - - 0.32 0.05 2.04
PD vs CBT 1 1.21 0.27 5.35 0.52 0.15 1.80
PD vs WL - - - - 0.69 0.19 2.50
PD vs NT - - - - 3.31 0.11 97.03
APP vs SP - - - - 0.84 0.07 10.61
APP vs PT - - - - 1.10 0.10 12.30
APP vs BT - - - - 0.92 0.08 10.49
APP vs CT 1 0.97 0.08 11.51 0.80 0.09 7.21
APP vs CBT - - - - 1.32 0.12 14.61
APP vs WL - - - - 1.75 0.16 19.51
APP vs NT - - - - 8.37 0.21 333.81
APP vs PD - - - - 2.53 0.17 36.70
PE vs SP - - - - 0.84 0.01 97.42
PE vs PT - - - - 1.10 0.01 119.64
PE vs BT - - - - 0.92 0.01 100.89
PE vs CT - - - - 0.80 0.01 77.96
PE vs CBT - - - - 1.32 0.01 142.93
PE vs WL - - - - 1.75 0.02 189.75
PE vs NT - - - - 8.36 0.04 1954.05
PE vs PD - - - - 2.53 0.02 316.00
PE vs APP - - - - 1.00 0.02 55.66
3W vs SP - - - - 0.36 0.06 2.12
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Table 7. Short-term dropouts: pairwise meta-analyses and NMA results (Continued)
3W vs PT - - - - 0.47 0.08 2.65
3W vs BT - - - - 0.39 0.07 2.15
3W vs CT - - - - 0.34 0.04 3.03
3W vs CBT 1 0.56 0.13 2.51 0.56 0.11 2.88
3W vs WL - - - - 0.74 0.14 4.04
3W vs NT - - - - 3.55 0.10 126.65
3W vs PD - - - - 1.07 0.13 8.31
3W vs APP - - - - 0.42 0.02 7.74
3W vs PE - - - - 0.42 0.00 60.45
OR (X vs Y) is defined as (Odds X)/(Odds Y). Of course, since this is dropout outcome, an OR smaller than one favours treatment X.
Statistically significant results are written in bold.
3W: third-wave
APP: attention/psychological placebo
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CrI: credible interval
CT: cognitive training
NMA: network meta-analysis
NT: no treatment
PD: psychodynamic therapies
PE: psychoeducation
PT: physiological therapies
SP: supportive psychotherapy
SSE: small study effects
WL: wait list
Table 8. Short-term dropouts: I2 values and their 95% confidence intervals
Comparison I2(%) 95% CI
CBT vs SP 49 0 to 85
WL vs CBT 0 0 to 55
CBT vs BT 0 0 to 62
WL vs BT 0 0 to 85
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Table 8. Short-term dropouts: I2 values and their 95% confidence intervals (Continued)
WL vs PT 25 0 to 70
CBT vs PT 12 0 to 91
This values refer to standard meta-analyses, where each comparison has its own heterogeneity variance.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CT: cognitive training
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list
Table 9. Short-term dropouts: ranking of treatments
Treatment SUCRA
NT 85
PD 75
WL 67
3W 67
CBT 51
APP 42
PE 42
PT 38
CT 29
BT 28
SP 26
Note that higher ranking treatments correspond to lower dropout rate.
3W: third-wave
APP: attention/psychological placebo
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PD: psychodynamic therapies
PE: psychoeducation
PT: physiological therapies
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SP: supportive psychotherapy
WL: wait list
Table 10. Short-term improvement: pairwise meta-analyses and NMA results
Comparison
(X vs Y)
Pairwise meta-analysis Network meta-analysis
(τ = 0.34)
# of studies SMD CI (lower) CI (upper) SMD CI (lower) CI (upper)
PT vs SP - - - - 0.24 -0.35 0.84
BT vs SP - - - - 0.16 -0.42 0.74
BT vs PT 1 -0.26 -0.98 0.46 -0.08 -0.47 0.31
CT vs SP - - - - 0.17 -0.56 0.90
CT vs PT 1 -0.02 -0.67 0.64 -0.08 -0.63 0.48
CT vs BT 1 0.65 -0.16 1.46 0.00 -0.56 0.57
CBT vs SP 3 -0.08 -0.40 0.24 -0.05 -0.56 0.47
CBT vs PT 5 -0.05 -0.30 0.19 -0.29 -0.60 0.02
CBT vs BT 10 -0.24 -0.45 -0.03 -0.21 -0.48 0.07
CBT vs CT 2 0.03 -0.88 0.94 -0.21 -0.73 0.31
WL vs SP - - - - 1.05 0.49 1.60
WL vs PT 4 0.87 0.09 1.65 0.80 0.47 1.13
WL vs BT 3 0.92 0.59 1.26 0.89 0.57 1.20
WL vs CT 1 0.60 -0.27 1.47 0.88 0.34 1.42
WL vs CBT 17 1.14 0.87 1.41 1.09 0.88 1.31
NT vs SP - - - - 0.78 -0.06 1.63
NT vs PT 1 0.36 -0.26 0.98 -0.46 -1.12 0.21
NT vs BT - - - - 0.62 -0.09 1.33
NT vs CT 1 0.39 -0.25 1.03 0.61 -0.11 1.34
NT vs CBT 1 1.30 0.46 2.14 0.83 0.16 1.50
NT vs WL - - - - -0.27 -0.96 0.42
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Table 10. Short-term improvement: pairwise meta-analyses and NMA results (Continued)
PD vs SP - - - - -0.21 -1.05 0.63
PD vs PT 1 -1.18 -1.79 -0.57 -0.46 -1.12 0.21
PD vs BT - - - - -0.38 -1.09 0.34
PD vs CT - - - - -0.38 -1.21 0.45
PD vs CBT 1 0.57 -0.07 1.2 -0.17 -0.83 0.50
PD vs WL - - - - -1.26 -1.95 -0.57
PD vs NT - - - - -1.00 -1.91 -0.07
PE vs APP 1 -0.25 -0.87 0.38 - - -
3W vs SP - - - - 0.20 -0.82 1.22
3W vs PT - - - - -0.04 -0.98 0.90
3W vs BT - - - - 0.04 -0.89 0.97
3W vs CT - - - - 0.04 -0.99 1.07
3W vs CBT 1 0.26 -0.33 0.84 0.25 -0.64 1.14
3W vs WL - - - - -0.84 -1.76 0.07
3W vs NT - - - - -0.58 -1.69 0.53
3W vs PD - - - - 0.42 -0.69 1.53
A positive SMD for X vs Y means treatment Y is better than X, the opposite for a negative SMD (this is because for the scales used a
lower score corresponds to a better treatment). Statistically significant results are written in bold.
3W: third-wave
APP: attention/psychological placebo
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PD: psychodynamic therapies
PE: psychoeducation
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list
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Table 11. Short-term improvement: I2 values and their 95% confidence intervals
Comparison I2(%) 95% CI
CBT vs SP 0 0 to 90
CBT vs PT 0 0 to 79
WL vs PT 79 45 to 92
CBT vs BT 0 0 to 62
WL vs BT 23 0 to 92
WL vs CBT 61 34 to 77
This values refer to standard meta-analyses, where each comparison has its own heterogeneity variance.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CT: cognitive training
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list
Table 12. Short-term improvement: ranking of treatments
Treatment SUCRA
PD 83
CBT 79
SP 69
CT 54
3W 53
BT 52
PT 43
NT 14
WL 4
3W: third-wave
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
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NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list
Table 13. Long-term remission/response: pairwise meta-analyses and NMA results
Comparison
(X vs Y)
Pairwise meta-analyses Network meta-analysis
# of studies OR CI (lower) CI (upper) OR CI (lower) CI (upper)
PT vs SP - - - - 1.31 0.33 5.25
BT vs SP - - - - 1.27 0.38 4.27
BT vs PT 1 1.17 0.28 4.87 0.97 0.37 2.57
CT vs SP - - - - 0.96 0.21 4.36
CT vs PT 1 0.83 0.25 2.80 0.74 0.26 2.06
CT vs BT 1 0.38 0.08 1.86 0.76 0.28 2.31
CBT vs SP 1 2.09 0.80 5.47 2.09 0.73 5.98
CBT vs PT 2 1.33 0.47 3.76 1.60 0.64 3.95
CBT vs BT 5 1.66 0.80 3.44 1.64 0.90 2.97
CBT vs CT 1 1.56 0.34 7.11 2.16 0.73 6.37
PD vs SP - - - - 1.67 0.33 8.33
PD vs PT - - - - 1.28 0.28 5.81
PD vs BT - - - - 1.31 0.34 5.07
PD vs CT - - - - 1.73 0.34 8.79
PD vs CBT 1 0.80 0.26 9.86 0.80 0.24 2.69
OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less
than one favours treatment Y. Note that in the main text, where necessary, we inverted the values presented in Table 4 for an easier
presentation, in which an OR greater than 1 stands for a higher number of events (short-term remissions) in the intervention group
when compared to the control group.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
PD: psychodynamic therapies
PT: physiological therapies
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SP: supportive psychotherapy
WL: wait list
Table 14. Long-term remission/response: ranking of treatments
Treatment SUCRA
CBT 85
PD 64
PT 49
BT 43
SP 31
CT 27
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list
Table 15. Sensitivity analyses: pairwise meta-analyses and NMA results for short-term remission excluding group therapy trials
Compar-
ison
Pairwise meta-analyses
(common τ 0.05)
Standard NMA
(τ 0)
NMA adjusted for SSE
(τ 0.60)
# of stud-
ies
OR CI
(lower)
CI
(upper)
OR CI
(lower)
CI
(upper)
OR CrI
(lower)
CrI (up-
per)
PT vs SP - - - - 0.27 0.11 0.64 0.34 0.10 1.08
BT vs SP - - - - 0.35 0.16 0.75 0.38 0.12 1.16
BT vs PT 2 0.98 0.26 3.74 1.29 0.69 2.42 1.10 0.51 2.52
CT vs SP - - - - 0.43 0.13 1.47 0.44 0.10 1.87
CT vs PT - - - - 1.60 0.51 4.96 1.27 0.41 3.90
CT vs BT 1 0.95 0.19 4.84 1.24 0.44 3.51 1.15 0.37 3.68
CBT vs
SP
3 0.67 0.33 1.35 0.67 0.34 1.27 0.67 0.24 1.77
228Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 15. Sensitivity analyses: pairwise meta-analyses and NMA results for short-term remission excluding group therapy trials
(Continued)
CBT vs
PT
3 2.02 0.85 4.76 2.46 1.39 4.33 1.94 1.02 3.97
CBT vs
BT
9 1.90 1.15 3.16 1.90 1.26 2.88 1.76 1.02 3.13
CBT vs
CT
1 1.69 0.33 8.76 1.54 0.55 4.32 1.53 0.52 4.66
WL vs SP - - - - 0.07 0.03 0.15 0.22 0.06 0.76
WLvs PT 4 0.22 0.09 0.53 0.25 0.14 0.45 0.64 0.27 1.66
WL vs
BT
3 0.17 0.08 0.36 0.19 0.12 0.31 0.58 0.26 1.36
WL vs
CT
2 0.12 0.03 0.46 0.16 0.06 0.43 0.51 0.15 1.82
WL vs
CBT
11 0.10 0.05 0.19 0.10 0.07 0.16 0.33 0.16 0.70
PD vs SP - - - - 0.61 0.21 1.80 0.24 0.03 1.64
PD vs PT 1 4.22 1.17 15.15 2.25 0.93 5.42 0.70 0.14 3.66
PD vs BT - - - - 1.74 0.68 4.47 0.64 0.11 3.60
PD vs CT - - - - 1.41 0.37 5.34 0.55 0.11 2.74
PD vs
CBT
1 0.51 0.15 1.76 0.91 0.38 2.19 0.36 0.07 1.87
PD vs
WL
- - - - 8.97 3.50 22.95 1.09 0.18 6.45
OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less
than one favours treatment Y. Note that in the main text, where necessary, we inverted the values presented in Table 4 for an easier
presentation, in which an OR greater than 1 stands for a higher number of events (short-term remissions) in the intervention group
when compared to the control group. Statistically significant results are written in bold.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CI: confidence interval
CrI: credible interval
CT: cognitive training
NMA: network meta-analysis
NT: no treatment
PD: psychodynamic therapies
PE: psychoeducation
PT: physiological therapies
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SP: supportive psychotherapy
SSE: small study effects
WL: wait list
Table 16. Sensitivity analyses: I2 values and their 95% confidence intervals for short-term remission excluding group therapy
trials
Comparison I2(%) 95% CI
WL vs PT 56 0 to 85
WL vs BT 34 0 to 78
WL vs CBT 21 0 to 60
CBT vs BT 6 0 to 67
CBT vs SP 0 0 to 90
CBT vs PT 0 0 to 90
This values refer to standard meta-analyses, where each comparison has its own heterogeneity variance.
BT: behaviour therapy
CBT: cognitive behaviour therapy
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list
Table 17. Sensitivity analyses: ranking of treatments for short-term remission excluding group therapy trials
Treatment SUCRA
SP 89
CBT 76
PD 73
CT 50
BT 40
PT 35
NT 26
WL 13
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
230Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list
Table 18. Sensitivity analyses: pairwise meta-analyses and I2 for short-term remission excluding trials in which a concomitant
pharmacotherapy is allowed
Comparison (X vs
Y)
Pairwise meta-analyses
# of studies OR CI (lower) CI (upper) I2
WL vs CBT 3 0.07 0.01 0.30 0.0%
CBT vs BT 2 2.21 0.96 5.10 0.7%
CBT vs SP 2 0.51 0.22 1.23 0.0%
WL vs BT 1 0.22 0.11 0.44 -
NT vs CT 1 0.57 0.17 1.91 -
CT vs PT 1 1.22 0.36 4.12 -
NT vs PT 1 0.70 0.27 1.10 -
OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less
than one favours treatment Y. Note that in the main text, where necessary, we inverted the values presented in Table 4 for an easier
presentation, in which an OR greater than 1 stands for a higher number of events (short-term remissions) in the intervention group
when compared to the control group. Statistically significant results are written in bold.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list
Table 19. Sensitivity analyses: pairwise meta-analyses with their I2 and NMA results for short-term remission excluding from
the analyses trials in which pharmacotherapy stabilisation was not required
Compari-
son
(X vs Y)
Pairwise meta-analyses Network meta-analysis
(tau = 0.63)
# of studies OR CI (lower) CI (upper) I2 OR CI (lower) CI (upper)
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Table 19. Sensitivity analyses: pairwise meta-analyses with their I2 and NMA results for short-term remission excluding from
the analyses trials in which pharmacotherapy stabilisation was not required (Continued)
BT vs PT - - - - - 0.56 0.12 2.67
CBT vs PT 3 1.56 0.69 3.55 30 1.80 0.69 4.67
CBT vs BT 2 4.04 0.73 22.52 72 3.16 0.93 10.71
WL vs PT 3 0.22 0.01 4.04 69 0.11 0.03 0.36
WL vs BT 1 0.02 0.00 0.32 - 0.19 0.04 0.87
WL vs CBT 6 0.06 0.03 0.014 0 0.06 0.02 0.16
OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less
than one favours treatment Y. Note that in the main text, where necessary, we inverted the values presented in Table 4 for an easier
presentation, in which an OR greater than 1 stands for a higher number of events (short-term remissions) in the intervention group
when compared to the control group. Statistically significant results are written in bold.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list
Table 20. Sensitivity analyses: pairwise meta-analyses for short-term remission using a fixed-effect rather than a random-effects
model
Comparison
(X vs Y)
# of studies Random-effects
pairwise meta-analyses
Fixed-effect
pairwise meta-analyses
OR CI (lower) CI (upper) OR CI (lower) CI (upper)
BT vs PT 2 1.09 0.22 5.52 0.96 0.27 3.46
CT vs PT 1 1.22 0.36 4.12 1.22 0.36 4.12
CT vs BT 1 0.95 0.20 4.54 0.95 0.20 4.54
CBT vs SP 3 0.67 0.35 1.27 0.67 0.35 1.27
CBT vs PT 4 1.43 0.78 2.62 1.43 0.78 2.62
CBT vs BT 10 2.05 1.29 3.27 2.05 1.30 3.22
CBT vs CT 1 1.69 0.35 8.22 1.69 0.35 8.22
PT vs WL 4 4.55 0.89 25.00 4.55 1.96 10.00
BT vs WL 3 8.33 2.33 25.00 5.56 2.94 11.11
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Table 20. Sensitivity analyses: pairwise meta-analyses for short-term remission using a fixed-effect rather than a random-effects
model (Continued)
CT vs WL 2 8.33 2.22 33.33 8.33 2.22 33.33
CBT vs WL 18 9.09 4.76 20.00 5.56 3.70 8.33
PT vs NT 1 1.43 0.41 5.00 1.43 0.41 5.00
CT vs NT 1 1.75 0.52 5.88 1.75 0.52 5.88
PD vs PT 1 4.22 1.27 13.95 4.22 1.27 13.95
PD vs CBT 1 0.51 0.16 1.613 0.51 0.16 1.613
OR (X vs Y) is defined as (Odds X)/(Odds Y). For each comparison X vs Y, an OR greater than one favours treatment X, an OR less
than one favours treatment Y. Statistically significant results are written in bold.
BT: behaviour therapy
CBT: cognitive behaviour therapy
CT: cognitive training
NT: no treatment
PD: psychodynamic therapies
PT: physiological therapies
SP: supportive psychotherapy
WL: wait list
A P P E N D I C E S
Appendix 1. CCDANCTR-References Register search (psychotherapies for panic)
1. (therap* or psychotherap*) [ti,ab]
2. psychotherapy [kw]
3. (acceptance* or commitment* or “activity scheduling” or adlerian or art or aversion or brief or “client cent*” or cognitive* or color
or colour or compassion-focused or “compassion* focus*” or compassionate or conjoint or conversion or conversational or couples or
dance or dialectic* or diffusion or distraction or eclectic or (emotion and focus*) or emotion-focus* or existential or experiential or
exposure or expressive or family or focus-oriented or “focus oriented” or freudian or gestalt or “group” or humanistic or implosive or
insight or integrative or interpersonal or jungian or kleinian or logo or marital or metacognitive or meta-cognitive or milieu or morita
or multimodal or multi-modal or music or narrative or nondirective or non-directive or “non directive” or nonspecific or non-specific
or “non specific” or “object relations” or “personal construct” or “person cent*” or person-cent* or persuasion or play or ((pleasant
or pleasing) and event*) or primal or problem-focused or “problem focused” or problem-solving or “problem solving” or process-
experiential or “process experiential” or psychodynamic or “rational emotive” or reality or “reciprocal inhibition” or relationship* or
reminiscence or restructuring or rogerian or schema* or self-control* or “self control*” or “short term” or short-term or sex or “social
effectiveness” or “social skill*” or socio-environment* or “socio environment*” or “solution focused” or solution-focused or “stress
management” or supportive or time-limited or “time limited” or “third wave” or transference or transtheoretical or validation)
4. (abreaction or “acting out” or “age regression” or ((assertive* or attention or autogenic or mind or sensitivity) and train*) or
autosuggestion or “balint group” or ((behavior* or behaviour*) and (activation or therap* or treatment or contracting or modification))
or bibliotherap* or biofeedback or catharsis or *cognitive* or *CBT* or “mind training” or counsel* or “contingency management”
or countertransference or “covert sensitization” or “eye movement desensiti*” or EMDR or “crisis intervention” or “dream analysis” or
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“emotional freedom” or “free association” or “functional analys*” or griefwork or hypno* or imagery or meditation* or “mental healing”
or mindfulness* or “panic program” or psychoanaly* or psychodrama or psychoeducat* or (psycho* and support*) or psychotherap*
or relaxation or “role play*” or “self analysis” or “self esteem” or “self-help or “self help” or “sensitivity training” or “support group*” or
therapist or “therapeutic technique*” or “transactional analysis”)
5. ((1 or 2) and 3) or 4
6. panic
7. (5 and 6)
Appendix 2. PubMed search strategy
(((”randomized controlled trial“[Publication Type]) OR (”controlled clinical trial“[Publication Type]) OR (”clinical trials as
topic“[MeSH Terms]) OR ((randomized[Title/Abstract]) OR randomised[Title/Abstract]) OR (randomly[Title/Abstract]) OR
(placebo[Title/Abstract]) OR (trial[Title])) NOT (”animals“[MeSH Terms] NOT ”humans“[MeSH Terms])) AND ((”psychother-
apy“[MeSH Terms]) OR (psychotherap* OR psychoanaly* OR psychodynamic OR psychodrama OR psychoeducat*[Title/Abstract]))
AND ((”agoraphobia“[MeSH Terms]) OR (”panic disorder“[MeSH Terms]) OR (”panic“[MeSH]) OR (panic OR agoraphobi*[Title/
Abstract]))
Appendix 3. Statistical software details
We used Stata for most analyses presented in this review. We employed the mvmeta command for the network meta-analyses (White
2011). We performed network plots and inconsistency plots using the network˙graphs package in Stata (Chaimani 2013).
We used OpenBUGS to fit the small study effects network meta-analyses. We assumed minimally informative prior distributions for
the logarithm of the treatment effects, and the heterogeneity standard deviation, τ~U(0,5). The results presented pertain to a sample
obtained from two independent chains with 100,000 iterations each, after a 10,000 burn-in period. We confirmed convergence using
the Brooks-Gelman-Rubin criterion (Brooks 1998).
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We first planned to use scale endpoint data, which typically cannot have negative values and are easier to interpret from a clinical point
of view. However, as a post hoc decision, we decided to use change data in an attempt to reduce the amount of heterogeneity due to
the baseline imbalance found across studies.
235Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
